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Background and Aims 
Sacral nerve stimulation (SNS) is an established therapy for faecal 
incontinence (FI). Percutaneous tibial nerve stimulation (PTNS) is a newer, 
less-invasive treatment. The effectiveness, cost and acceptability of these 
treatments have not been systematically compared. 
 
Methods 
A systematic review of neuromodulation interventions for FI and an 
investigator-blinded, randomised pilot trial of PTNS vs. SNS including parallel 
quantitative (clinical outcomes and cost) and qualitative studies.  
 
Results 
The systematic review determined on intention-to-treat, the median success 
rates for SNS were 63% (range 33-66%), 58% (range 52-81%) and 54% 
(range 50-58%) in the short, medium and long terms respectively. The 
success rate for PTNS was 59% at 12 months. In the pilot trial: 40 patients 
(39 female; mean age 59 years) met eligibility criteria. As designed, 23 were 
randomised to receive SNS and 17 PTNS. 15 patients progressed to 
permanent SNS implantation and 16 patients received a full course of PTNS. 
Within group effect sizes were marginally greater for SNS than PTNS on 
available case analysis. FI episodes per week at baseline, 3 months and 6 
months follow-up: SNS median 5.75 (IQR 5.75-15.5 ) [mean 11.4 (SD 12.0)], 
2.5 (2-4.5) [4.0 (4.0)], 1.75 (1.5-5) [4.9 (6.9)], vs. PTNS median 6.5 (IQR 2.5-
16.5) [mean 10.6 (SD 11.2)], 3.5 (0.75-7.25) [5.8 (6.9)], 2.5 (0.75-10.75) [6.3 





(6.9)]. At least 50% improvement in FI episodes per week at 6 months: SNS 
61% vs. PTNS 47%. Effect estimates for SNS with chronic implanted 
stimulation were larger (67% at 6 months). Clinical FI scores and quality of life 
improvements complemented these results. Qualitative analysis 
demonstrated a very high acceptability and safety profile for both treatments. 
Total costs were £2,906 (SD £122) per patient for PTNS and £12,748 (SD 
£4,175) for SNS.  
 
Conclusions 
Definitive trial data between SNS or PTNS is lacking. This RCT pilot study 
determined that in the short-term, SNS confers a small clinical benefit over 
PTNS for FI but is much more expensive.  
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1.1 FAECAL INCONTINENCE 
 
Faecal incontinence (FI) can be defined as the involuntary and 
recurrent uncontrolled passage of faecal material from the 
anus for a least one month in individuals with a 
developmental age of at least four years old 1, 2. The 
International Continence Society have defined anal incontinence to be the 
involuntary loss of flatus, liquid or solid stool that is a social or hygienic problem 3. 
Although sometimes used interchangeably, there is a widely accepted distinction 
between "anal incontinence" denoting any loss of stool or flatus per anus and "FI" 
indicating loss of solid or liquid stool.  
 
Being both devastating and common, FI remains a taboo subject with only about a 
third to half of symptomatic patients discussing their problems with a medical 
professional 4, 5. Embarrassment, hopes of spontaneous resolution, assumptions that 
FI is normal with aging and poor expectations of treatment often prevent patients 











underreported and undertreated “silent affliction” 4 can be devastating, leading to 
low self esteem, social isolation and an impaired quality of life (QoL) 8. 
 
Clinically, FI can be categorised into three different types: urge incontinence, passive 
incontinence, and post defaecatory faecal seepage 9. Urge incontinence occurs when 
a strong desire to defaecate cannot be deferred appropriately, passive incontinence 
is the involuntary loss of faecal material without awareness, and faecal seepage (or 
post defaecatory FI) is leakage after evacuation, usually presenting as undergarment 
staining 10 [Table 1.01]. Although categorisation may be useful in indicating any 
underlying pathophysiology, in reality FI often presents with a combination of 
symptoms substantiating the aetiological complexity of this condition. Furthermore, 
the severity of FI can range from unintentional passing of flatus to complete 
elimination of bowel contents 10. The patient's ability to cope and motivation to seek 
treatment is usually dependant on the severity of symptoms, therefore accurate 
assessment is imperative. 
 
Table 1.01: Faecal incontinence sub-types and possible mechanisms 
 Sphincter impairment Rectal impairment 
Passive FI Internal sphincter weakness or 
tear 
 
Loss of rectosigmoid perception 
and/or anorectal reflexes 
Urge incontinence Disruption of external anal 
sphincter function  
 
Diminished rectal capacity 
Post defaecatory faecal soiling Normal anal sphincter function Incomplete evacuation of stool 
and/or impaired rectal 
sensation 
 





1.2 EPIDEMIOLOGY OF FAECAL INCONTINENCE 
 
Since 2004, there have been several large studies on the epidemiology of FI 11-18. 
International population-based studies have provided varying estimates of 
prevalence, showing that up to 18% of adults are affected by FI 19-21. It is also 
estimated that 0.5-1.0% of adults experience regular severe FI effecting their QoL 20. 
In England the prevalence of FI is approximately 200,000 people as a crude estimate 
of those currently presenting to the NHS 22. FI can affect both men and women of all 
ages and most epidemiological studies have shown an approximate equivalence in 
sex distribution 20, 21, 23, 24. Despite this, some reported clinical series have a 
substantial predominance of female sufferers 25. Variations in the prevalence of FI 
among studies may partly reflect differences in the populations sampled, survey 
methods (e.g., by phone or in person), the screening questions used, the reference 
time frame, patient underreporting and the definition of incontinence (e.g. anal  
incontinence vs. FI).  
 
There is good evidence that the prevalence of FI increases steadily with age, even 
after controlling for concurrent illnesses, activity levels, and overall health 26, 27. 
Reports have demonstrated a rise in daily or weekly FI, from about 1-2% of the adult 
population to approximately 7% in healthy independent adults over the age of 65 4, 
28, 29. Patients aged 80 years and older demonstrate a prevalence reaching 11%; with 
frequency and severity also increasing 20. In particular, patients living in institutions 






have an extremely high prevalence of FI with reports of between 33 and 65% of 
nursing home residents being afflicted 30-32. Despite not being a life threatening 
condition, studies have found an association between severe FI and increasing 
mortality 24, 33. It is clear that FI is a growing problem in an aging global population 
and will become a more prominent health issue in the future. 
 
 
1.3 AETIOLOGY OF FAECAL INCONTINENCE 
 
FI may be caused by any disturbance of the mechanisms that are required to 
maintain continence: sphincter function, rectal sensation, rectal capacity, colonic 
transit time, stool consistency, and cognitive factors 34. In community surveys, bowel 
disturbances, especially diarrhoea (mean odds ratio 53 [95% Confidence Interval (CI) 
6.1–471]), the symptom of rectal urgency, and the burden of chronic illness but not 
obstetric history (e.g., forceps use, complicated episiotomy) were the most 
important independent risk factors for FI 1, 17, 35-38. Other factors associated with FI 
include previous cholecystectomy, current smokers, rectocele, stress urinary 
incontinence, obesity, advanced age, co-morbid disease, anal sphincter trauma 
(obstetrical injury, prior surgery), and decreased physical activity 1, 12, 17, 18, 28, 39. Due 
to the complex and overlapping function of continence mechanisms, there is usually 
an underlying combination of impaired pelvic floor mechanisms and/or disordered 
bowel habit.  





Nevertheless, traditionally FI aetiology has been classified into the following 
categories: obstetric, traumatic (including iatrogenic), inflammatory or neoplastic 
colorectal disease, neurologic diseases (cerebral, spinal, peripheral), congenital and 
idiopathic conditions 40. 
 
Table 1.02: Risk factors for faecal incontinence 
Category Examples of condition 
Lifestyle Obesity, Cigarette smoking, COPD, Cholecystectomy, Bariatric surgery, 
Institutionalisation, Limited mobility, Laxative abuse 
 
Obstetric Parity, Birth trauma, Tear, Episiotomy, Forceps delivery, Prolonged labour 
 
Traumatic Haemorrhoidectomy, Sphincterotomy, Fistulotomy, Anal instrumentation, Low 
anterior resection, Penetrating/blunt force perineal trauma, Iatrogenic 
 
Colorectal conditions Colon cancer, Inflammatory bowel disease, Anal fistula, Chronic anal sepsis, 
Large haemorrhoids, Radiation proctitis, Rectal prolapse, Systemic sclerosis 
 
Neurological Dementia, Stoke, Cauda equina, Diabetes, Multiple sclerosis, Neuropathy, 
Brain injury 
 
Congenital Imperforate anus, Hirschsprung disease, Cloacae, Spina bifida, 
Meningomyelocele 
 
Idiopathic Diarrhoea, Faecal impaction, Urinary incontinence, Female, Age, Comorbid 




1.3.1 OBSTETRIC INJURY 
 
Obstetric trauma has historically been thought to be a significant cause of FI in 
women. The most frequent type of injury reported, is direct mechanical sphincter 
disruption; occurring in approximately 0.6–16% 21 of vaginal deliveries with women 
undergoing forceps delivery being at particular risk 41-43. The disruption of the 






sphincter complex (even occult) may be associated with diminished anal canal 
pressures 44, and therefore FI. Isolated pudendal nerve damage is rare 29 but traction 
injury to the pudendal nerve can accompany obstetric sphincter lacerations, lengthy 
vaginal deliveries (particularly second stage) and forceps use 45, 46. Other obstetric 
risk factors include primiparity, baby weight over 4 kg, and deliveries in the 
occipitoposterior position 47. Among women in the community, the median age of 
onset of FI is the 7th decade 11. Interestingly, current evidence indicates that 
obstetric anal sphincter injury is not, after adjusting for bowel disturbances, a major 
risk factor for FI occurring many decades after vaginal delivery in women 38. 
 
1.3.2 TRAUMATIC INJURY 
 
Sphincter damage from anal surgery may be unavoidable after some surgical 
procedures: for example, in complex anal fistula or chronic anal fissure surgery. FI 
may also occur as a complication of common operations such as 
haemorrhoidectomies, anal advancement flaps or from transanal surgery 46. Other 
less common causes of sphincter damage are with low anterior resections 
(particularly after neoadjuvant radiotherapy), accidental penetrating trauma, 









1.3.3 COLORECTAL DISEASE 
 
Rectal inflammation and/or irritability causing faecal urgency and incontinence can 
provide subtle symptoms of underlying colorectal disease necessitating further 
investigation. Colorectal conditions associated with FI include inflammatory bowel 
disease, intestinal malabsorption, malignancies, infectious diseases and internal 
rectal prolapse. Patients with progressive systemic sclerosis 48 or chronic idiopathic 
intestinal pseudo-obstruction may also develop degeneration and fibrosis of the 
internal anal sphincter leading to passive FI.  
 
1.3.4 NEUROPATHIC DISEASE 
 
Acquired neurological conditions affecting the brain, spinal cord, or peripheral 
nerves such as strokes, tumours, spinal-cord injury, multiple sclerosis, and diabetic 
autonomic neuropathy can all be causes FI. Often in these longstanding conditions, 
the combination of anal sphincter weakness, blunted rectoanal sensation and 
diarrhoea predispose to FI 49. Patients with severe learning difficulties and many 
patients with dementia may be incontinent because of a lack of interest or 










1.3.5 CONGENITAL MALFORMATIONS 
 
Congenital malformations such as imperforate anus, rectal agenesis, cloacal defect, 
Hirschsprung's disease, spina bifida, meningocele, and myelomeningocele may also 
cause FI. The severity depends on the bulk and development of pelvic-floor muscles 
and the degree of impairment of the sensory mechanisms. Even children with 
normal anal sphincters can pass stool inappropriately (encopresis), or may leak 
faeces as a result of faecal impaction with overflow 2.  
 
1.3.6 AETIOLOGICAL DIFFERENCES IN MALES 
 
Only a few studies have focused on investigating FI aetiology in men 50. Disruption of 
the anal sphincter complex in males is most commonly caused by anal trauma (see 
section 1.3.2). In addition existing anorectal diseases, including haemorrhoids, 
fissures or fistula have been reported as significant risk factors, even in the absence 
of surgery 51. Reports suggest that male FI most often takes the form of passive 
leakage with faecal staining of underwear 52. In the absence of any anatomical 
abnormality, the presence of a long anal canal leading to trapping of stool and 
subsequent expulsion 52, 53, pelvic dyssynergia resulting in incomplete evacuation 54, 
abnormal rectal sensation 55, 56 and isolated degeneration of the internal anal 
sphincter 57 may all be possible mechanisms.  
 





1.4 PATHOPHYSIOLOGY OF FAECAL INCONTINENCE 
 
The ability to maintain continence requires structural and functional integrity of the 
neuromuscular apparatus of the anorectum including: the internal and external anal 
sphincters, pelvic floor musculature and anorectal angle, pudendal nerve function,  
rectal compliance and rectal sensation. In addition, adequate colonic transit time, 
stool volume, stool consistency, cognitive function and appropriate ability to access 
bathroom facilities are necessary 58. When one or more of these continence 
mechanisms are disrupted to an extent that others are unable to compensate, then 
FI can occur 59.  
 
Table 1.03: Pathopysiological mechanisms leading to faecal incontinence 
Structure Function Stool  Mechanism Cause 
Anal sphincter High pressure zone  Sphincter weakness Obstetric injury, 
Haemorrhoidectomy, Anal 
trauma/dilatation, Infection, IBD 
 
Rectum Rectal sensation Volume and 
consistency,  
Irritants 
Diarrhoea and urgency, 
Impaired 
accommodation, Rapid 
stool transport, Faecal 
impaction and overflow 
 
Infection, IBD, IBS, Prolapse, 
Aging, Drugs, Metabolic, Bile salt 
malabsorption, laxatives, 
dyssynergic defaecation 
Pudendal nerve Anorectal sensation  Sphincter weakness, 
Sensory loss, Impaired 
Reflexes 




CNS, Spinal cord, 
Autonomic 
nervous system 
Anorectal sensation  Loss of sensation, 
Impaired Reflexes, 
Secondary myopathy, 
Loss of accommodation 
 
Spinal cord injury, Back 
surgery/trauma, Multiple 




















The anal sphincter is comprised of the internal anal sphincter (IAS), which is a 0.3-
0.5 cm expansion of the circular smooth muscle layer of the rectum and the external 
anal sphincter (EAS), a 0.6-1.0 cm expansion of the levator ani muscles. Anal 
sphincter weakness is the most frequently identified disturbance in incontinent 
patients. In controlled studies, approximately 40% of older women with FI have 
reduced anal resting pressure and 80% had reduced squeeze pressure 60.  The IAS is 
chiefly responsible for maintaining continence at rest and contributes approximately 
70-80% of the resting sphincter tone. Decreased anal resting pressure may be 
associated with structural disturbances (i.e., defects and/or thinning) of the internal 
sphincter or anal sphincter dysfunction which may be characterized by exaggerated 
spontaneous relaxation of the internal anal sphincter (sampling reflex) 61. At rest, 
the levator ani muscles and external anal sphincter are in a unique state of 
continuous tonic activity by a spinal reflex, ‘the postural reflex’. This status is 
changed in response to different stimuli and conditions (rectal distension, increase 
of intra-abdominal pressure) to facilitate defecation or to prevent FI 62. This high 
pressure zone is further reinforced by anal mucosal folds, endovascular cushions 
and voluntary squeezing of the EAS. External anal sphincter weakness may result 
from one or more of the following factors: sphincter damage, neuropathy, 




















Figure 1.01: Factors contributing to the maintenance of faecal continence (reproduced from 
Whitehead & Schuster. Am J Gasroenterol 1987; 82: 487-497 © 1987 Blackwell Publishing, with 
permission from Blackwell Publishing). 
 
 
The puborectalis muscle slings around the rectum and acts like a "flap valve" pulling 
the anorectal junction forward to reinforce the anorectal angle (approximately 90 
degrees at rest). During squeeze, the puborectalis contracts further to make the 
angle more acute, whereas during defecation, the puborectalis relaxes. Evidence 
suggests that the inward traction exerted by the puborectalis can be reduced in FI, 
correlating more closely with symptoms than changes in squeeze pressure 63.  
 
Continence requires the complex integration of signals among the smooth muscle of 
the colon and rectum, the puborectalis muscle, and the anal sphincters. Innervation 
of the EAS is from the pudendal nerve, a mixed motor and sensory nerve that arises 
from the second, third, and fourth sacral nerves (S2, S3, and S4). Innervation of the 






puborectalis arises from a branch directly from the sacral plexus (levator ani nerve) 
64. Stool is transferred into the rectum by colonic high-amplitude propagated 
contractions, which tend to occur after awakening or meals 65. As colonic contents 
are presented to the rectum, the rectum distends. The sensation of rectal distension 
is most likely transmitted along the S2, S3, and S4 parasympathetic nerves. This 
results in a parasympathetically mediated relaxation of the IAS (rectoanal inhibitory 
reflex) and a contraction of the EAS (rectoanal contractile reflex). The epithelial 
lining of the upper anal canal has a rich supply of sensory nerve endings, especially 
in the region of the anal valves. The rectal contents are sampled as to their nature 
(i.e., gas, liquid, or solid) seen as an equalisation of the rectal and upper anal canal 
pressures. Decreased anorectal sensation and less frequent sampling have been 
hypothesised to contribute to the pathogenesis of FI 66. If evacuation of the rectum 
is not socially appropriate, sympathetically mediated inhibition of the smooth 
muscle of the rectum and voluntary contraction of EAS and puborectalis 
musculature occur increasing the high pressure zone and narrowing the anorectal 
angle.  
 
Rectal hypersensitivity may also be associated with reduced rectal compliance which 
has been found to be reduced in women with FI, and associated with the symptom 
of urgency and anal incontinence 60, 67. Again the exact mechanism of this is not fully 
understood and debate continues as to whether it is a cause or effect of FI. 
Furthermore sphincter pressures do not always distinguish continent from 





incontinent patients, emphasising the complex interplay and importance of rectal 
compliance and sensation in maintaining continence 68.  
 
 
1.5 COSTS AND BURDEN OF FAECAL INCONTINENCE 
 
Although FI is a major public health problem with varying degrees of severity, little is 
known about the exact cost burden to patients and to the NHS in the UK. This lack of 
knowledge is compounded the fact that many patients are reluctant to reveal the 
full extent of their disorder. They may instead attempt to hide and bear the brunt of 
the social and financial burden by themselves. Even though only estimates can be 
calculated, it is thought that the socio-economic burden of the disease is substantial. 
Considering direct medical costs alone i.e. those incurred by obtaining medical care 
for prevention, diagnostics, therapeutics, rehabilitation and care; adult urinary and 
faecal incontinence account for 2% of total UK healthcare budget with an annual 
NHS spend in excess of £500 million 69. If FI is compared to the better-studied 
disease of urinary incontinence (with which it is closely associated), it could account 
for a mean cost per patient (females) per year of at least £218 in the UK.  
 
Unlike other conditions FI does not lead to extensive inpatient hospitalisations. 
Most of the investigations and treatments are undertaken on an outpatient basis. In 
the USA, the annual average cost per patient with either urinary or faecal 






incontinence in the outpatient setting is estimated at $17,166 70. The main expense 
coming from a build up of extensive investigations and repeated outpatient 
treatments.  
 
Direct healthcare costs include expenditure on pharmaceutical drugs, which in 
patients with FI are mainly antidiarrhoeal and laxatives. These drugs do not have a 
high unit costs and account for less than 10% of the total costs. The items weighing 
most heavily on the total cost undoubtedly concern incontinence protection 
(disposable pads and pants, washable nappies, anal tampons, under blankets and 
waterproof sheets, faeces bags, etc.), which account for approximately 25% of total 
expenditure 71 and may be born both or totally by the healthcare provider or the 
patient. In the United States approximately $400 million/year is spent on adult 
incontinence diapers 4 and between $1.5 and $7 billion/year is spent on care for 
incontinence among institutionalised elderly patients 72, 73. During 1999 the direct 
costs of pads, appliances and other prescription items throughout hospitals and long 
term care settings in the UK for incontinence in general was estimated at 
£82.5million 74. Studies by National Institute of Health and Clinical Excellence (NICE) 
suggest that 10–20% of the total identified population presenting with FI (200,000 
people) use incontinence pads. Assuming a midpoint of 15%, it can be estimated 
that approximately 30,000 patients are using incontinence pads. At an average of 4 
incontinence pads per day for each patient 75, this would work out as a cost of 
approximately £21,024,000 per year to the NHS. In the NHS the patient can receive 





incontinence pads free of charge and, theoretically at least, do not have to bear this 
burden. Other direct non-medical costs are those associated with travel/time for the 
purpose of obtaining health care and extra costs of cleaning or skincare products. 
These include but are not limited to over the counter antidiarrhoeal medication 
(26%), skin care products (11%), special articles of clothing (10%), cleaning products 
(9%), and special foods (6%) 76 Many patients are either too embarrassed to ask or 
do not know that they can obtain these products from the NHS and therefore put a 
large long-term financial burden on themselves. 
 
In terms of direct and indirect costs, cleaning after incontinence accounts for a large 
proportion of the total cost involved in the disorder. Indeed, taking into account 
how much time is spent cleaning patients who are permanently in institutions, it has 
been estimated that the personnel in charge of caring for incontinent patients 
devote 13% of their time to this duty. Therefore, the loss of the same percentage of 
the carer's salary should be regarded as a indirect costs generated by FI.  
 
Indirect non-medical costs are costs due to productivity losses associated with paid 
and unpaid work 22. These costs vastly outstrip direct costs to the NHS in terms of 
working days lost and decreased productivity in other areas of social functioning 77-
79. In essence FI can jeopardise employment, and may lead to institutionalisation 80-
82. The population of FI patients can be relatively young and of working age, the cost 
of the disorder in terms of lost working hours can be high in terms of absenteeism 






or, in the very severe cases, early retirement. Moreover, these indirect costs are not 
attributable exclusively to the patients themselves; they may also be generated by 
those assisting them. Particularly with congenital incontinence, there is a heavy 
impact on parents, who often have to restrict their own employment to care for 
their children. 
 
Intangible costs are related to pain, suffering, and discomfort. Whereas these effects 
cannot be evaluated in monetary terms, they nevertheless contribute to the overall 
burden of the disorder. With FI, intangible costs primarily concern impaired social 
activity resulting from shame and embarrassment. The socio-economic combined 
cost of healthcare utilisation 83 is indicative of the unmet clinical need in this area 
with attendant high economic costs to both patients and the NHS 84. Management 
of FI is a major problem due to not only to a high prevalence but also to a lack of 
widespread expertise. A true panacea for this difficult condition which is both 
clinically and cost effective remains elusive. 
 
 
1.6 CLINICAL EVALUATION OF FAECAL INCONTINENCE 
 
Baseline evaluation of FI should include a detailed clinical assessment together with 
appropriate physiological tests and imaging of the lower gastrointestinal tract. 
Results can provide information regarding severity, impact and possible aetiology. 





Due to the overlap and complexity of continence mechanisms previously discussed, 
no one test is superior. Therefore it must be considered that FI arises from multiple 
contributory factors rather than a single diagnosis and consequently one may need a 
combination of different modes of investigation and treatments to manage this 
condition effectively. 
 
1.6.1. FOCUSED HISTORY  
 
Initially clinicians need to establish a favourable rapport with their patient and 
approach the whole subject with sensitivity. Thereafter, a thorough assessment of 
the features of FI: the onset (timing and duration); nature of symptoms (flatus, 
liquid, or solid faeces); frequency of episodes; and related changes in bowel function 
or stool consistency can be explored 21. Personal questions about the current impact 
of FI on QoL, sexual health, daily activity, the use of pads or other devices and co-
existing urinary incontinence are also essential. Further inquiry into the patient's 
medical background, including an assessment of their: obstetric history, social 
history, co-existing medical problems, dietary history, concurrent medications and 
family history must also be completed. Co-existing physical and cognitive disabilities 
can exacerbate the effect of FI by impeding access to toilets, interfering with 
transfers to the commode, or preventing adequate cleaning after defaecation 21. 
Most importantly, any possibilities of an organic condition particularly a colorectal 
cancer must be explored and treated before focusing on FI management. 






1.6.2 CLINICAL EXAMINATION 
 
A detailed general physical and neurological examination should be performed to 
rule out systemic or neurological disorders. Following this, a meticulous perineal 
inspection and digital rectal examination are critical. Upon inspection, the presence 
of soiling, prolapsed haemorrhoids, dermatitis, deformities, anal stenosis, fistula, 
abscesses or a gaping anus may be identified 34. Other pertinent findings include a 
thinned or deformed perineal body and scars from previous surgery or trauma. A 
rectal prolapse and excessive perineal descent can be demonstrated by a Valsalva’s 
manoeuvre with an outward bulge exceeding 3 cm usually abnormal 85. The perianal 
sensation should also assessed by eliciting the anocutaneous reflex. This reflex 
examines the integrity of the connection between the sensory nerve and the skin, 
the intermediate neurones in the spinal cord segments S2, S3, and S4 and the motor 
innervation of the EAS. A digital rectal examination assesses the anal resting tone, 
the strength of the sphincters, length of anal canal, the integrity of the puborectalis, 
the acuteness of the anorectal angle, and the elevation of the perineum during 
voluntary squeezing 86. Finally a vaginal examination should be performed to 












Established first line tests: colonoscopy/CT colonography, anorectal manometry, 
rectal sensory testing, endoanal ultrasonography, pudendal nerve terminal latency 
testing and evacuation proctography are generally used in combination by any 
specialist investigating FI. They are relatively cheap, readily available, easy to 
perform and interpret and are informative especially when analysed in combination. 
In the UK they have been approved by NICE as standard investigation for ongoing FI 
87. If cases are more complex they may need further assessment using novel 
techniques. 
 
Table 1.04:  Assessment of anorectal function maintaining continence 






Pudendal nerve latency 
MRI 
 
High definition manometry, 
Saline continence test, 
Dynamic MRI proctography 
Sphincter EMG 
 
Rectal sensation Rectal perception of distension by manual 
syringe, 

























1.6.3.1 Standard investigations 
 
Endoscopy 
A colonoscopy or flexible sigmoidoscopy is usually the first investigation of choice 
when evaluating any abnormal bowel condition 88. The ability to directly visualise 
the lumen of the colon and rectum ensures that colonic polyps, inflammatory bowel 
disease and cancer are detected and histological confirmation undertaken. In 
patients who cannot tolerate these investigations CT colonography may be an 
appropriate alternative test. Most patients attending specialist consultation will 
already have completed these tests and therefore the next investigational step is a 
combination of standard anorectal physiology studies and imaging. 
 
Anorectal manometry  
Anorectal manometry measures the resting pressure, squeeze  pressures and canal 
length of the anal sphincter complex 57. If required, further evaluation of canal 
pressures can be conducted during coughing, Valsalva and straining manoeuvres. 
With traditional water perfused manometry, pressures are recorded via a 
transducer introduced into the rectum and withdrawn through the anal canal (pull 
through technique). Nowadays, different types of solid state transducers, 
pressure-recording devices and computer software are able to conduct high 
resolution or high definition stationary manometry. High resolution catheters 
provide a single averaged circumferential pressure, at 6-mm intervals along the 





entire length of the anal canal 89. High definition catheters use 256 circumferentially 
distributed pressure sensors and therefore can provide greater definition of 
sphincter morphology and defects 90. Despite advances in techniques, measurement 
of anal canal pressures can still only determine the function of the anal complex 
without differentiation between different causes of sphincter weakness 89. 
Variations in catheter designs, overlapping values between patient groups, and lack 
of standardised methods of analysis between centres mean that the value of this 
utility as an independent investigation has been debated. However, anal manometry 
is technically undemanding and widely available and is most usefully interpreted in 
correlation with other physiological test findings 91. 
 
 
Figure 1.02: High-resolution anorectal manometry, comparisons between resting and squeeze 
pressures in a control patient and one with FI. (reproduced from Costilla et al. Gastroenterol Hepatol 
2012; 9: 423-433 © 2012 Wiley Publishing, with permission from Wiley Publishing). 
 
 






Rectal sensory testing 
Rectal sensation can be assessed using progressive air or water distension of either a 
latex balloon manually, or more accurately a polyethylene balloon attached to a 
barostat machine, situated in the rectum. Volume thresholds of sensation are 
recorded at first perception, desire to defecate, and severe discomfort intervals 92. 
Rectal balloon distension together with anal manometry can also be used to 
evaluate the recto-anal inhibition reflex (RAIR). An impaired or absent reflex 
suggests either afferent or efferent neuronal injury 10, 86. 
 
Simple neurophysiological testing  
The pudendal nerve terminal motor latency (PNTML) measures the conduction time 
of the right and left pudendal nerve (ms), via a stimulating electrode mounted on 
the index finger of the glove of the examiner. Long latencies are associated with 
neuropathy or traction injury to the nerve. Despite its common use, uncertainty 
exists on the accuracy of PNTML and its predictive value on outcomes 21.  
 
Endoanal ultrasonography 
This technique provides real time, detailed information about the general integrity 
of the sphincter muscles and remains the standard for identifying anal sphincter 
injuries, including tears, scars, atrophy, and anal fistulae 93, 94. Several ultrasound 
devices are currently available including those with 3D reconstruction. In general 
scanning provides excellent resolution of the IAS but is less accurate in assessing the 





EAS; this is operator-dependent and the analysis is subject to substantial 
interoperator variability 95, 96. The use of endoanal ultrasound has certainly 
increased the detection of occult injuries and scarred sphincters. The extent to 
which these clinically occult isolated sphincter defects are responsible for FI is still 
unclear, although some have advocated surgical repair 97. Anal endosonography is 
often one of the first preferred investigations for FI as it is easy to perform, safe, 




Figure 1.03: Normal endoanal ultrasound scan image (reproduced 
from Kamm. BMJ 1998; 316: 528-532 © 1998 BMJ Publishing, with 




Evacuation proctography (defaecography)  
Evacuation proctography is a dynamic radiological study of attempted rectal 
evacuation in the natural defecating position 98. Thickened barium contrast is 
introduced into the rectum and whilst the patient defaecates seated on a commode, 
their anorectal anatomy and pelvic floor motion are recorded via X-ray images. 
During imaging at rest, coughing, squeezing, and straining to evacuate; the anorectal 
angle and position of the anorectal junction can be assessed. Defaecography can 
also reveal a poorly distensible rectum suggesting capacity abnormalities 99. 
Evacuation proctography may be most useful in the diagnosis of incontinent 






patients with anatomical abnormalities such as intussusception, rectal prolapse, 
excessive perineal descent, and rectocele.  
 
 
Figure 1.04: Normal evacuation proctography images (reproduced from Costilla et al. Gastroenterol 
Hepatol 2012; 9: 423-433 © 2012 Wiley Publishing, with permission from Wiley Publishing). 
 
 
1.6.3.2 Advanced and novel investigations 
 
Anal sensory testing  
Anal sensation is a summation of properties of central and peripheral nerve function 
of the submucosa and mucosa. Anal sensation is assessed by determining the 
perception threshold to a thermo or electrical stimulus in the anal canal. With both 
techniques, an altered anal sensation has been demonstrated in patients with FI 
which may play a part in its pathophysiology 100. 
 
 





Further neurophysiological testing 
Electromyography (EMG), uses a concentric needle electrode or a surface electrode, 
to demonstrate functional muscle tissue in the anus by quantifying motor unit 
potentials. EMG provides a sensitive measure of denervation (fibrillation potentials) 
and can usually identify myopathic, neurogenic, or mixed injury 101. Using novel 
techniques to assess somatic pathways, evoked potentials elicited by peripheral or 
central electrical or magnetic stimulation can provide information about the neural 
pathways mediating anorectal function. Depending on the site of stimulation and 
recording, afferent and efferent pathways can be evaluated 102, 103 These techniques 
are still experimental and further investigation and validation is necessary before 
more widespread use 104. 
 
Rectal pressure and compliance testing 
If the pressure applied to the rectal wall is also recorded when using the balloon 
distension technique, the compliance of the rectum can be determined by 
calculating rectal pressure-volume relationships. Abnormal rectal compliance is felt 
to be associated with FI 105.  Rectal pressure and diameter, hence rectal stress-strain 
relationships (or stiffness) can be directly measured by integrating MRI with rectal 










Magnetic resonance imaging (MRI) 
MRI, like anal endosonography, can give an excellent impressions of the anatomy of 
the anus and pelvic floor. MRI plays a major role in establishing atrophy of the 
external anal sphincter by demonstrating the amount of fat present and revealing 
the thickness and surface area of the external anal sphincter. This estimate is useful 
for predicting success of sphincter repairs 107. In addition, MRI is preferred in cases 
with high anorectal malformations (anorectal atresia and related urogenital 
abnormalities).  
 
Magnetic resonance proctography 
With the advent of rapid MRI sequences, dynamic MRI imaging can visualise both 
anal sphincter anatomy and global pelvic floor motion in real-time, without 
radiation exposure. The anal sphincters are visualised by axial T2-weighted fast spin-
echo images and corresponding T1-weighted spin-echo images with a disposable 
endorectal colon coil 108. The dynamic images of defaecation are acquired providing 
a unique appreciation of global pelvic floor motion, i.e., in addition to the 
anorectum, the bladder and genital organs are also visualised. This examination can 
be performed using conventional, closed-configuration MRI systems because there 
is little difference in the detection of clinically relevant findings between supine MRI 
and seated MRI 109.  
 






Figure 1.05: Normal dynamic MR proctogram images (reproduced from Costilla et al. Gastroenterol 




1.7 TREATMENT OF FAECAL INCONTINENCE 
 
Management of FI is a major problem, not only due to its high prevalence but also 
to a lack of widespread expertise. Treatment must always be tailored to the specific 
needs of the individual but in general a stepwise approach should be undertaken. 
Initially, conservative measures are recommended. Although these treatments can 
improve symptoms in more than half of patients, they may not be universally 
successful or long lasting 110, 111. Therefore, patients with intractable symptoms and 
impaired QoL, may seek a surgical solution. Operative intervention to the anorectum 
is not to be undertaken likely and is usually only considered after appropriate 
assessments have indicated a surgically correctable problem. Despite enthusiasm 
and evolution in operative techniques, these procedures are still invasive, 
irreversible, and have at best variable success rates with significant risk of morbidity 
87, 112. 






1.7.1 CONSERVATIVE MANAGEMENT 
 
1.7.1.1  Diet and medication 
 
First-line measures are mainly dietary and pharmacological modification. Dietary 
changes (e.g. avoidance of foods causing diarrhoea or urgency), a high fibre intake, 
sufficient fluids and stool-bulking agents (psyllium products or methylcellulose) may 
all help to improve stool volume and consistency. In addition, medical management 
using: Loperamide (Imodium), Diphenoxylate Hydrochloride plus Atropine Sulphate 
(Lomotil) or Codeine Phosphate, can help alter colonic transit. With these simple 
lifestyle modifications, many patients can manage their FI independently, 
monitoring their diet and titrating their medication as required.  
 
1.7.1.2  Bowel management 
 
Cleansing rectal irrigation, rectal enemas, laxatives and suppositories can be used in 
patients with overflow incontinence for disimpaction: emptying the rectum and 
diminishing the chance of FI during the day. Although these measures are easy to 
learn, safe and have only minor side effects, they may be inconvenient and 
uncomfortable in the long term and therefore their use can be limited 113.  
 
 





1.7.1.3  Anal plugs 
 
A foam anal plug is designed to block the loss of stool 114. Patients with anal seepage 
and subsequent faecal odour seem most effectively managed with this device. 
Although simple to use, the achievement of continence is only possible if the plug is 
supported by a functioning pelvic floor 114, 115. 
 
1.7.1.4  Physiotherapeutic interventions 
 
Pelvic physiotherapeutic interventions are generally non-invasive, inexpensive, have 
few complications and require no sophisticated equipment 116. Moreover, all other 
therapeutic options are still available while physiotherapy is being used 117. Kegal 
exercises form the mainstay of therapy, activating latent motor units to allow these 
muscles to become functional again 118. Other physiotherapeutic techniques used to 
improve FI include biofeedback and direct electrical stimulation. 
 
Biofeedback and rectal balloon training  
Nowadays, three modalities of biofeedback in the treatment of FI are recognised 119. 
The first technique uses either an intra-anal electromyographic (EMG) sensor, an 
anal manometric probe (measuring intra-anal pressure), or a perianal surface 
electrode to inform the patient about the activity of the pelvic floor muscles by way 
of a visual display and/or an auditory signal. The second technique involves the use 






of a distended manometric rectal balloon (rectal balloon training) to imitate rectal 
contents and aid defaecation practice. The third modality is a three-balloon system 
used to train forceful external anal sphincter contraction after a stimulus of rectal 
distension 116, 120. Although biofeedback requires a series of outpatient attendances, 
it is simple, easily accessible, painless and risk-free 110, 120. The benefit of 
biofeedback can be variable but improvements have been cited in around 64-89% of 
patients 120, 121. 
 
Direct electrical stimulation  
Direct electrical stimulation is achieved by applying an electrical current via probes 
in either the vagina or anal canal, or through surface electrodes on the perineum; 
passively stimulating the pelvic floor muscles, sphincters and accompanying nerve 
structures 122. The purpose of electrical stimulation is to re-educate and strengthen 
weakened or poorly functioning pelvic floor muscles by increasing awareness and 
contractions of the targeted muscles 122. Any abnormalities or infections of the 
perineum may contraindicate the use of this type of therapy 123.  
 
1.7.2 OPERATIVE MANAGEMENT  
 
A wide range of operative techniques have been developed through the ages. Most 
traditional surgical approaches target deficits in the pelvic floor or anal sphincters. 
Although a place in the treatment algorithm for these operations still exist, they do 





carry a significant risk of severe complication and morbidity. Nowadays after 
conservative measures have failed, a minimally invasive approach is most often 
advocated. These techniques have gained widespread popularity and are evolving 
quickly. Unlike, traditional approaches, they may prevent surgery to the perineum 
and its associated morbidity. More and more, direct "open surgery" is now being left 
as a second-line operative option. To decide which surgical therapy is most suitable, 
the causal determinants of an anatomical or functional nature need to be analysed 
and matched to the expertise of the surgeon.  
 
1.7.2.1  Traditional surgical approaches 
 
Sphincteroplasty  
Immediate anal sphincter repair is an established operation in acute situations (e.g., 
when an obstetric sphincter injury is recognised). Unfortunately, as many as 75% of 
women have persistent external anal sphincter defects after primary repair, and 
about 60% have some degree of incontinence 124. For incontinent patients with 
established sphincter defects, overlapping sphincteroplasty is an option. Overlapping 
sphincteroplasty yields substantial clinical improvement in approximately 65 to 80% 
of patients 125, 126. Unfortunately, current data indicates that the results deteriorate 
























Figure 1.06: Intraoperative views of sphincter repair (reproduced from Meurette. J Visc Surg 2014; 
154: 29-39 © 2014 Elsevier Masson Publishing, with permission from Elsevier Masson Publishing) 
 
 
Pelvic floor repairs 
Sir Alan Parks devised the postanal repair in the 1970s to treat FI in the absence of 
sphincter defects 130. The aim is to strengthen the posterior pelvic floor including the 
puborectalis and accentuate the flap valve effect of the puborectalis sling. The initial 
results were encouraging but were found to deteriorate over time and therefore 
this operation is rarely performed today 131, 132. An alternative operation is the 
anterior sphincter levatorplasty. In this procedure, the dissection plane is found 
anterior to the anus, and the levator ani is plicated. The surgeon can also repair 
occult anterior sphincter injuries, coexisting rectoceles and increase the length of 
the anal canal 133. A total pelvic floor repair combines both procedures. Although 
this is not a common operation, it may be an option for the treatment of post  
obstetric neurogenic FI 134.  
 





1.7.2.2  Anal encirclement procedures 
 
Artificial anal sphincters 
The artificial anal sphincter is an implantable system consisting of three parts: an 
inflatable perianal cuff, a pressure-regulating balloon, and a control pump that is 
implanted in the scrotum or the labia majora. The artificial sphincter is placed 
around the native sphincter and is kept inflated until the patient wishes to defecate, 
at which time the device is deactivated 135. Good results (approximately 50%) have 
been reported in individual case series but device infection and the risk of erosion 








Figure 1.07: Diagrammatic representation of the artificial anal sphincter device (reproduced from 
Kamm. BMJ 1998; 316: 528-532 © 1998 BMJ Publishing, with permission from BMJ Publishing). 
 
 
Magnetic anal sphincters 
A magnetic anal sphincters is a new device consisting of a ring of 14–20 magnetic 
titanium beads that are placed to surround and reinforce the anal sphincter. This 
magnetic device may prevent FI by supporting the closure of the sphincter muscles. 






Recent comparative studies indicates that MAS may be as effective as the artificial 




Figure 1.08: Magnetic anal sphincter device (a) in a closed position (b) in an open position 
(reproduced with permission from Torax Medical, Shoreview, MN). 
 
 
Electrically stimulated neosphincter procedures  
Procedures creating a neosphincter from transposed skeletal muscle date back to 
the early 20th century and mostly surgeons have made use of either the gluteus 
maximus 140 or the gracilis muscles 141. To overcome the long-term muscle fatigue 
issues with static muscular transposition, stimulated neosphincters were pioneered. 
The first successful electrically stimulated gracilis neosphincter procedure was 
reported in 1988 142. Chronic stimulation of the muscle, with a neurostimulator, 
alters its morphological, physiological and biochemical characteristics, resulting in 
two main effects. Firstly, conversion of the fast-twitch, rapidly fatigable gracilis 
muscle to a slow-twitch, fatigue-resistant muscle capable of prolonged tonic 
contraction 143. Secondly, electrical stimulation maintains tonic muscle contraction 





without the need for continuous voluntary control. In this way, an imitation of 
normal anal function is achieved, which enables the patient to maintain continence 
for a prolonged period of time 144. Gracilis neosphincter operations are often 
complex and are undertaken in stages. They can be considered a salvage option in 
well motivated patients, at centers with the requisite expertise and experience. 
However, three large multicenter trials have reported less encouraging results with 







Figure 1.09: Diagram of a gracilis neosphincter wrap (reproduced from Meurette. J Visc Surg 2014; 





Antegrade continence enema (ACE) 
This rare procedure requires a stoma formation (appendicostomy, caecostomy, or 
sigmoidostomy) and antegrade irrigation of the colon and rectum. Like retrograde 
irrigation, cleansing the distal bowel may prevent involuntary loss of enteric 
content. However, some patients may still have fluid leakage from rectum or the 






stoma, or may develop stomal strictures. Despite these complication, ACEs can 
result in improvements in symptoms and QoL for carefully selected patients 148.  
 
 
Figure 1.10: Schematic diagram of different approaches for colonic irrigation (a) Caecostomy (b and c) 
Antegrade continence enemas (d) retrograde irrigation (reproduced from Meurette. J Visc Surg 2014; 




If all other treatments fail or if the patient wishes, a colostomy can be fashioned. 
Colostomies provide a degree of bowel control in a manner that allows patients to 
resume normal activities and improve their QoL 149, 150. Adverse effects of stoma 
creation may include significant psychosocial issues and stoma-related 
complications. Little data is available regarding colostomy for incontinence; 
however, in one survey, 83 percent of patients reported a significant improvement 
in lifestyle and would choose to have the stoma again 150.  





1.7.2.4  Minimally invasive therapies 
 
Injectable biomaterials 
Injection of biomaterials either around the internal anal sphincter or into defects to 
provide bulk can be simple surgical procedures 151. The materials employed include 
autologous fat, cross-linked collagen, silicone, Teflon paste and carbon-coated beads 
151, 152. Positive results have been found in a pivotal trial of 206 patients, assessing  
dextranomer in stabilized hyaluronic acid (NASHA Dx). The 6-month response based 
on 50% FI episode reduction was higher for NASHA Dx (52%) than sham injections 





Figure 1.11: Schematic diagrams of possible placement of biometrials (a) submucosal, (b) 
intramuscular, (c) intermuscular (reproduced from Meurette. J Visc Surg 2014; 154: 29-39 © 2014 
Elsevier Masson Publishing, with permission from Elsevier Masson Publishing) 
 
 






Radiofrequency ablation (SECCA) 
The SECCA device delivers temperature-controlled circumferential radiofrequency 
energy directly to the anal sphincters via the anal canal 154. Aimed at improving 
passive FI, the radiofrequency energy causes collagen contraction, healing, and 
remodelling of the anal sphincter, thereby increasing the outlet resistance. Recent 
studies have shown that the ‘Secca procedure’ can be a successful (approximately 
60%), safe, minimally invasive, procedure which can be performed under local 
anaesthesia 155, 156. However, no changes in anorectal manometry or anal 
sonography after treatment have been seen and long-term results are less 









Stem cell injection 
Recent studies have proposed stem cell injection as an alternative new therapeutic 
approach with low morbidity. In these studies, autogenous bioproducts, such as 
myoblasts, have been used to enhance sphincter muscle cell growth. This therapy is 
still very much in the investigational stages of use 158.  






Minimally invasive neuromodulation methods have 
been developed to bridge the treatment gap between 
conservative and surgical management for FI. 
Neuromodulation (NM) therapies encompasses any 
technology that impacts upon neural interfaces to 
produce benefit, and is one of the fastest growing areas of medicine. NM is defined 
by the International Neuromodulation Society as "the alteration of nerve activity 
through the delivery of electrical stimulation or chemical agents to targeted sites of 
the body" 159. NM devices stimulate nerves using pharmaceutical agents, electrical 
signals and other forms of energy by modulating abnormal neural pathway 
behaviour caused by the disease process and "normalising" them. The use of NM 
therapies has been common since the 1980s, with indications in all facets of 
medicine expanding. Common treatments include: spinal cord stimulation for 
neuropathic pain, deep brain stimulation for Parkinson's disease and epilepsy, sacral 
nerve stimulation for neurogenic bladder and bowel conditions as well as miniature 
implants for auditory and visual sensory impairment.  
 
In the last 30 years, neuromodulation has gained support as a treatment for FI 
employing chronic, low-voltage electrical stimulation to recruit residual function of 
pelvic organs by direct or indirect stimulation of the sacral spinal nerves 160. It is 
based on the concept that residual anorectal neuromuscular function pertinent to 






continence can be recruited by electrical stimulation of its peripheral nerve supply. 
NM treatments bridge the gap between conservative therapies and potentially 
hazardous surgery to the bowel or anal sphincter. The most established of these is 
sacral nerve stimulation (SNS) and the next most popular technique is percutaneous 
tibial nerve stimulation (PTNS). This thesis focuses on evaluating the clinical 
effectiveness of these two interventions. 
 
 
1.8 SACRAL NERVE STIMULATION (SNS) 
 
Sacral spinal nerve stimulation was originally investigated as a possible treatment 
for paraplegic patients with the intention of assisting rehabilitation and walking 161. 
In the late 1970s, as a consequence of his early work, Brindley found that this 
treatment had a more profound effect on inducing micturition in neurogenic urinary 
retention 162. The first series of implanted sacral nerve stimulators was undertaken 
by Tanagho et al. in 1989 for the treatment of urinary voiding disorders 163. 
Subsequently it was found that stimulation of the sacral nerve had a concomitant 
effect on the bowel and was reported as a successful treatment of FI by Matzel 1995 
164. Since then indications for sacral neuromodulation therapy have significantly 
widened and now include many functional pelvic pathologies including constipation, 
irritable bowel syndrome, and chronic pelvic pain 165. Despite these developments, 
the most compelling data for its success, has been from the treatment of FI 166.  
















Figure 1.13: Diagrammatic representation of in-situ SNS and a neurostimulator (reproduced with 
permission from Medtronic PLC) 
 
 
SNS has gained popularity and acceptance due to the advantages of a minimally 
invasive technique, high cited success rates (approximately 70%) 7, minimal 
morbidity (overall complications rates of 5% to 26% 8) and no reported mortality 9. 
SNS is a safe and effective option for most patients failing non-interventional 
therapies regardless of FI aetiology e.g. sphincter injury, neurological impairment 167-
171. A temporary percutaneous nerve evaluation (PNE) allows patients to trial the 
SNS system and test the feasibility of success before an expensive and slightly 
invasive permanent stimulator is implanted. The technique of PNE followed by 
permanent tined lead implantation has been well described in the literature (and 
below in section 2.2.2). With impressive reported success rates for a very 
challenging condition, SNS has become the "gold standard" treatment to which 
other treatments are now being compared.  






Internationally SNS has been shown to be a cost effective treatment overall 11, 12, 
with reports of the financial advantage over colostomy and dynamic graciloplasty at 
5 years 13, 14. Despite these reports, costs of SNS still remain an issue of on-going 
discussion. The initial outlay is still considerable both in terms of direct equipment 
cost (approximately £7,000 in the UK) and indirect hospital admission costs (£12,959 
in the UK) 11. Particularly given the high equipment costs, patients who require SNS 
in the UK often necessitates prior individual funding approval which can delay 
treatment. Since other treatments for FI are reported to lose effectiveness over 
time, for example sphincteroplasty 15, there is a great deal of interest into whether 
SNS has sustained benefits and remains cost effective. Data on long-term 
effectiveness are now available 16, 17. At a time when many institutions face financial 




1.9 PERCUTANEOUS TIBIAL NERVE STIMULATION (PTNS) 
 
Over the last few years, cheaper, less invasive and technically simpler 
neuromodulatory therapies have been developed. These aim to achieve minimally 
invasive therapy in the outpatient setting, easily performed by specialists without 
the need for surgical training. Currently the commonest form of distal 
neuromodulation treatment in clinical practice is percutaneous tibial nerve 





stimulation (PTNS) 172. PTNS uses a small electrode needle to stimulate the tibial 
nerve near the ankle in order to achieve effects via its origin, which is common to 
the spinal roots that control bowel function. The idea of stimulating the tibial nerve 
is based upon the knowledge of traditional Chinese acupuncture points over the 
common peroneal or tibial nerves inducing reflex inhibition to the pelvic organs 173. 
Similar to the development of SNS, neuromodulation of the tibial nerve was first 
shown to have an effect on bladder continence in 1983 by Nakamura 174 and 
McGuire et al. 175 In 2000 the method was further modified by Stoller in San 
Francisco by stimulation of a percutaneously placed needle electrode at the level of 
the ankle and was soon popularised as an effective treatment for urinary 
incontinence. It was first described as a treatment of FI in 2003 by Shafik, who 
achieved a reported 78% functional success in 32 patients 172. 
 
 
Figure 1.14: Placement of percutaneous tibial nerve stimulation (PTNS) (reproduced from 
www.uroplasty.com © Uroplasty PLC, with permission from Uroplasty) 
 
 






It has been hypothesised that PTNS and SNS treatments may have the same 
outcomes because the mode of action on the sacral nerve plexus is thought to be 
the same. In principle, PTNS aims to use peripheral neuromodulation to recruit and 
retrain latent nerve fibres in the sacral plexus via stimulation of the tibial nerve. In 
turn this may allow improved innervation to the muscles of the pelvic floor and 
therefore improved continence.  
 
Although definitive trial data, which are available for over-active bladder therapy 176, 
is currently not available for FI, limited published case series have shown an 
approximate 60-78% success rate 172, 177, 178. The cost of PTNS is estimated to be less 
than one-tenth that of SNS; in the presence of a trained healthcare specialist, the 
setup costs for PTNS are less than £1000 for the stimulator (which can be used on 
multiple patients) and a cost of £500 per patient for the disposable equipment for 
the treatment course 178. PTNS is simple to perform in the outpatient clinic without 
anaesthesia or radiation exposure. The optimal protocol for FI using PTNS is still not 
standardised and various treatment frequencies have been described. As mentioned 
already the effects of PTNS may wear off in time and therefore intermittent "top-
up" treatments may be required to maintain its effectiveness, the exact number of 
these and the long term effectiveness and cost of repeated treatment is still yet to 
be determined. It is suspected that depending on the frequency of PTNS top-up 
treatments, a large number of hospital visits may be required, which might limit its 
use to patients living near specialist hospitals. Unlike SNS there is no prescribed 





evaluation phase to determine treatment responders therefore a lengthy and 
potentially resource intensive programme of treatment may needed to assess its 
effectiveness.  
 
Akin to SNS, there are relatively few contraindications to PTNS however these 
include: the presence of a pacemaker or implantable defibrillator, bleeding 
disorders, the presence of a painful or total peripheral neuropathy (which may 
result in over or under stimulation), and patients who are pregnant or intending to 
become pregnant whilst receiving the treatment. Prior to commencement of PTNS, 
patients should be counseled regarding expectations and must be motivated to 
comply with ongoing sessions of therapy. Side effects can include occasional 
tenderness at the site of needle insertion, swelling and inflammation around the 
needle site, toe/foot pain and small haematomas 178, 179. So far this therapy has been 
found to be completely reversible, if the effects are not adequate or adverse 
reactions occur then the treatment course can simply be halted with spontaneous 
resolution. 
 
More recently attempts to make this therapy needleless have resulted in the 
development of devices using adhesive surface electrodes placed over the tibial 
nerve. This form of transcutaneous electrical nerve stimulation (TENS) is based on 
the principle of PTNS but is even less invasive allowing delivery of the electrical 
stimulus to the tibial nerve without piercing the skin 180. Transcutaneous tibial nerve 






stimulation (TTNS) involves electrical stimulation which is delivered via two-pad 
electrodes placed over the tibial nerve just above the ankle. This is usually delivered 
via a TENS machine. Treatment regimens vary considerably, although administration 
is usually in 20- to 30-minute sessions over a period of weeks or months. The main 
advantage of PTNS over TTNS is the proximity of the needle to the tibial nerve, 
enabling higher treatment amplitude to be delivered while avoiding the painful skin 
sensations associated with transcutaneous treatment. To avoid confusion, as this 










Figure 1.15: Diagrammatic representation of the mechanism of PTNS (reproduced from 
www.uroplasty.com © Uroplasty PLC, with permission from Uroplasty) 
 
 
Figure 1.16: Transcutaneous tibial nerve 
stimulation (TTNS) (reproduced from 
Thomas. Colorectal Dis  2013; 15:519-26 © 
2013 Wiley publishing, with permission from 
Wiley publishing) 





1.10 STUDY RATIONALE AND AIMS 
 
Although PTNS is gathering popularity as a minimally invasive treatment for FI, it is 
still not clear where it stands within the algorithm of FI treatment. Knowledge of the 
efficacy of PTNS is paramount to informing NHS (National Institute of Health and 
Clinical Excellence - NICE) policy on the management of patients with FI. Accepting 
the limitations of available data (absence of pivotal randomised control trial data for 
either treatment), PTNS has the potential to be a very attractive alternative to SNS, 
at the very least in the short-term. In order to confirm this possibility, it would have 
to be proven that PTNS is largely equivalent in clinical effectiveness and is more cost 
effective when compared to an established comparator (SNS). Such results may 
have enormous relevance to patients both within the NHS and internationally. 
Specifically, the adoption of PTNS would have the potential to: 
 
 Expand treatment choice for patients  
 Enable treatment of patient groups currently marginalised from interventional 
therapy e.g. the very elderly / care home residents (PTNS could be provided in 
the future as a visiting specialist service) 
 Reduce need for operative surgery 
 Reduce need for inpatient stays 
 Reduce operative morbidity including hospital acquired infections 
 Reduce waiting times for treatment 






Such information has the potential to change the current algorithm of management 
of FI and thus impact on future NHS resource utilisation; PTNS could thus become 
the routine first ‘invasive’ intervention in patients with FI failing prior conservative 
physician- and nurse-led approaches. Furthermore, PTNS could be relatively easily 
implemented within the NHS, requiring only modest training and expertise, and 
little financial outlay on specialist equipment. 
 
The primary aim of this thesis is to provide a broad overview, determining the short 
term clinical effectiveness, costs and patient acceptability of PTNS when compared 
directly to the more established neuromodulation method of SNS. To our knowledge 
a prospective randomised comparison of clinical outcomes and full health-related 
costs between these two treatments has never before been undertaken but is 
clearly relevant to future health provision and policy making. The studies within this 
thesis therefore aims to provide pilot data which may aid the planning of further 
definitive studies on this topic. In keeping with the convention of pilot studies, a 
hypothesis is unable to be offered but there seems to be current equipoise in the 
literature between the effectiveness of each technique. By directly comparing SNS 
and PTNS, the series of studies within this thesis may provide some evidence that 
PTNS in the short term can have comparable clinical outcomes and patient 
acceptability to SNS but at a lower cost. 
 
 





1.11 SPECIFIC PROJECT AIMS 
 
To achieve our primary aim, we devised three studies to assess both PTNS and SNS. 
1. A systematic review of clinical effectiveness for both neuromodulation 
techniques in FI. 
2. A pilot randomised control trial (RCT) comparing SNS and PTNS. 
3. A qualitative interview study of SNS and PTNS patients 
 
1.11.1 A REVIEW OF CLINICAL EFFECTIVENESS OF NEUROMODULATION IN FAECAL 
INCONTINENCE 
 
The aim of this study is to (1) systematically review the current literature clinical 
outcomes of SNS in the short, medium and long term on an intention-to-treat (ITT) 
basis, (2) describe outcomes of PTNS and TTNS; and (3) to report congruence of 
clinical outcome measures in the evaluation of success for FI therapies. 
 
1.11.2 RANDOMISED PILOT TRIAL OF SACRAL AND PERCUTANEOUS TIBIAL NERVE 
STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
The overall aim for this exploratory study is to acquire, using a phase II mixed 
methods pilot trial design, the necessary quantitative and qualitative data to inform 
a subsequent definitive randomised control trial (RCT) comparing SNS and PTNS. In 






keeping with the pilot design, endpoints are selected to give an indication of the 
short-term effectiveness and acceptability of both treatments with no pre-specified 
primary outcome. For the same reason, no specific hypotheses are provided. 
 
1.11.3 QUALITATIVE INTERVIEW STUDY OF SACRAL AND PERCUTANEOUS TIBIAL 
NERVE STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
Qualitative methodology concerns the detailed examination of personal change. 
With this innovative research technique we hope to provide an aid to understanding 
our patient’s experiences and views of the two FI treatments 181. This study is 
designed to conduct a robust qualitative analysis to complement the quantitative 
study of neuromodulation treatments running in parallel. By analysing the personal 
accounts of our participants, we anticipate acquiring a unique insight into the lived 
experience of those undergoing NM treatments for FI. We can foresee that the data 
attained will give those interested in managing FI a new perspective on the two 
presented treatments. 
 
Our aim is to use the inductive and deductive principles of qualitative research to 
find out the patient’s experience of their “life world” 182. It is accepted and 
encouraged that the course and content of the interview is not laid down in 
advance. The aim of the interviews are to provide a snapshot of the patient’s 
attempts to make sense of their experiences. The thoughts accessed in the 





interviews are not necessarily held to be the truth but instead are personally 
“meaning-full” originating from the situated concerns of the participants 183. 
Through this study we want to explore patients' experiences, acceptability and 
preferences around the two treatments (SNS and PTNS) for FI. 














This chapter covers two main aspects of the project. In the first part we discuss the  
materials, methods and considerations required in preparing patients and delivering 
both SNS and PTNS as clinical treatments. Both interventions are newer minimally 
invasive techniques and therefore many healthcare professionals may not yet be 
familiar with the concept of NM. Moreover, it is imperative to understand the 
technical, clinical and organisational considerations for each technique, therefore 
maximising the benefit, safety and satisfaction for all patients. As with all 
procedures there is a learning curve in perfecting each approach. As a method of 
validation, the Clinical Research Fellow (CRF) undertook a training period of 
approximately 12 months studying the SNS technique. The CRF was then assessed 
by the Senior Investigator (Professor Charles Knowles) and was approved to be 
competent to perform the intervention independently. Similarly a three month 
training period was required for PTNS, after which a certification of proficiency was 











The second section of this chapter covers the material and methods for the 
proposed pilot studies. The three studies were designed to be undertaken 
simultaneously with the two prospective studies using the same cohort of recruited 
patients. Where organisational and recruitment methods are common to all three 
studies, they have been included in the generalised methodology section with 
specific study methods described individually thereafter. 
 
  
2.2 GENERAL TECHNICAL, CLINICAL AND ORGANISATIONAL PRINCIPLES OF SNS 
THERAPY  
 
SNS can be considered as a two stage procedure comprising of a 2-3 week test 
phase known as the PNE followed by the surgical implantation of a permanent 
implantable pulse generator (IPG). The InterStim system Medtronic can be simplified 
into its two main functioning parts: the lead (or wire) and the stimulator, also known 
as the IPG or battery. The lead is percutaneously inserted and positioned in an 
appropriate sacral foramen (usually S3 or S4) to lie adjacent to the sacral nerve. The 
stimulator, lead and nerve form a conducting circuit whereby mild electrical 
impulses generated by the stimulator pass along the lead and stimulate the nerves 
to innervate organs that contribute to bowel function; such as the anus, rectum and 
pelvic floor. Any complications breaking or impeding the continuity of this electrical 
circuit can cause the system to fail; including lead displacement, lead breakage, 






stimulator failure or high resistance caused by excess fibrosis. Hetzer et al. reported 
that the percutaneous  technique, first described by Spinelli and colleagues 184, had 

















Figure 2.01: Temporary peripheral nerve evaluation (PNE) set up with monopolar lead (reproduced 





2.2.1 PATIENT SELECTION AND PRE-OPERATIVE CONSIDERATIONS 
 
Before undertaking SNS, patients should undergo a full assessment of their 
condition including anorectal physiology testing (see section 1.6) 87. Although the 
procedure is not technically complicated, a permanent implant can have a 
significant impact on individual lifestyle. Implanted patients may need to make 
adjustments to their usual routines and therefore need to be counselled of the 
possible restrictions of living with a permanent implant. Although the aim of 
successful control of FI is to allow the patients to regain their "freedom", a 
permanent implant will bring about restrictions similar to those for other implanted 





devices such as cardiac pacemakers. Absolute contraindications to implantation can 
be considered to be: requirements for MRI scanning, participation in contact or 
extreme sports (especially with changes in atmospheric pressure) and pregnancy. 
Other patient considerations include adjustment of air travel routines with 
particular reference to airport security gates: this requires the deactivation of 
implants when going through detectors and informing security staff appropriately. 
In addition invasive medical procedures may need cover with antibiotics.  
 
From our own experience, time set aside from busy clinics prior to surgery, in a 
dedicated counselling session is very worthwhile. Not only does it give healthcare 
professionals the chance to discuss expectations of the treatment but it also allows 
patients to voice concerns over changes which may affect their lifestyle. These in-
depth sessions help patients build a rapport with the SNS team and aim to improve 
post operative compliance. The author echoes the sentiments of other authors 186 
who feel that SNS should be conducted in a suitable multidisciplinary environment 
with specific points of contact within the hospital and access to rapid outpatient 
consultation.    
 
2.2.2 INTRA-OPERATIVE CONSIDERATIONS 
 
The technique of SNS placement can be carried out effectively and safely under both 
general and local anaesthetic with/without sedation 187; however it is important to 






appreciate the variations in equipment and surgical skill required at each stage. Of 
course both stages require careful aseptic technique and correct positioning of the 
lead. This can be achieved at the time of insertion by careful skin marking, optimal 
lead positioning using cross table lateral intra-operative X-rays and acute lead 
testing, ensuring either perineal sensation or anal muscle contraction (Bellow’s 
response) +/- plantar flexion of the ipsilateral great toe is elicited. All muscle 
blocking agents should be avoided at this stage to avoid false negative responses.  
 
 
Figure 2.02: Insertion of tined lead into the S3 foramen (reproduced from http://www.rcsed.ac.uk © 
Medtronic PLC, with permission from Medtronic) 
 
 
To facilitate successful SNS, familiarity with the equipment and careful consideration 
for its organization whilst in theatre is essential. Below is a brief outline of the 
operative steps at each stage. The equipment required and key differences between 
the procedures are outlined in Table 2.01. 






Table 2.01: Key differences in test and permanent SNS techniques 
 
 
 Equipment Intra-operative Consideration General Consideration 




Test Duration Removal 




















r Lead test 
(Stage 1) 
3093-28 - tined 
lead kit 













and 3 post op 
doses 
Required Subcutaneous 
tunnel for lead.  




Up to 6 weeks Operative 




3093-28 - tined 
lead kit 













and 3 post op 
doses 
Required Subcutaneous 
tunnel for lead. 














There are two methods of performing the test phase. The first uses a non-tined 
monopolar lead (3065USC; Medtronic, Minneapolis, Minnesota, USA) and is known 
as the PNE method. At our institution unilateral percutaneous insertion of this lead 
is performed under local anaesthetic with or without sedation. The lead is inserted 
percutaneously through a needle introducer positioned in the appropriate sacral 
foramen. After correct positioning and acute testing, the needle introducer is 
removed leaving the lead in place. Approximately ¾ of the lead remains outside the 
skin. The free end of the lead is connected to an extension wire and earth pad 
secured with dressings. Care must be taken to secure this properly, preventing lead 
displacement for the duration of the PNE period. The extension wire is then 
connected to an external pulse generator (3625; Medtronic) approximately the size 
of a pager; then stimulation is commenced the same day at 14Hz, pulse width 210µs 
for a total of 14 days. The amplitude is controlled at a comfortable sub-sensory level 
by the patient (usually 1-3 mA). Patients assess their own response to PNE through 2 
week bowel diaries and then the lead is removed in the outpatient setting. The 
disadvantage of this technique is that even though a response is found, the carefully 
placed lead has to be removed. If the patient goes on to have a permanent implant, 
a new lead will need to be sited, attempting to replicate the exact position and 
response again. This is not always possible and may be made more difficult by 
scarring around the sacral foramen following the initial procedure. 
 





The alternative test stimulation method uses the tined quadripolar lead (3093-28; 
Medtronic) to perform the chronic test. It is also known as the first stage procedure 
in a 2 staged implantation method. This procedure is slightly more challenging and 
some surgical skill is required for its insertion. The tined lead is designed to be more 
permanent and has little barbs (plastic hooks) on the lead to allow anchoring to the 
sacrum as it passes through the foramen. Before implantation the tined lead is 
soaked in antibiotic solution (4ml of 80mg Gentamicin diluted in a saline solution). 
Insertion of the tined lead is performed under local anaesthetic with sedation. First 
an introducing needle is used to locate the optimum response from the sacral nerve. 
A guide wire then replaces the needle and a rigid dilator and lead introducer is 
inserted over the guide wire into position. It is important to assess the depth of the 
introducer with intra-operative X-ray to ensure safe and accurate positioning of the 
lead. The lead is placed through the introducer and then the introducer is removed 
leaving the tined lead in position. The tined lead is then tunnelled subcutaneously to 
a small pocket created in the ipsilateral buttock. This pocket will house an 
interconnector to an exteriorised wire which will allow connection to an external 
stimulator (3625; Medtronic). With this set up, the testing phase can be lengthened 
to 6 weeks rather than two. 
 
The clear advantages of using the permanent tined quadripolar lead are (1) the 
longer test period gives the patient a more accurate representation of the effect of 
the permanent system and (2) the placement of the lead remains constant. The 





disadvantages are that (1) the tined lead is more expensive then the unipolar lead 
and (2) a small surgical procedure is required to remove the tined lead if 
unsuccessful. Therefore whether an implant is required or not, careful planning and 
co-ordination of available theatre space must be undertaken at 6 weeks to ensure 
that there are no unnecessary delays to the second stage procedure.  
 
Permanent stimulation 
If a monopolar lead test had been carried out previously, unilateral percutaneous 
insertion of a permanent tined quadripolar lead (3093-28; Medtronic) and 
implantable pulse generator (3023; Medtonic) is required. Again the author prefers 
to perform this under local anaesthesia with sedation but this can also be done 
under general anaesthetic. Where possible this should be inserted in the same 
sacral foramen as the temporary lead. The technique for the insertion of the tined 
quadripolar lead is the same as has been described above. After correct insertion 
and positioning of the lead, a subcutaneous tunnel is created allowing the lead to be 
connected to the IPG placed in a subcutaneous pocket in the ipsilateral buttock of 
the implanted electrode. The key to a patient friendly implant is to get the depth of 
the subcutaneous pocket right. Too shallow and it will be uncomfortable for the 
patient, too deep and it will be difficult for the patient to use with their hand held 
controller (3037; Medtronic). It is important to ensure that the lead is tucked deep 
to the implant before closure as this will protect the lead when IPG replacement is 
necessary. 





If the tined lead is already in position then the second stage procedure is even 
simpler. The subcutaneous pocket already fashioned can be re-opened and the 
interconnector located. The interconnector and externalised wire can be removed 
and the free end of the lead can be attached to the IPG. The subcutaneous pocket 
may require widening to house the IPG; at all times care must be taken to protect 
the lead from injury. Once the implant has been inserted, stimulation can be 
commenced the same day using the stimulation parameters mentioned previously. 
At our institution an intra-operative dose Co-Amoxiclav is given at induction with 3 
post operative doses for all permanent implants. Short-term complications include 
bleeding, wound and lead infection. Medium-term complications include sleep 
disturbance, perineal or leg pain, lead displacement or damage 188. The implant 
should not be visible and does not restrict normal activities although rigorous 
activities again should be avoided for the first three to six weeks. 
 
2.2.3 POST-OPERATIVE CONSIDERATIONS 
 
After the patient is suitably alert and recovered on the ward, the initial set up of the 
IPG can be undertaken along with patient programmer training (InterStim Icon 3037, 
Medtronic). In the initial post operative period before natural tissue fibrosis has 
occurred to anchor the lead, it is imperative to ensure that the lead does not 
become displaced. Again the importance of a multidisciplinary team approach 
cannot be overemphasised. The patient should have a point of contact at the unit 





and mechanisms in place to ensure prompt follow up. SNS is still a relatively new 
concept and healthcare services outside specialists unit may be unfamiliar with its 
set up and equipment. Upon discharge we provide our patients with written 
information detailing the restrictions for the immediate post operative period and 
contact details for our unit. Post operatively we follow up our patients at 6 weeks 
and then at suitable regular intervals. At these appointments it is important to 
review the stimulator and electrode settings. It is often necessary to adjust 
electrode settings more frequently in the early stages of the therapy to ensure that 
optimum stimulation parameters are achieved. The IPG is equipped with a battery 
which discharges with time, lasting approximately seven years.  At the end of the 
batteries life, a small operation is required to replace the IPG. 
 
 
2.3 GENERAL TECHNICAL, CLINICAL AND ORGANISATIONAL PRINCIPLES OF PTNS 
THERAPY  
 
Since 2005, Uroplasty has marketed the Urgent ® PC Neuromodulation System, the 
only presently available commercial device to deliver PTNS (Uroplasty Ltd., 
Manchester, UK) 178, 179, 189. The system comes in two parts: a single use disposable 
pack of two needle electrodes and a lead wire set (UPC250), and the reusable 
battery operated Urgent PC stimulator (UPC200).  





Unlike SNS no surgical skill is required for performing this procedure and the 
technique itself is easy to learn. The patient is seen in an Outpatient clinic room, 
ideally sitting up on a comfortable examination couch. Either leg can be used for the 
procedure and preference is usually left up to the patient. Shoes and socks of the 
preferred foot are removed and the trouser leg rolled up to approximately mid calf. 
The site of needle insertion is identified at a location on the lower inner aspect of 
the patient's leg, three finger breaths (5 cm) cephalad to the medial malleolus and 
one fingerbreadth (2 cm) posterior to the tibia. The area is cleaned with ethanol and 
the needle electrode-guide tube assembly is placed over the identified insertion site 
at a 60-degree angle between electrode and ankle. The fine 34 gauge needle 
electrode is gently tapped to pierce the skin and then advanced using a rotating 
motion approximately 2cm. The lead wire is connected to the needle and the 
calcaneal reference electrode placed on the ipsilateral calcaneum. The lead wire is 
then connected to the Urgent PC stimulator. The PTNS stimulator (UPC200) is an 
external pulse generator that provides visual and auditory feedback. It has an 
adjustable current setting from 0-9mA in pre-set 0.5mA increments, a fixed-pulse 
frequency of 20Hz and a pulse width of 200 microseconds. The setting for therapy is 
determined by increasing the current whilst observing the patient response. 
Stimulation of the tibial nerve produces a motor (plantar flexion or fanning of the 
toes) and/or sensory (tingling in the ankle, foot or toes) response. Once the 
appropriate level for therapy is found, the 30-minute treatment is started. Therapy 
is given for a period of 12 weeks, in weekly 30-minute sessions, although others 





have used alternative treatment protocols. Following the 12 initial weekly 
treatments, some patients may need intermittent ‘top-up’ sessions. At our 
institution 3 top-up sessions are given at 2 weeks, 4 weeks and 8 weeks after the 
completion of the initial 12 weekly sessions. Further top-up sessions may be offered 











Figure 2.03: Urgent PC system (reproduced from www.uroplasty.com © Uroplasty PLC, with 




2.4 GENERAL PROJECT MANAGEMENT 
 
All three studies were performed in conjunction with the ‘Pragmatic Clinical Trials 
Unit’ (PCTU). This unit, situated within the Centre for Health Science at QMUL, leads 
and supports clinical trials when the primary question of interest relates to 
intervention effectiveness i.e. whether complex interventions work under real-life 
conditions.  





2.4.1 MANAGEMENT STRUCTURE 
 
The project was overseen by a Study Steering Group (SSG). 
The SSG met/teleconferenced, on a quarterly basis throughout the project. The 
remit of the SSG was to ensure: 
1) That views of users and carers are always taken into consideration 
2) The scientific rigour of the study 
3) That project milestones are met 
4) Expertise / advice are provided to the Project Management Group (PMG) 
 
2.4.2 MEMBERSHIP OF THE STUDY STEERING GROUP 
 
The applicants, 2 user group representatives, the Executive Director of Bladder and 
Bowel Foundation, Health Economist, Senior Clinical Physiologist and 2 peer experts 
in this field: internal: Mr Peter Lunniss, Consultant Colorectal Surgeon (Barts and 
Royal London) and external: Dr Anton Emmanuel, Consultant Gastroenterologist 
with interest in neuromodulation (University College, London). 
 
A PMG was responsible for the day to day project delivery. It met fortnightly and 
included the Senior Investigator (Professor Knowles), Research Nurse (RN), CRF, 
study nursing leads and a Project Finance Officer from the joint (Trust and Medical 





College) R&D Office. This group was informed by the SSG. The group was responsible 
for overseeing and managing: 
1. trial recruitment and retention rates 
2. site initiation, training, monitoring, compliance and correction/preventative 
actions 
3. data management (collection, quality control, entry and query management) 
4. adverse and serious adverse event (SAE) reporting 
5. study milestones 
6. study reporting 
7. budget expenditure and accruals 
 
A Patient Advisory Group was also established to advise the SSG and the PMG via 
representation (2 nominated members) at meetings. The project acted under the 
auspices of the PCTU.  
 
 
2.5 RESEARCH PLAN 
 
The research plan comprised of six work packages (WP) 
 
WP1: Ethical permission was attained prior to the study start date. The research 
team undertook final public consultation  and research governance checks. The PMG 
and SSGs were convened. 
 





WP2: Training (0-6 months): The CRF received formal training in qualitative 
methodologies by attending a short course run by Aston University, Birmingham. 
The CRF was also trained to perform both SNS and PTNS treatments. The CRF  had 
already been training to perform SNS 6 months before the start of the project. The 
RN was trained in all other outcome assessment tools (and in aspects related to 
maintaining blinding). 
 
WP3: Trial roll out (7-31 months). During this phase of the study, the clinical trial 
was formally opened and conducted by the CRF. Active recruitment of patients for a 
9-10 month period (months 7-17) with interventions thence administered by 
specialist surgical and nursing staff. All treatments were conducted over a 12 month 
duration and were completed by end of month 22. Blinded data acquisition was 
undertaken by the RN for all quantitative outcome measures. Qualitative interviews 
were undertaken by the research assistant and analysed iteratively by the CRF. This 
period of follow up finished at end month 28 with a minimum of 6 months follow up 
after completion of either treatment arm. Regular 2 weekly meetings by the were 
conducted by the PMG to continue to guide and when necessary make 
modifications to the protocol detail as well as to monitor satisfactory recruitment 
targets. On-going discussions with trial participants and their carers allowed a 
feedforward analysis throughout the trial. 
    
Milestones were: start month 6 - first recruitment, end month 17 - last recruitment, 
end month 23 - end last treatment, end month 28 - last FU visit. 
 
WP4: Data analysis and start of process of dissemination. During this phase of the 
study, the research team commenced the task of data analysis. Qualitative 
(unblinded) data analysis had a rolling process of analysis from 24 month. In 
conjunction with the trial statistician, quantitative data was cleaned and locked after 
3 and 6 months follow ups, with the randomisation coding only broken after month 





30, and all outcomes analysed. The data was disseminated after end month 36 by 
national and international presentation as well as by publication [British Journal of 
Surgery].  
 
WP5: Project management (0-36 months). This was a continuous phase of 
managerial meetings to ensure quality control. 
 
WP6: Systematic Review (0-36 months). This was a continuous background activity 
along with the prospective studies. The review was devised to provide background 
supportive evidence on both treatment modalities on an intetion-to-treat basis. To 












 09 2010 2011 2012 
Month D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
STAFFING             
RN                                     
CRF                                     
S&HE                                     
WP1 TRIAL FINALISATION             
Public 
consult 
                                    
Convene SSG                                     
WP2 TRAINING             
RN                                     
CRF                                     
WP3 TRIAL ROLL OUT & QUALITATIVE  STUDY              
Recruitment                                     
Random-
isation 
                                    
Interventions                                     
Follow up                                     









Abbreviations: RN = Research Nurse, CRF = Clinical Research Fellow, S&HE = Statistician & Health Economist, WP = work package, PMG = project management group, SSG = 
study steering group, Qualitative = qualitative interviews and analysis 
 
 
 09 2010 2011 2012 
Month D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
WP4 DATA ANALYSIS AND START DISSEMINATION 
Qualitative 
analysis 
                                    
Clean / lock 
down 3/12  
                                    
Clean / lock 
down 6/12 
                                    
Code break & 
analysis 
                                    
Plan 
dissemination 
                                    
WP5 PROJECT MANAGEMENT 
PMG 
meetings 
                                    
SSG meetings                                     
WP6 SYSTEMATIC REVIEW 
CRF                                     





2.6 DATA MANAGEMENT  
 
The PCTU data manager designed a secure database for entering, storing and 
transferring all pertinent patient data. Automated validation checks were carried 
out at the point of data entry. Data entry and cleaning was done by the researchers 
and further checks performed on receipt by the study statistician. The database was 
locked for analysis once the data manager and statisticians were satisfied with the 
quality and completeness. 
 
 
2.7 PROJECT FUNDING 
 
This exploratory project was funded by a £160,000 Research for Patient Benefit 
Programme grant awarded in open competition from the National Institute of 
Health Research (ref: PB-PG-0909-20150). Queen Mary University of London acted 
as study sponsor. Neither relevant commercial organization (Medtronic Inc. or 
Uroplasty) had any role in the design, conduct or analysis of the trial. 
 
 






2.8 SPECIFIC STUDY METHODS 
 
2.8.1 A REVIEW OF CLINICAL EFFECTIVENESS OF NEUROMODULATION IN FAECAL 
INCONTINENCE 
 
A systematic review was performed, adhering as closely as possible to the PRISMA 
190 framework, which provides clear guidance on the methodology by which 
empirical evidence should be collated, therefore minimising bias and providing for 
reliable conclusions. 
 
2.8.1.1  Protocol development 
 
Two primary investigators (CRF and another independent researcher) and Senior 
Investigator (Professor Knowles) developed the protocol for review, detailing pre-
specified methods of the analysis and eligibility for the study. Final decisions upon 












2.8.1.2  Inclusion criteria 
 
Report eligibility  
All published studies reporting results of permanent SNS, PTNS and other NM 
therapies from January 1995 until July 2012 were eligible for inclusion. Non-English 
language papers were excluded unless they contained an abstract in English 
providing sufficient information to meet inclusion criteria. It was stipulated that 
each study must provide data for at least 10 patients treated with permanent SNS or 
other NM therapy. Only reports which (a) clearly documented the number of 
patients having permanent SNS or other NM therapy performed (b) reported at 
least one chosen outcome measure (baseline and post intervention) and (c) 
recorded a clear follow up period were eligible for inclusion.  Studies reporting solely 
on the PNE and chronic testing phase of SNS were excluded. 
 
Participants 
No exclusions were placed upon study centre or patients regarding age, gender, 
ethnicity or aetiology of FI.  
 
 Interventions 
All eligible studies required a definitive intervention by permanent SNS, PTNS or 
other NM technique in patients with FI. Reports which included a NM therapy 






together with a concurrent operative procedure for FI were excluded as were 
reports of NM therapies for primary urinary symptoms. 
 
Outcomes 
The chosen primary outcome was "success rate" of therapy based on a ≥50% 
improvement in FI episodes. Secondary outcomes were: (a) cure rates of the therapy 
i.e. 100% reduction in FI episodes (b) improvement of CCIS 191 (c) ordinal reductions 
in faecal incontinence episodes (FIE) per week; (d) other success measures of 
incontinence based on individual symptoms or scores and (e) QoL measures (generic 
and condition-specific). Outcome measures have been presented according to the 
median length of follow-up of the study data: short-term (0-12 months), medium-
term (>12-36 months) and long-term (>36 months).   
 
Study selection 
Eligibility assessment was performed independently by three review authors, in an 
un-blinded but standardised manner. Methodological quality of included studies 
was assessed independently using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) assessment criteria. Disagreement between 
reviewers was resolved by consensus and by the Senior Investigator. The CRF and 
other research investigator independently undertook data extraction. Exact 
duplicate data sets generated from the same cohort of patients were excluded.  In 
instances of doubt, authors from the relevant institutions were contacted to confirm 





or refute any repetition of results. Because SNS and other NM therapies have in 
general been performed in specialist centres, it is accepted that results may have 
been published at more than one time point as experience developed. Inevitably 
there may be some longitudinal overlap in patient data sets, but in keeping with 
previous reviews 188 such data were not excluded. This represents a necessary trade-
off between the benefit of greater numbers (of patients and studies) and length of 
follow-up against the significant likelihood that some of the data will be a 
continuation of those previous published (this has been highlighted in tables where 
the numbers of such patients were documented). 
 
Search 
For SNS studies, two authors individually carried out comprehensive searches of the 
literature in July 2012 using PubMed, Medline, Embase and Evidence Based 
Medicine reviews (including the Cochrane database of systematic reviews and the 
Cochrane central register of controlled trials). Full-text copies of all studies deemed 
to be potentially relevant were obtained and assessed for inclusion. Where papers 
cited other potentially important references, these were assessed. For other NM 
studies two authors individually carried out comprehensive searches in July 2012. 
Systematic reviews, randomised controlled trials, controlled clinical trials, 
comparative observational studies, population-based registry studies, case series, 
case reports and narrative reviews on patients with FI who had received NM were 






extracted and then hand searched for relevant data sets. The reviewers were not 
blinded to the names of studies, authors, institutions or publications.  
 
For SNS data the initial search terms used were 'sacral nerve stimulation faecal 
incontinence' and 'sacral neuromodulation faecal incontinence ("sacrum"[MeSH 
Terms] OR "sacrum"[All Fields] OR "sacral"[All Fields]) AND nerve [All Fields] AND 
stimulation [All Fields] AND ("faecal incontinence"[All Fields] OR "fecal 
incontinence"[MeSH Terms] OR ("fecal"[All Fields] AND "incontinence"[All Fields]) 
OR "fecal incontinence"[All Fields]). Search results were hand searched and cross 
referenced with bibliographies of relevant papers. One author was contacted and 
further clarification on the data was provided. For PTNS and other NM techniques, 
search terms 'percutaneous tibial nerve stimulation', 'percutaneous tibial nerve 
neuromodulation', 'posterior tibial nerve stimulation', 'posterior tibial nerve 
neuromodulation'. Further search terms for other NM strategies, 'Tibial Nerve 
Stimulation', 'percutaneous', 'transcutaneous', 'electrical', 'neuromodulation', 'faecal 
incontinence', 'fecal incontinence', and 'anal incontinence', were used.  
 
Risk of bias 
It is acknowledged that by limiting the inclusion criteria to English series with only 
greater than 10 patients, selection bias may have been introduced. This search 
strategy however ensured that individual case reports and smaller series would not 





bias the results towards specific patient sub-populations or to investigators with 
limited experience.   
 
Summary measures and analysis 
Meta-analysis of data was not deemed appropriate because of heterogeneity 
between study designs and outcome measures and the absence of any genuine 
comparator for nearly all studies (the only published meta-analysis of SNS used 
baseline values as a comparator denoting these as maximum conservative therapy 
192). Summary measures (for individual outcome variables across roughly 




2.8.2 RANDOMISED PILOT TRIAL OF SACRAL AND PERCUTANEOUS TIBIAL NERVE 
STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
The study was designed as a 24 month, mixed methods project involving two 
studies: (1) a pilot randomised single-blinded, external 193, comparison trial of SNS 
and PTNS and (2) a qualitative study of patients' experiences and preferences 










2.8.2.1  Setting and patients 
 
The study was undertaken across 2 sites with recruitment over 12 months of 
patients attending the Royal London Hospital (Barts Health) and University College 
Hospital - London (UCLH) NHS trusts for specialist investigation and treatment for FI. 
Ethics approval was granted by King’s College Hospital Research Ethics Committee 
(Dulwich): NREC REF: 10/H0808/38 with local approvals at participating hospitals. 
The trial was registered on the UK clinical research network portfolio database 
(UKCRN ID: 10479 and European Clinical Trials Database (EduraCT) number: 2010-
018728-15). Patients were eligible for inclusion based on meeting NICE criteria 87 for 
symptom severity and failure of prior conservative therapy; patients with specific 
contraindications to either therapy were excluded [Table 2.03]. All patients had 
NICE-recommended appropriate specialist investigations including structural and 
functional anorectal assessments 87. Baseline data and eligibility were assessed and 
informed consent obtained at a clinical visit 2-4 weeks before treatments were 
assigned. All patients participating in the trial had funding approved for SNS from 
their Primary Care Trusts before randomisation. 
 





Table 2.03: Inclusion and exclusion criteria 
Inclusion  Exclusion 
Aged > 18 years Inability to provide informed consent for the research study 
Meets NICE criteria for SNS 
treatment (2007) 
Severe concomitant medical conditions precluding randomization 
to operative treatment 
(Faecal incontinence 
sufficiently severe to warrent 
investigation and failure of all  
Neurological diseases, such as diabetic neuropathy, multiple 
sclerosis and progressing Parkinson's disease  
appropriate conservative 
measures) 
Other medical conditions precluding stimulation: e.g. bleeding 
disorders, certain cardiac pacemakers, peripheral vascular disease  
 Congenital anorectal anomalies or absence of native rectum due to 
surgery  
 Present evidence of external full thickness rectal prolapse  
 Previous rectal surgery (rectopexy / resection) < 12 months ago (24 
months for cancer) 
 Stoma in situ  
 Chronic bowel diseases such as inflammatory bowel disease, 
chronic uncontrolled diarrhoea 
 Anatomical limitations that would prevent successful placement of 
electrodes  
 Pregnancy or intention to become pregnant 
 Previous experience of SNS or PTNS 
 






Figure 2.04: Study design flow chart  
 





2.8.2.2  Interventions 
 
Sacral Nerve Stimulation (SNS) 
SNS was performed by the standard two stage approach 164 as detailed earlier in this 
chapter (section 2.2). For test stimulation, unilateral percutaneous insertion of a 
stimulating electrode (3065USC; Medtronic, Minneapolis, Minnesota, USA) into the 
sacral foramen was performed under local or occasionally (n=2) general anaesthesia. 
The unipolar PNE was used over the 2 stage quadripolar testing technique 
previously mentioned because (a) funding for each SNS treatment was easier to 
attain for PNE with a unipolar lead as  the equipment was cheaper, (b) the unipolar 
technique was more established at the time of study and therefore easier to 
standardise across all units, (c) any externalised quadripolar leads require operative 
removal/IPG insertion within 6 weeks to minimise the infection risks. Pragmatically 
theatre sessions dedicated to SNS were limited and this could not be guaranteed at 
the investigator's institution. 
 
Stimulation was then commenced the same day at 14 Hz and at a pulse width of 210 
µs for a total of 14 days using an external pulse generator (3625; Medtronic). 
Amplitude was controlled at a comfortable sensory level by the patient (1-3mA). 
Patients progressed to permanent stimulation if a ≥50% decrease in FI episodes was 
determined on 2 week bowel diary review 164. Permanent stimulation used 
unilateral percutaneous insertion of a permanent tined lead (3093-28; Medtronic) 






and implantable pulse generator (3058; Medtronic) under general or local 
anaesthesia, and where possible on the same side as temporary stimulation. 
Stimulation was commenced the same or following day using similar stimulation 
parameters as those described above. Meticulous attention was made to asepsis 
throughout, and Co-Amoxiclav given for 3 post-operative doses 194.  
 
Percutaneous Tibial Nerve Stimulation (PTNS) 
PTNS was administered  by a  nurse consultant with the assistance of the CRF using 
the Urgent® PC neuromodulation system (Uroplasty, Minneapolis, USA) 195. The 
patient was positioned in a comfortable supine or sitting position on an outpatient 
couch and the procedure performed as described in detail previously in this chapter 
(section 2.3) 196. If the patient had no preference, the right ankle was usually used 
for ease of ergonomic insertion (positioned on a couch with left side of patient 
adjacent to the wall). Amplitude of stimulation was determined by increasing the 
current slowly whilst observing the participant’s sensory (appropriate response 
being in great toe or sole of foot) or motor response (plantar-flexion of foot or great 
toe). Current was then reduced by one level for therapy, and continued for 30 
minutes. Stimulation parameters were set to pulse width 200s, frequency of 20Hz 
and average treatment amplitude was 7mA (range 1-10). Treatment was repeated 
for 12 initial sessions within 3 months with an interval tolerance of 1 week. Three 
maintenance treatments were then given to all patients over a 2 month period i.e. 
in total, patients received 15 sessions over a 5 month period. 





2.8.2.3 Preliminary data 
 
Prior to the study commencing, audited data showed 51 patients completing the 
treatment cycle of SNS at Barts and The London with median follow up of 14 
months. The treatment cycle consisted of patients having temporary stimulation for 
2 weeks with an intention to proceed to permanent stimulation. 37 patients 
proceeded to have permanent stimulation. The dropout rate from failures of 
temporary stimulation was estimated at 27% (n = 14) and patient choice 10% (n = 
10). In the trial the SNS group was therefore over recruited to account for the 
substantial temporary test failure rate and therefore dropout rate. 
 
Similar departmental data from 42 patients was also analysed from those 
completing PTNS with a median of 5 months follow up at Barts and The London 
suggested a success rate at of 27/42 = 64% with no complications. Dropout rates 
from treatment were only 5%.  
 
2.8.2.4  Sample size calculation and feasibility 
 
Formal sample size calculations for a fully powered RCT revealed that >2000 patients 
would be required to detect a difference in proportions of at least 5%. Since such a 
study would prove impracticable even on a multicentre basis (a realistic figure for a 
multi-centre trial would be nearer 200 patients), this pilot was needed to determine 






the variability and distribution of a variety of quantitative endpoints as well as 
qualitative data to inform the most suitable/responsive outcome measures for a 
subsequent well designed and sufficiently powered RCT. If, accepting the difficulties 
of design and conduct, a full equivalence trial were planned, the equivalence 
margins could be determined from the results of the trial. 
 
Based on the experience and throughput of the unit, approximately 45 patients 
were broadly eligible for recruitment over a 9 month period [Department data 9 
month period 2008: n = 22 permanent SNS and n = 30 PTNS]. Therefore, allowing for 
refusal/specific exclusions, a total starting sample size of 40 was feasible for the 9 
month recruitment period. The randomisation allowed for a 25% failure rate of 
temporary stimulation. Despite our previous experience of very high compliance for 
both treatments (near 100%) the study also allowed for an overall additional 
dropout rate off 10% for both interventions during treatment or follow-up. This 
yielded an estimated final figure of 15-16 patients for each group with complete 












2.8.2.5  Randomisation, allocation and blinding 
 
Eligible patients were allocated to receive either SNS or PTNS by restricted 
randomisation. Minimisation by sex and by symptom severity [2 groups: 1-6 and 6+ 
FIE per week] was used to balance the groups on these potential confounding 
factors. The figure of 6 FIE per week was chosen as an arbitrary figure locally agreed 
by the steering group that denoted severe FI if >6 episodes (i.e. daily episodes) were 
determined on initial questioning. A pre-determined allocation ratio allowed for a 
greater number of patients in the SNS group (n = 23 vs. 17 in PTNS group) to negate 
the established failure rate (approximately 25%) at the temporary SNS evaluation 
stage in order to have approximately equal numbers of patients having a full course 
of treatments. The randomisation sequence was generated remotely by a 
statistician uninvolved in recruitment and requests were made and actioned by 
email. A dedicated member of the study team (research nurse) recruited 
participants, collected all baseline and follow up data, and (the research nurse) 
remained blind to patients’ allocation throughout the study. This allowed the direct 
clinical care of the patients to be undertaken by the research fellow, who remained 











2.8.2.6  Outcome measures 
 
Clinical outcomes 
The following assessments were undertaken 2-4 weeks pre-intervention, and at 3 
and 6 months post-intervention completion (copies of these questionnaires can be 
found in Appendix i.):  
a) FIE per week: 2 week bowel diaries recorded number and type of incontinence 
episodes per week (and associated symptoms). These have formed the basis of 
the established 166 definition of ‘success’ in previous studies: ≥ 50% reduction in 
FIE per week 197. 
b) validated and reliable patient-rated quantitative outcomes including symptom 
severity score (CCIS) 191, validated disease-specific: American Society of Colon 
and Rectal Surgeons Faecal Incontinence Quality of Life (FIQL) 82 and generic: 
Social Function 36 (SF-36) 198 and EQ-5D 199 quality of life measures. 
c) novel patient centred outcome measure (PCOM) developed specifically for this 
study. This outcome measure consists of one specific question about the 
effectiveness of current treatment and a further five questions regarding the 
general effects of FI on patient wellbeing. 
 
Cost utility data 
Economic evaluation methods adhered, as far as possible, to the NICE Guide to the 
Methods of Technology Appraisal 2013 200. The costs of the SNS and PTNS 





treatments included both the cost of the respective intervention and the cost of 
healthcare services and medication. A micro-costing of the intervention included a 
bottom-up construction of the costs associated with delivering SNS and PTNS in the 
NHS setting. These included SNS and PTNS equipment, consultations, physiology 
testing and investigations, counselling, pre-assessment for operation, SNS and PTNS 
procedures, post-operative medication, re-programming of the pulse generator and 
post-operative checks. Data on the use of healthcare services and medication by 
participants over the past three months was extracted from participants' 
questionnaires. These included: number of contacts with GP, nurse and consultants 
(including telephone consultations), outpatient attendances, inpatient stays and 
A&E admissions. Questions were also asked about the use of pre-specified 
medication for managing incontinence and gastrointestinal disorders. Individual-
level resource use data were combined with unit costs to calculate the total cost of 
healthcare service use for each participant. Primary care unit costs were taken from 
the UK Unit Costs of Health and Social Care, PSSRU 2012 201. The unit costs for 
secondary care were based on the National Schedule of Reference Costs 2011-2012 
202. The unit costs for medications were obtained from the British National 
Formulary 203, 204. 
 






2.8.2.7 Statistical analysis 
 
Sample size considerations 
A sample size of 40 was selected based on recruitment feasibility over a 12 month 
period (no sample size calculation was performed in keeping with pilot study). The 
randomisation schedule allowed for a 25% failure rate of temporary SNS stimulation 
and a drop-out rate of 10% from either intervention. Thus recruitment of 23 
patients for SNS and 17 for PTNS would yield a final figure of 15-16 patients for each 
group potentially having complete data for analysis of effects of chronic stimulation.  
 
Quantitative clinical outcome data 
Data were summarised to provide estimates of the variability of outcomes. We also 
estimated within group effects, and 95% confidence intervals, rather than between 
group effects as the two treatments were expected to be similar to each other. 
Statistical hypothesis testing was not carried out, following principles of pilot studies 
193, and no formal comparison of interventions was undertaken. All available cases 
were analysed in the groups to which they were randomised without imputation of 
missing data. A per protocol analysis was also performed for SNS patients 
considering only those patients receiving complete protocol of therapy i.e. 
progression to permanent implantation. 
 
 





Health economics analysis 
We considered that the economic analysis, like the other clinical outcomes in this 
pilot, was not designed to find a definitive answer. In keeping with the exploratory 
nature of the study, a cost utility analysis only was undertaken with no intention of 
directly comparing cost effectiveness.  Instead estimates of costs could be used to 
inform a future trial design. In this pilot study, we collected all micro costings to aid 
calculation of an economic analysis on an "all-available-cases" basis. A sensitivity 
analysis was conducted to address uncertainties and to provide upper and lower 
limits of costs.  
 
 
2.8.3 QUALITATIVE INTERVIEW STUDY OF SACRAL AND PERCUTANEOUS TIBIAL 
NERVE STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
2.8.3.1  Consent 
 
Because of the sensitive and personal nature of the interviews, patients who wanted 
to participate were consented separately for the qualitative study. 
 
2.8.3.2  Sampling 
 
We aimed to reflect the diversity within the population with FI 205. We used 
purposive (theoretical) 206 sampling with interest to include “outliers” conventionally 






discounted in quantitative approaches 207. The two equivalent groups were: those 
undergoing SNS and another undergoing PTNS. We examined the comparable 
groups following the principles of purposive homogeneous sampling 208. For each 
treatment arm we found a small group of patients (5 in each group, total number of 
10) who were willing to undertake interviews. 
 
2.8.3.3  Interviews 
 
Semi-structured in-depth interviews were conducted as an exploration of the 
patient’s personal experience of their treatment (SNS or PTNS). A topic guide using a 
set of pre-determined open-ended questions was developed and used to provide 
some structure to the interviews. With this framework, the interviews aimed to 
collect appropriate data whilst retaining the flexibility to allow patients to speak 
freely about their experiences. Each interview was approximately one hour long, 
was digitally recorded throughout and undertaken by a trained independent 
research assistant.  
 
2.8.3.4  Data collection 
 
The goal of data collection was to engage in conversational dialogue until the 
experience was fully depicted; this process is described as listening fully in the 
moment 182, 209. All interviews were undertaken over a period of 24 months. To 





capture a wealth of experiences at different stages of each therapy, the patients 
were analysed as a case series with each interview conducted at an interval at least 
three months after the treatment had been completed. 
 
2.8.3.5  Pilot interview study and topic guide development 
 
The development of our topic guide was informed by existing literature and our 
patient advisors. The questions were non-directive, open-ended, and designed to 
encourage participants to express themselves without feeling constrained. The topic 
guide was developed by the CRF and the research assistant. Before interviews on 
patients were carried out, a single pilot interview was conducted using the topic 
guide on a volunteer from our patient advisory group with experience of SNS at the 
Royal London Hospital. The pilot interview was critically appraised for content by the 
CRF, research assistant and Senior Supervisor (Professor Taylor) to ensure the style 
and depth of the interview was appropriate. After refinement of the interview topic 
guide the interviews were conducted on the 10 recruited participants. The data 












2.8.3.6  Data analysis 
 
Through in depth analysis of the transcripts, the CRF examined the patent’s 
experiences in a high level of detail collating the rich source of data (all annotated 
transcripts can be found in appendix ii [CD included]). The analysis using a thematic 
content analysis methodology was conducted iteratively 182. This study was 
constructed from the outset to be partly phenomenological and heavily idiographic 
collecting the data from a relatively small number of subjects rather than surveying 
a large sample. Because the CRF identified closely with the stories being told by 
participants, immersion in the data was facilitated 210. Thematic Content Analysis 
involved identifying themes and categories that ‘emerged from the data’. This 
involved discovering themes in the interview transcripts and attempting to verify, 
confirm and qualify them by searching through the data and repeating the process 
to identify further themes and categories 211. A process of open coding followed by 
grouping of categories was undertaken. Words and phrases used by participants 
were coded according to meaning and these concepts were then grouped into 
categories based on shared characteristics. Themes were identified by examining 
and grouping these categories. Once the themes and categories were identified, the 
data was again examined and further categories and themes searched for. From 
these categories emergent sub-ordinate and super-ordinate themes were identified 
and described 182.  
 





2.8.3.7  Validation 
 
The interviews themselves were carried out by an independent fully trained 
researcher who was not involved in the clinical treatment of the participants. This 
ensured that the information given by the interviewee was completely voluntary 
and impartial. To validate the interview analysis, we used multiple coding for each 
theme and a process of inter-rater reliability 206. Cross checking of coding strategies 
and interpretation of data was independently undertaken by both the CRF and RN in 
a random sample of three transcripts. Furthermore the RN analysis found them to 
be accurate reflections of the original digital recordings and confirmed the themes 
to be credible and faithful descriptions as interpreted from the transcripts. A 
meeting between the CRF, RN and Senior Supervisor Professor Taylor reviewed the 
three triangulated transcripts discussing themes and coding. Any significant 
disagreements between the CRF or RN's subjective coding was resolved by the 
Senior Supervisor's (Professor Taylor) decision. The rest of the transcripts were 
solely coded by the CRF and analysis reviewed by the Senior Supervisor. 











3.1 A REVIEW OF CLINICAL EFFECTIVENESS OF NEUROMODULATION IN FAECAL 
INCONTINENCE  
 
For SNS, 321 citations were identified on the basis of initial electronic search terms 
and eligibility criteria, of which 214 were selected for retrieval for detailed 
evaluation [Figure 3.01]. Ten articles did not have abstracts to view; their full texts 
were reviewed and the articles excluded for not meeting the inclusion criteria. After 
detailed evaluation of all remaining 204 abstracts, 132 more citations were 
excluded. The reasons for exclusion are shown in Figure 3.01. Seventy-two full text 
articles were assessed in detail and a further 11 studies were also excluded. The 
reasons for these exclusions were: one study used mixed urinary and faecal 
incontinence indications for implantation 212,  one study did not have original clinical 
outcome data 213,  2 studies had PNE data only 214, 215, 3 studies had no documented 
baseline of the chosen outcome measures 216-218, 2 studies had no follow up terms 
documented 219, 220,  1 study did not clearly document the results of the chosen 
outcome measures 221 and 1 study was excluded 170 as it exactly duplicated the data 
set of another included study 169; further clarification was not possible. This left 61 









order to present data on ITT analysis, we separated studies into (a) those including 
all consecutive patients (including failures) attempting PNE [Table 3.01a] from (b) 
those who only reported outcomes of positively responding patients to the test 
phase [Table 3.01b]. Patients who were still awaiting permanent implantation 
despite a successful PNE were excluded from the analysis. The initial electronic 
search for PTNS and TTNS revealed 22 relevant citations of which 11 remained when 
eligibility criteria were applied [Figure 3.02]. Of these, 7 studied PTNS and 4 TTNS.  
 
 
3.1.1 SUMMARY OF STUDY CHARACTERISTICS [TABLE 3.01a, 3.01b AND 3.02] 
 
Of 61 SNS studies reviewed, the majority (50 studies) were prospective case series. 
Only two randomised controlled trials were eligible for inclusion 168, 169. Each study 
was graded for its quality of evidence upon guidance set out by the Oxford Centre of 
Evidence–based Medicine 222. The majority (N=55) of the studies were evaluated as 
only level 4 evidence [Table 3.01a and 3.01b]. The combined median follow up 
duration of all SNS studies was 24 months, with a median of 77% (40-100) 
implantation rate from PNE to permanent stimulators.   
 
Of 7 PTNS case series, 6 were prospective and one retrospective [Table 3.02]. A total 
of 216 patients (181 female) were studied with a median duration of treatment of 3 
months (range 1-11 months). Follow-up ranged from 0 to 29 months after 






treatment. The 4 included TTNS studies 180, 223-225 were prospective case series with a 
total of 78 patients (median 18, range 10-32). Their treatment durations were 3 
months in three studies and 6 months in one, with follow-up ranging from 0 to 15 
months post treatment. 
 
Figure 3.01: SNS PRISMA flow diagram
142 excluded: 
 
10 = full texts without abstracts excluded 
41 = no original data (reviews, comments, editorials) 
21  = data on <10 perm implants 
21  = data outcomes measures not appropriate 
20 = non English + insufficient abstract 
9 = PNE test data only  
7 = SNS as secondary operative  procedure 
5 = mixed urinary and FI indication 
3 = urological data only 
3 = paediatric data only 
2 = non human data 
11 excluded: 
 
3 = no baseline data 
2 = PNE data only 
2 = no FU terms reported 
1 = exact duplicate data series 
1 = mixed urinary and faecal incontinence 
1 = not meet inclusion criteria 
1  = no original outcome data 
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Table 3.01a: SNS study characteristic (all undertaking PNE) 








PNE (n) Perm 
SNS (n) 
% of Perm 
implants 
Rosen H  226 2001 SC PCS 4 15 20 16 80 
Kenefick N  227 2002 SC PCS 4 24 15 15 100 
Altomare D  228 2004 SC PCS 4 14 40 16 40 
Jarrett M  229 2004 MC (3) PCS 4 12 59 46 78 
Matzel KE  230 2004 MC (8) PCS 4 24* 37 34 92 
Rasmussen O  231 2004 SC PCS 4 6 45 37 82 
Uludag O  232 2004 SC PCS 4 12 63  50 79 
Hetzer FH  185 2005 SC PCS 4 13 20 13 65 
Jarrett M  233 2005 SC PCS 4 12 13 12 92 
Faucheron J  234 2006 SC PCS 4 6† 40 29 73 
Kenefick N  235 2006 SC PCS 4 24 19‡ 19 100 
Gourcerol G  236 2007 SC PCS 4 12 61 33 54 
Hetzer FH  237 2007 SC PCS 4 13 44 37 84 
Holzer B  238 2007 SC PCS 4 35 36§ 28 77 
Melenhorst J  239 2007 SC PCS 4 26* 134\\ 100 75 
Navarro J  240 2007 SC PCS 4 12† 26 24 92 
Dudding T  241 2008 SC PCS 4 24 60  51 85 








Munoz-Duyos A 243 2008 SC PCS 4 35 43  29 67 
Stelzner S 244 2008 SC PCS 4 10 20 13 65 
Tjandra J  169 2008 SC RCT 1b 12† 60 53 88 
Altomare D  245 2009 SC PCS 4 74 * 94 60 64 
Boyle DJ 246 2009 SC PCS 4 6† 15 13 87 
Govaert B 247 2009 ns PCS 4 31* 208 145 70 
Govaert B 248 2009 SC RCS 4 35 * 245 173 71 
Vallet C  249 2009 SC PCS 4 37 * 45 32 71 
Faucheron J  250 2010 SC PCS 4 45 123 87 71 
Hollingshead J 251 2010 SC PCS 4 22 113 86 76 
Koch SM  252 2010 MC (16) PCS 4 24 * 35 19 54 
Michelsen HB  253 2010 SC PCS 4 24 167¶ 126 75 
Oom D  254 2010 SC PCS 4 32 46 37 80 
Sharpe A  255 2010 SC PCS 4 50 54 44 79 
Wexner SD  256 2010 MC (6) PCS 4 28* 133** 120 90 
George AT 257 2011 SC PCS 4 44 30 23 77 
Lim JT 258 2011 SC PCS 4 51* 80†† 53 66 
Leroi AM  259 2011 MC (20) PCS 4 24† 94 60 64 
Maeda Y 260 2011 SC RCS 4 33 245 176 72 
Pascual I 261 2011 MC (4) RCS 4 13 50§§ 48 96 
Wong MT 262 2011 SC RCS 4 31 91 61 67 
Mellgren A  263 2011 MC (16) PCS 4 37 133\\\\ 120 90  
Duelund-Jakobsen J 264 2011 MC (2) RCS 4 46 ns (87) 158 (70) n/a (80) 
Boyle DJ 265 2011 SC PCS 4 17† 50 37 74 
Wong MT 266 2012 SC PCS 4 22 28 16 57 
Devroede G 267 2012 MC (16) PCS 4 39 133\\\\ 120 90 
George AT 268 2012 SC PCS 4 114 25 23 92 
Santoro GA 269 2012 SC PCS 4 18 28 28 100 





Key: LoE = Level of Evidence; RCT = randomized controlled study; DBC = double blind cross over study; 
CCS = case controlled study; PCS = prospective case series; RCS = retrospective case series; MC= multi 
centre; SC = single centre; * = mean values (integer values); † = values taken at time point; ‡ = 15 
patients included from previous study 227; § = 15 patients included from previous study 226; \\ = 63 
patients included from previous study 232; ¶ = 19 patients used tined PNE; ** = 112 patients used tined 
PNE; †† = 28 patients included from previous study 169; §§ = all used tined lead for PNE; \\\\ = 120 
patients included from previous study 256; ns = not stated; n/a = not able. 
 
 
Table 3.01b: SNS study characteristic (permanent implants only) 
 
Key: LoE: Level of Evidence; RCT: randomized controlled study; DBC: double blind cross over study; 
CCS: case controlled study; PCS: prospective case series; RCS: retrospective case series; MC: multi 







Author Year Centre  
(No. 
Hosp) 








Ganio E 270 2001 MC (ns) PCS 4 16* ns 16 
Leroi AM 168 2005 MC (ns) RCT (DBC) 1b 6† ns 34 
Michelsen HB 271 2006 SC PCS 4 6† ns 29 
Uludag O 272 2006 SC PCS 4 1† ns 14 
Roman S 273 2008 SC PCS 4 3† ns 18 
Dudding T 274 2009 SC CCS 2b A: 51 
B:  8 
ns 18 
30 
Matzel KE 197 2009 SC PCS 4 118* ns 12 
Brouwer R 275 2010 SC PCS 4 37  ns 55 
Lombardi G 276 2010 SC RCS 4 38 ns 11 
Otto S 277 2010 SC PCS 4 6† ns 14 
Ratto C 278 2010 SC CCS 2b 33 ns 10 
Uludag O 279 2010 SC PCS 4 6† ns 12 
Gallas S 280 2011 MC (9) PCS 4 12 ns 200 
Soria-Aledo V 281 2011 SC PCS 4 6† ns 23 










Table 3.02: PTNS study characteristics 
































Shafik 172 2003 SC NCT 3b 14 8 22* 32 25 78 
De la Portilla 177 2009 SC PCS 4 12 8 6† 16 11 69 
Govaert 283 2009 SC PCS 4 12‡ >72 12† 22 18 82 
Boyle 178 2010 SC PCS 4 12 3 14 31 21 68 
Findlay 284 2010 SC PCS 4 12 0 3† 13 12§ 92§ 
Hotouras 285 2011 SC PCS 4 12 0 3 100 ns n/a 
Hotouras 286  2012 SC PCS 4 12 0 3† 88 ns n/a 
 
Key: LoE = Level of Evidence; NCT = non-randomised controlled trial, PCS = prospective case series; SC = single centre; * = mean value; † = at specific me point; ‡ = twice 
weekly sessions over 6 weeks; § = completed initial course; ns = not stated; n/a = not available. All values are calculated to nearest integer.





3.1.2 PRIMARY OUTCOME 
 
The success rates for SNS based on a ≥ 50% improvement in FIE per week are shown 
in Table 3.03. On ITT, the median success rates were 63% (range 33-66%), 58% (range 
52-81%) and 54% (range 50-58%) in the short, medium and long terms respectively. 
Only two long-term SNS studies, following up a total of 86 permanent implants, could 
be used to calculate ITT. The per-protocol median success rates were also 79% (range 
69-83%), 80% (range 65-88%) and 84% (range 75-100%) in the short, medium and long 
terms. The success rates of PTNS are shown in Table 3.04. Only short-term follow-up 
data was reported. The 2 studies 178, 283 which reported this outcome, used different 
treatment protocols (6 weeks and 3 months) although the longest follow-up showed a 
59% success rate at 12 months 283. There were no reports of this outcome for TTNS. 
 
3.1.3 SECONDARY CLINICAL OUTCOMES [TABLES 2.05, 2.06 AND 2.07]  
 
For SNS, the median rates of perfect continence through all follow-up durations are 
shown in Table 3.03. Five long- term studies reported perfect continence rates that 
could be analysed on ITT with median of 20% (2-48%). The rate of perfect continence 
following PTNS therapy was reported only with short-term follow-up in one study of 
31 patients as 39% immediately following treatment [Table 3.04]. The composite 
scores for the CCIS and the number of FIE per week after SNS in the short, medium 
and long terms are shown in Tables 3.05 and 3.06 respectively.  The equivalent short-






term results are shown for PTNS in Table 3.04. All PTNS studies reported a statistically 
significant improvement in aggregate CCIS scores post compared to pre-treatment. All 
four of the TTNS studies used the CCIS as an endpoint. Two studies did not perform 
statistical analysis of results due to small patient numbers 180, 224. In the remaining two 
studies, one showed a significant improvement in the mean CCIS at 3 months and 6 
months following treatment 223 and the other showed no statistically significant 
improvement at a mean follow-up of 15 months 225.  
 
3.1.4 QUALITY OF LIFE 
 
Although not used exclusively, the FIQL 82 and the SF-36 198 scores were the 
commonest QoL outcome measures reported throughout the SNS literature. Thirteen 
studies using FIQL 168, 169, 226, 228-230, 233, 238, 243, 256, 259, 275, 287 reported short-term results 
(median 12 months) with median score improvements for each category post SNS of: 
1 (0-2) lifestyle, 1 (0-2) coping/behaviour, 1 (0-2) depression/self-perception, 1 (0-2) 
embarrassment. Statistically significant improvements in all categories were reached 
in 11 studies 168, 169, 226, 228-230, 238, 243, 256, 275, 287. In the medium-term (median 36 
months), 8 series 230, 238, 243, 256, 259, 262, 263, 275 reported a median score increase of: 2 (1-
2) lifestyle, 1 (0-2) coping/behaviour, 1 (0-2) depression/self-perception, 1 (0-2) 
embarrassment. All medium-term reports presented a statistically significant FIQL 
score increases in all categories except for Leroi’s non randomised study 259, where 
the increase was not statistically significant for depression/self-perception. Four 





studies had follow-up periods of more than 36 months; Matzel 197 reported on 4 
patients at a follow-up of 84 months, Munoz-Duyos 243 documented FIQL scores in 5 
patients at 60 months, Brouwer 275 reported on 13 patients followed up at 48 months 
and Uladag 282 50 patients at a median of 85 months. All four studies showed an 
increase in FIQL scores post SNS with an aggregate median score change of 2 (1-2) 
points in lifestyle, 2 (1-2) points in coping/behaviour, 1 (0-2) point in depression/self-
perception and 1 (1-2) point in embarrassment subcategories. Eleven studies 
measured generic changes in quality of life using the SF-36 score. Although there was 
variability in reports, there was a strong trend towards an overall improvement in the 
aggregate scores post SNS. Four studies reported long-term results with a median 
follow up of 61 (46-85) months, showing an increase in the overall SF-36 scores and 
improvements in all SF-36 domains 245, 275, 276, 282. In particular, statistically significant 
improvements were reported in the mental health component scores which were not 
found in the physical component scores 245, 276, 282.   
 
Four studies, all short-term, included data on quality of life both before and after 
PTNS treatment 177, 283-285 and all used the disease-specific FIQL scale. In one study, 
the FIQL results were grouped by aetiology so no comparison was possible 285. 
Govaert 283 showed statistically significant improvements in coping/behaviour and 
embarrassment immediately post-treatment, and in lifestyle and coping/behaviour at 
1 month after treatment cessation and De la Portilla 177 showed significant 
improvements in the domains of coping/behaviour, depression/self-perception and 






embarrassment at 6 months follow-up. The fourth study showed a statistically 
significant improvement in the mean score in the lifestyle domain only 284. Three 
other QoL measures were also reported in three studies 177, 283, 284. These include the 
SF-36, a Visual Analogue Scale for QoL and the ICIQ-B 78. PTNS studies using these QoL 
scores showed significant improvements in most of their domains at their latest 
follow-up. Only Eléouet's study 223 reported QoL measures pre and post TTNS, with 
significant improvements found in all 4 categories of the FIQL scores at 3 months 
although this decreased to only 2 categories at 6 months. 
 



















imp in FI 
episodes 














Short Term Follow Up (up to and including 12 months) 
Jarrett M 233 12 12 12 100 ns 42 ns 8 
Leroi AM 168 6* 34 19 56 ns 26 ns n/a 
Gourcerol G 236 12 33 29 89 69 21 33 10 
Tjandra J 169 12*  53 53 100 71 47 63 42 
Boyle D 246 6* 13 13 100 77 46 66 40 
Dudding T 274 8 30 30 100 80 40 n/a n/a 
Hollingshead J 251 12 86 86 100 81 Ns 62 ns 
Wexner SD 256 12* 120 106 88 83 41 66† 32 
Santoro GA 269 6* 28 28 100 ns 68 ns 68 
Medium Term Follow Up (between 12 and 36 months) 
Kenefick N 227 24 15 15 100 ns 73 ns 73 
Matzel KE 230 24 34 34 100 88 35 81 32 
Kenefick N 235 24 19 19 100 ns 74 ns 74 
Melenhorst J 239 26‡ 100 100 100 79 Ns 59 Ns 
Dudding T 241 24 51 48 94 65 40 52 32 
Munoz-Duyos A 243 35 29 29 100 86 48 58 33 
Govaert B 247 31‡ 145 145 100 80 Ns 56 ns 
Govaert B 248 35‡ 173 169 98 77 Ns 53 ns 
Koch SM 252 24‡ 19 19 100 ns 21 ns 11 
Oom D 254 32 37 37 100 81 5 65 4 
Mellgren A  263 36* 120 77 64 86 40 59† 26 
Boyle DJ 265 17 37 37 100 73 35 54† 26† 
Long Term Follow Up (more than 36 months) 
Altomare D 245 74‡ 60 52 87 ns 18 ns 10 
Dudding T 274 51 18 18 100 94 39 n/a n/a 
Matzel KE 197 118 12 9 75 78 44 58 33 
Vallet C 249 44‡ 32 23 72 ns 4 ns 2 
Hollingshead J 251 60* 86 18 21 83 Ns n/a n/a 
Lombardi G 276 46‡ 11 11 100 100 27 n/a n/a 
Duelund-Jakobsen J 264 46 158 91 58 75 36 n/a n/a 
Uludag O 282 85 50 50 100 84 Ns n/a n/a 
Devroede G 267 48* 120 77 64 87 34 50 20 
George AT 268 114 23 19 83 ns 52 ns 48 
Summary (median and ranges) 
Short term 12 
 (6-12) 












Medium term  25  
(13-36) 


























Key: * = values taken at time point; † = inten on to treat reported; ‡ = mean values (integer values); ns 







Table 3.04: Effect of PTNS on clinical outcomes 
Author Follow up  
(months) 
>50% imp in 
FI episodes 














Episode diff Significance 
Short Term Follow Up (up to and including 12 months) 
Shafik 172 22* ns ns a) 17 to 2* 
b) 18 to 3* 







ns ns ns 





ns ns 13 to 9* 
13 to 8 * 







ns ns ns 




ns 12 to 8*  





7 to 3 





Boyle 178 5 71 39% 13 to 7 -6 <0.0001 4  to 0 -4 p<0.0001 
Findlay 284 4 ns ns Ns Ns ns L: 3 to 0 





Hotouras 285 3 ns ns U= 11 to 8* 
P= 12 to 9* 







4 to 0 
4 to 3 







Hotouras 286 3 ns ns 12 to 9* -4 <0.0001 4 to 1 -3 <0.0001 
Summary (median and ranges) 
Short term 5 (3-22) 59-71% 39% 13 to 9  -4 (-4 to -15)   5 to 1  -4 (-3 to -6)  
 
Key: * = mean value; ns = not stated; a) = good response group; b) = fair response group; c) = poor response group; L= liquid incontinence; S= solid incontinence; not sig = 
reported as no statistically significant difference. All values are calculated to nearest integer.

























Short Term Follow Up (up to and including 12 months) 
Jarrett M 229 12 27 27 100 14 (5-20) 6 (1-12) -8 <0.001 
Rasmussen O 231 6 37 37 100 16 (9-20) 6 (0-20) -10 <0.0001 
Hetzer FH 185 1* 13 13 100 14 (6-20) 4 (0-12) -10 <0.001 
Leroi AM 168  1* 28 28 100 16 (8-20) 9 (0-19) -7 0.0002 
Michelsen HB 271 6* 29 29 100 16 (6-20) 4 (0-12) -12 <0.0001 
Hetzer FH 237 6* 37 30 81 14 (6-20) 5 (0-13) -9 <0.001 
Navarro J 240 12* 24 24 100 15 (+/- 1.81)† 5(+/- 2.54)† -10 =0.0018 
Tjandra J 169 12* 53 53 100 16 (+/-1.3)† 1 (+/-1.8)† -15 <0.0001 
Boyle D 246 6* 13 11 85 12 (9-18) 9 (4-14) -3 0.0005 
Brouwer R 275 12* 55 48 87 15 (13-18) 6 (4-8) -9 =0.001 
Gallas S 280 12* 200 130 65 14 (2-20) 7 (0-19) -7 =0.0011 
Otto S 277 6* 14 14 100 16 (+/- 3.1)† 10 (+/- 5.9)† -6 =0.002 
Medium Term Follow Up (between 12 and 36 months) 
Brouwer R 275 36* 55 31 56 15 (13-18) 7 (5-8) -8 =0.001 
Hollingshead J 251 33 86 86 100 15 (+/-3)† 9 (+/-5)† -6 <0.001 
Michelsen HB 253 24 126 126 100 16 (6-20) 10 (0-20) -6 <0.0001 
Ratto C 278 33 10 10 100 18 (+/- 2.0)† 10 (+/- 3.7)† -8 =0.0001 
Pascual 261 13 48 48 100 18 (ns) 4 (ns) -14 <0.01 
Boyle DJ 265 17 37 33 89 15 (3-20) 8 (0-17) -7 <0.0001 
Gallas S 280 24* 200 54 27 14 (2-20) 7 (0-19) -7 =0.0011 
Wong MT 262 31 61 61 100 14 (ns) 8 (ns) -6 ns 
Wong MT 266 22 16 16 100 15 (11-18) 12 (0-14) -3 =0.0001 
Santoro GA 269 18* 28 16 57 16 (12-20) 3 (1-8) -13 =0.0017 
Long Term Follow Up (more than 36 months) 
Altomare D 245 74† 60 52 87 15 (+/- 4)† 5 (+/- 5)† -10 <0.001 
Matzel KE 197 118 12 9 75 17 (12-19) 10 (3-14) -7 <0.007 
Vallet C 249 37† 32 23 72 16 (+/- 3)† 10 (+/- 4.7)† -6 ns 
Brouwer R 275 48* 55 13 24 15 (13-180) 6 (2-8) -9 =0.008 
Faucheron J 250 45 87 87 100 13 (6-19)† 8 (1-17)† -5 ns 
Lombardi G 276 46 11 11 100 13 (11-18)† 5 (3-9)† -9 <0.018 
Michelsen HB 253 72* 126 10 9 20 (12-20) 7 (2-11) -13 <0.0001 
Sharpe A 255 50 44 37 73 16 (9-20) 4 (0-10) -12 ns 
Lim JT 258 51† 53 41 77 12 (9-15) 8 (5-11) -4 0.001 
Summary (median and ranges) 
Short term  6  
(1-12) 









(-3 to -15) 
 
Medium term 24  
(13-36) 









(-3 to -14) 
 
Long term  50  
(37-118) 









(-4 to -13) 
 
  
Key: * = values taken at time point; † = mean values (integer values); ns = not stated. All values are 
calculated to nearest integer. 
 






















Stat Sig  
(P value) 
Short Term Follow Up (up to and including 12 months) 
Altomare D 228 12* 14 8 57 7 (n/a)  1 (n/a) -6 <0.01 
Jarrett M 229 12 46 46 100 8 (1-78) 1 (0-39) -7 <0.001 
Matzel KE 230 12* 37 30 81 16 (+/- 19.3)† 3 (+/- 5.5)† -13 <0.0001 
Uludag O 232 12* 50 27 54 8 (ns) 1 (ns) -7 <0.001 
Jarrett M 233 12 13 12 92 9 (+/- 7.64)† 2 (+/- 3.69)† -7 =0.012 
Leroi AM 168 1* 28 28 100 7 (0-17) 1 (0-10) -6 <0.05 
Kenefick N 235 12* 19 12 63 12 (ns) 2 (ns) -10 <0.01 
Uludag O 272 1* 14 14 100 9 (ns) 0 (ns) -9 <0.01 
Gourcerol G 236 12* 33 15 45 5 (ns)† 1 (ns)† -4 <0.05 
Hetzer FH 237 6* 37 30 81 8 (ns) 2 (ns) -6 0.07 
Melenhorst J 239 12* 100 76 76 10 (n/a)† 2 (n/a)† -8 <0.0001 
Munoz-Duyos A 243 12* 29 25 86 1 (0-16) 0 (ns) -1 <0.001 
Stelzner S 244 10 13 11 85 10 5 -5 0.045 
Tjandra J 169 12* 53 53 100 10 (+/- 12.8)† 3 (+/- 10.1)† -7 <0.0001 
Boyle D 246 6* 13 13 100 8 (n/a) 2 (n/a) -6 =0.01 
Dudding T 274 8 30 30 100 3 (0-28.5) 0 (0-25) -3 <0.001 
Michelsen HB 253 12* 126 49 39 8 (n/a)  1 (n/a) -7 <0.0001 
Uludag O 279 6* 12 12 100 6 (ns) 1 (ns) -5 =0.001 
Wexner SD 256 12* 120 106 88 9  (+/- 7.3)† 2 (+/- 3.8)† -7 <0.0001 
Soria-Aledo V 281 6* 23 23 100 3 (+/- 1.1)† 1 (+/- 0.6)† -2 <0.001 
Medium Term Follow Up (between 12 and 36 months) 
Ganio E 270 16 16 16 100 6 (n/a)† 0 (n/a)† -6 ns 
Rosen H 226 15 16 16 100 2 (n/a)  1 (n/a) -1 ns 
Kenefick N 227 24 15 15 100 11 (2-30) 0 (0-7)  -11 <0.001 
Altomare D 228 24* 14 5 36 7 (n/a) 1(n/a) -6 <0.01 
Matzel KE 230 24* 37 21 57 16 (+/- 19.3)†  2 (+/- 3.3)† -14 <0.0001 
Uludag O 232 24* 50 6 18 8 (ns) 1 (ns) -7 not sig 
Kenefick N 235 36* 19 5 26 12 (ns) 0 (ns) -12 <0.05 
Gourcerol G 236 36* 33 5 15 5 (ns)† 1 (ns)† -5 <0.05 
Holzer B 238 35 29 29 100 2 (n/a) 1(n/a) -1 0.002 
Melenhorst J 239 36* 100 33 33 10 (n/a)  2 (n/a) -8 <0.0001 
Dudding T 241 24 51 48 94 6 (0-81) 1 (0-59) -5 ns 
Melenhorst J 242 24* A: 20 
B: 20 




A: 9 (n/a)†  
B: 8 (n/a)† 
A: 4 n/a)†  





Munoz-Duyos A 243 36* 29 13 45 1 (0-16) 0 (ns) -1 0.002 
Hollingshead J 251 33 86 86 100 9 (+/-7.3) 1 (+/-2.4) -8 <0.001 
Koch SM 252 24^ 35 35 100 11 (+/- 11.7)† 2 (+/- 2.6)† -7 <0.0001 
Oom D 254 32 37 37 100 9 (3-35) 0 (0-15) -9 ns 
Ratto C 278 33 10 10 100 26 (ns)† 1 (ns)† -25 =0.0001 
Mellgren A 263 36* 120 77 64 9 (ns)† 2 (ns)† -7 <0.0001 
Boyle DJ 265 17 37 33 89 7 (n/a) 1 (n/a) -6 <0.0001 
Santoro GA 269 18* 28 16 57 14 (+/- 8)† 0 (+/- 0.8)† -14 <0.001 
Long Term Follow Up (more than 36 months) 




















































Stat Sig  
(P value) 
         
















Altomare D 245 74^ 60 52 87 4 (n/a)†  1 (n/a)† -3 =0.004 
Dudding T 274 51 18 18 100 6 (0-80) 0 (0-8.5) -6 <0.001 
Matzel KE 197 118 12 9 75 9 (2-58) 0 (0-29) -9 <0.001 
Lombardi G 276 46 11 11 100 5 (3-8.5) 1 (0-2.5) -4 <0.018 
Duelund-Jakobsen J 264 46 147 147 100 6 (n/a) 1(n/a) -5 <0.0001 
George AT 257 44 23 23 100 5 (n/a) 0 (n/a) -5 <0.001 
Uludag O 282 60 50 Ns Ns 8 (n/a) 0 (n/a) -8 <0.002 
Devroede G 267 48 120 77 64 9 (n/a) 2 (n/a) -7 <0.001 
George AT 268 114 23 19 83 11 (2-35) 0 (0-2) -11 0.001 
Summary (median and ranges) 
Short term  12  
(1-12) 










 -7  
(-1 to -13) 
 
Medium term  24  
(15-36) 










(-1 to -25) 
 
Long term  51  
(44-
118) 











(-1 to -12) 
 
 
Key: * = values taken at time point; † = mean values (integer values); ns = not stated; n/a = not able; 










3.2 RANDOMISED PILOT TRIAL OF SACRAL AND PERCUTANEOUS TIBIAL NERVE 
STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
3.2.1 PATIENT RECRUITMENT AND BASELINE CHARACTERISTICS 
 
Of 91 consecutive patients screened, 58 met the eligibility criteria and 40 patients 
(39 female, mean age 59 years) agreed to participate. As pre-determined, 23 
patients were randomised to SNS and 17 to PTNS. Baseline demographic, medical 
and physiological findings were similar in both groups [Table 3.07]. Eighteen patients 
that were eligible but did not participate in the trial, the reasons for not doing so 
and consequent management are presented in Table 3.08. Before any intervention 
had been carried out, 4 patients dropped out from the SNS group. Two patients 
chose not to undergo surgery after being randomised to SNS (one patient did not 
wish to be contacted further by our services and another elected to maintain her 
conservative management only); one patient declined further treatment because 
her symptoms had resolved and another had inter-current disease requiring urgent 
medical management. From the PTNS group one patient chose not to undergo the 
procedure because of spontaneous improvements in her symptoms. Thus 19 
patients underwent temporary SNS procedure. Of these, a further four patients did 
not progress to permanent implantation; three did not meet required success 
criteria to progress and one withdrew from therapy due to need for investigation 
(MRI) and surgical treatment of a para-rectal cyst]. These patients were referred 
back to the specialist nursing services for further conservative management but 
follow up data at 3 months and 6 months were collected to enable available case 
analysis [based on n = 19]. This left 15 patients undergoing definitive (permanent) 
SNS implantation. 16 PTNS patients underwent a full course of 15 PTNS therapies. 
See flowchart [Figure 3.03]. 
 





Table 3.07: Numbers and percentages or means and standard deviations of baseline characteristics by 
treatment type  
 
 PTNS (N=17) SNS all (N=23) 
Demographic   
Barts Health NHS Trust 15 20 
University College Hospital London 2 3 
Female 17 (100%) 22 (96%) 
Age (years) 59 (SD 11.1) 59 (SD 13.2) 
   
History   
Post-partum aetiology 10 (59%) 10 (45%) 
Traumatic deliveries 7 (41%) 8 (34%) 
Hysterectomy 7 (41%) 12 (55%) 
   
Previous / on-going treatments   
Previous anal sphincter repair 0 (0%) 2 (9%) 
Nurse led conservative management 12 (71%) 17 (74%) 
Biofeedback 4 (24%) 11 (48%) 
Incontinence pad usage 9 (53%) 23 (100%) 
Anal plug 0 (0%) 1 (4%) 
Anti-diarrhoeal medications 8 (47%) 17 (74%) 
Suppository use 2 (12%) 7 (30%) 
Enema use 1 (9%) 1 (4%) 
Irrigation 2 (12%) 2 (9%) 
   
Main Symptoms   
Severity  6 FI episodes/week 12 (71%) 16 (70%) 
Severity >6 FI episodes /week 5 (29%) 7 (30%) 
Urge Incontinence 14 (82%) 21 (91%) 
Passive Incontinence 15 (88%) 20 (87%) 
Flatus Incontinence 16 (94%) 20 (87%) 
Unable to defer defaecation 13 (76%) 20 (87%) 
Soiling 16 (94%) 21 (91%) 
Evacuatory difficulties 11 (65%) 10 (43%) 
   
Baseline Physiology   
Anal canal length (cm) 2.3 (SD 1.5) 2.0 (SD 1.2) 
Max rest pressure (mmH20) 43.6 (SD 27.7) 54.9 (SD 43.0) 
Max squeeze pressure 36.1 (SD 19.5) 44.0 (SD 47.8) 
FCS 41.6 (SD 23.9) 57.5 (SD 37.5) 
DDV 77.5 (SD 35.1) 119.0 (SD 73.3) 
MTV 120(SD 45.7) 163 (SD 80.8) 
L PTML 2.8 (SD 0.5) 2.6 (SD 0.3) 
R PTML 2.7 (SD 0.6) 2.7 (SD 0.5) 
Anal Sphincter def 21.8% (SD 11.2) 23.2% (SD 6.0) 
Key: SD = standard deviation 
 
 





Table 3.08: Outcomes of eighteen eligible non-participants  
 
Candidate Reason for non participation Further management 
   
1 FI symptoms manageable Discharge back to GP 
2 Actively losing weight and operation not 
appropriate 
Referral to specialist nurse for further 
conservative management 
3 Happy with conservative management Referral to specialist nurse for further 
conservative management 
4 Symptoms improved Discharged back to GP 
5 Back pain and due MRI (contraindication 
SNS) 
Referral to specialist nurse for further 
conservative management 
6 Happy with conservative management Referral to specialist nurse for further 
conservative management 
7 Did not want operation Referral to specialist nurse for further 
conservative management 
8 Happy with conservative management Referral to specialist nurse for further 
conservative management 
9 Pacemaker in situ Referral to specialist nurse for further 
conservative management 
10 Symptoms improved Discharged back to GP 
11 Symptomatic diverticular disease Awaiting colectomy 
12 Only wanted PTNS Referred to specialist nurse for PTNS 
13 Difficulty with transportation to hospital Discharged back to GP for local treatment 
14 Symptoms improved Discharged back to GP 
15 Learning difficulties and dyslexia Referral to specialist nurse for further 
conservative management 
16 Only wanted PTNS Referred to specialist nurse for PTNS 
17 Only wanted PTNS Referred to specialist nurse for PTNS 
18 Having In Vitro Fertilisation Referral to specialist nurse for further 
conservative management 
   














3.2.2 CLINICAL OUTCOME DATA 
 
Within group effect estimates for SNS were greater than PTNS especially in those 
patients progressing to permanent implantation [Tables 3.08 and 3.09]. On 
available case analysis, in the SNS group, FIE per week improved from a median 
(interquartile range (IQR)) of 5.75 (5.75-15.5) [mean (SD) of 11.4 (12.0)] at baseline 
to 2.5 (2-4.5) [4.0 (4.0)] and 1.75 (1.5-5) [4.9 (6.9)] at 3 months and 6 month follow 
up, respectively vs. the PTNS group who had improvements from median (IQR) 6.5 
(2.5-16.5) [means 10.6 (SD: 11.2)] to 3.5 (0.75 -7.25) [5.8 (6.9)] and 2.75 (0.75 to 
10.75) [6.3 (6.9)], respectively [Figure 3.04a]. Using the CCIS as a global 
incontinence measure, improvements were evident in the SNS group from median 
(IQR): 16.5 (14-19) [mean (SD) 16.2 (3.0)] points (baseline) to 13 (8-16) [11.1 (5.2)] 
and 12 (6-16) [10.4 (5.6)] vs. in PTNS group, 14 (13-17) [15.1 (2.7)] to 12.5 (7.5-15) 
[11.7 (4.4)] and 12 (9-16.5) [12.1 (5.2)] at 3 months and 6 months respectively 
[Figure 3.04b]. Using the 50% reduction in FIE as a measure of clinical response, in 
all available cases, this was achieved in 47% and 61% at 3 months and 6 months in 
the SNS group compared with 40% and 47% at 3 and 6 months in the PTNS group. 
We note that there were only 15 patients available for analysis in the PTNS group 
because during their 2 week baseline assessment, one of the participants in the 
PTNS group was found not have any FIE (although enrolled on their reported severe 
FI symptoms) and therefore was excluded from this analysis. More marked 
differences in categorical differences were observed for the 75% improvement 





quartile [Figure 3.04c]. Three patients in both groups had no episodes of 
incontinence during the 2 week bowel diary period at 6 months follow up. Analysis 
of the implanted SNS group demonstrated a greater effect of treatment than was 
observed with inclusion of all available cases. This pattern was upheld for most of 
the main measures and led to a 50% reduction in FI episodes in 53% and 67% 
patients at 3 and 6 months respectively [Figure 4.02].  
 
The two parts of the PCOM were analysed separately and therefore results 
presented for questions 1 and questions 2-6 respectively. In keeping with other 
clinical outcomes, the specifically developed patient satisfaction Likert scale for FI 
treatment (question 1 of PCOM) demonstrated median (IQR) [mean (SD)] score 
improvements in both neuromodulation therapy groups: 1 (1-3) [1.7 (1.5)] to 4.5 (3-
8) [5.3 (3.0)] and 6 (4-8) [5.8 (2.9)] for SNS vs. 2.5 (2-4) [3.2 (2.3)] to 5.5 (3-8) [5.2 
(3.0)] and 5 (3-7) [4.8 (2.9)] for PTNS patients at baseline, 3 months and 6 months 
respectively. The within group effects were notably larger for SNS and proved even 
greater when analysed with permanent SNS responders only: 1 (1-3) [1.4 (1.5)] at 
baseline improving to 7 (4-8) [6.7 (2.2)] and 7 (5-8) [7.2 (1.5)] at 3 and 6 months. 
Total aggregate median (IQR) [means (SD)] scores for PCOM questions 2-6 also 
followed this pattern and demonstrated improvement in all groups: 6 (3-15) [8.7 
(7.5)] to 23 (13-40) [26.5 (14.9)] and 30 (20-42) [28.7 (14.3)] for SNS on all available 
cases analysis vs. 13 (9-22) [16.1 (11.6)] to 28.5 (13-38.5) [25.9 (14.9)] and 23.5 
(12.5-36) [24.2 (14.5)] for PTNS at baseline, 3 months and 6 months respectively.  






In both groups, the FIQL measure showed improvements from baseline in all four 
domains (lifestyle, coping/behaviour, depression/self-perception and 
embarrassment), at both follow up points. In the SNS group, the change in 
aggregated means (SD) was from 7.2 (2.3) at baseline to 10.1 (2.9) at both 3 months 
and 6 months. The PTNS group also demonstrated an improvement in FIQL scores 
from 8.5 (2.9) at baseline to 10.2 (3.1) and 9.4 (3.1) respectively. Effect estimates in 
the SNS group were larger across all domains than PTNS [Table 3.09). SF-36 and EQ-
5D scores (global health scores) showed little improvement after treatment [Table 
4.04]. Changes in scores for EQ-5D (calculated using computer algorithm and 
expressed using descriptive system as a weighted index 199 from  -0.594 to 1.0 where 
0 represents death and 1.0 = perfect health) varied between 0.0 and 0.11 with no in 
group significant changes). On reviewing the SF-36 scale subscales (each scale ranges 
from 0-100% where 100 = perfect health), increases in physical role were observed 
for SNS, particularly after permanent implantation; modest increases were also 
observed in emotional role and social functioning for both interventions.  
 
3.2.3 HEALTH ECONOMIC DATA 
 
The direct intervention cost of PTNS was £2,260 compared to the cost of SNS of 
£13,922 per patient (£1,613 for temporary SNS plus £12,309 for permanent SNS). 
The breakdown of intervention costs is shown in Table 3.10. Sensitivity analyses 





were conducted to address uncertainty around major assumptions used for costing 
the intervention. Using minimum and maximum parameters estimates for uncertain 
variables (e.g. number of patients sharing PTNS stimulator; the proportion of 
patients failing permanent SNS; number of patients re-using temporary SNS device; 
number of re-programming sessions for SNS), the total cost of the intervention per 
person varied from £2,218 to £2,297 for PTNS and from £12,139 to £14,238 for SNS. 
The use of health care resources by participants was also analyzed. The total cost of 
treatment (including the cost of the intervention and resource use by participants) 
estimated on an intention-to-treat basis were £2,356 (SD £122) per person for PTNS 
and £12,748 (SD £4,175) per person for SNS (four participants failed temporary 
SNS). The health outcome of treatment estimated in quality adjusted life years 
(QALYs) was 0.299 (0.170) for PTNS and 0.343 (SD 0.102) for SNS. No treatment-
related adverse events were found in the trial and therefore no such costs could be 
assigned.  





Table 3.09: Numbers of patients analysed and medians and interquartile ranges (means and standard 
deviations) of pre- and post-treatment clinical outcome data 
 
Intervention  PTNS SNS (all) SNS (permanent implant) 
Visit  Base-
line 
3 months 6 months Base-
line 
3  months 6 months Base-
line 
3 months 6 months 
N  
 





































































































































































































           










































































































Key: med = median, IQR = interquartile range, PCOM = Patient Centred Outcome Measures





Table 3.10: Numbers of patients analysed proportions of "success"  of pre- and post-treatment clinical 
outcome data 
 
Intervention PTNS SNS (all) SNS (permanent implant) 
Visit Baseline 3 months 6 months Baseline 3  months 6 months Baseline 3 months 6 months 
N 
≥ 50%  

































≥ 75%  




































2   
(13%) 




2   
(11%) 





2   
(13%) 






























Key: FI = faecal incontinence, p/w = per week, CCIS = Cleveland Clinic Incontinence Score, * one 






Table 3.11: Means of within patient changes (baseline to 3 months, and baseline to 6 months), and 95% confidence intervals, by treatment group 
Intervention PTNS (n = 17) SNS all (n = 19) SNS permanent implant (n = 15) 




















































































































































































































































































































































































































































































































































































































































Key: FI = faecal incontinence; p/w = per week; CCIS = Cleveland Clinic Incontinence score; EQ-5D = EuroQol questionnaire; EQ-5D VAS = EuroQol Visual Analog Scale; FIQL = 









Figure 3.04: Main outcomes of percutaneous tibial nerve stimulation (PTNS) and sacral nerve 












































































































































(a) prevalence of faecal incontinence episodes per week; (b) Cleveland clinic incontinence scores. Box 
and Whiskers charts represent medians + interquartile range + range. 
 PTNS             SNS (All)             SNS (Permanent) 













 PTNS              SNS (All)          SNS (Permanent) 





Figure 3.05: Patient centred outcomes of percutaneous tibial nerve stimulation (PTNS) and sacral 

































































































































































(a) patient centred outcomes scores for question one only; (b) patient centred outcome summative 
scores for questions 2-6 only. Box and Whisker charts represent medians + interquartile range + range  
 
 PTNS                 SNS (All)              SNS (Permanent) 
















Temporary SNS        
     Temporary SNS kit (Medtronic) 210.00 [a] 210.00 
Includes 9 cm needles x 2, 
single use 
     12.5 cm needles pack of 6 
(Medtronic) 
135.00 [a] 0.45 
Single use, assumes 2 
needles per patient, 
requires for 1% of patients 
     Power source (Medtronic) 335.00 [b] 18.61 
Multiple use, assumes 18 
patients as per trial 
Total cost temporary SNS    229.06   
Permanent SNS        
     Patient programmer (Medtronic) 500.00 [a] 500.00 Single use 
     Pulse generator (Medtronic) 5,700.00 [a] 5,700.00 Single use 
     Tined lead (Medtronic) 1,350.00 [a] 1,350.00 Single use 
     Lead introducer kit (Medtronic) 200.00 [a] 200.00 Single use 
Total cost permanent SNS    7,750.00   
Total device cost SNS:    7,979.06   
PTNS        
     UPC stimulator  (Uroplasty) 868.84 [c] 51.11 
Multiple use, assumes 17 
patients as per trial 
     UPC lead set of 12  (Uroplasty) 417.88 [c] 522.35 
Single use, assumes 15 leads 
per patient 
 Total device cost PTNS:    573.46   
Resource use costs 
Temporary SNS        
Initial consultation 123 [d] 123 
Consultant Led: First 
Attendance Non-Admitted 
Face to Face, Colorectal 
Surgery 
Physiology testing        














       Outpatient appointment 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
       Ultrasound 51 [d] 51 
Diagnostic Imaging: 
Outpatient. Ultrasound 
Scan, less than 20 minutes 




less than 20 minutes 
Second consultation 93 [d] 93 
Consultant Led: Follow up 
Attendance Non-Admitted 
Face to Face,  Colorectal 
Surgery 
Counselling 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery  
Pre-assessment for operation 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
Procedure 599.00 [d] 599.00 
Intermediate pain 
procedure, day case 
Post-operative medication: 





Non-proprietary, 0.5–1 g 
every 4–6 hours 
Specialist nurse review 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
Total cost temporary SNS    1,383.88   














Permanent SNS        
Pre-assessment for operation 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
Procedure 4,268.00 [d] 4,268.00 
Insertion of neurostimulator 
or intrathecal drug delivery 
device, day case 
Post-operative medication        






Non-proprietary, 1–2 tablets 
every 4–6 hours 






Sandoz, one tablet every 12 
hours 
Re-programming pulse generator 99 [d] 89.10 
Requires for 90% of 
patients. Non-Consultant 
Led: Follow up Attendance 
Non-Admitted Face to Face,  
Colorectal Surgery 
Post-operation check at 6 weeks 93 [d] 93 
Consultant Led: Follow up 
Attendance Non-Admitted 
Face to Face,  Colorectal 
Surgery 
Total cost permanent SNS    4,558.93   
Total resource use SNS:    5,942.81   
 
PTNS 
       
Initial consultation 123 [d] 123 
Consultant Led: First 
Attendance Non-Admitted 
Face to Face, Colorectal 
Surgery 
Physiology testing        





       Outpatient appointment 99 [d] 99 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
       Ultrasound 51 [d] 51 
Diagnostic Imaging: 
Outpatient. Ultrasound 
Scan, less than 20 minutes 




less than 20 minutes 
Second consultation 93  93 
Consultant Led: Follow up 
Attendance Non-Admitted 
Face to Face,  Colorectal 
Surgery 
15 PTNS procedures 99 [d] 1,485.00 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
2 top-up PTNS procedures at 6 
months  
99 [d] 198.00 
Non-Consultant Led: Follow 
up Attendance Non-
Admitted Face to Face,  
Colorectal Surgery 
Total resource use PTNS:    2,168.00   
 
Key: [a] Medtronic Ltd UK. List prices 2012. Personal enquiry; [b] NHS purchasing and Supply Agency 
2010. Economic report. Sacral nerve stimulation for faecal incontinence; [c] Uroplasty Ltd UK. List 
prices 2012. Personal enquiry; [d] National Schedule of Reference Costs 2011-2012 - NHS trusts and 
NHS foundation trusts. Available at https://www.gov.uk/government/publications/nhs-reference-
costs-financial-year-2011-to-2012. Accessed 30 July 2013; [e] British National Formulary 2013. 
Available at http://www.bnf.org/bnf/index.htm. 





3.2.4 ADVERSE EVENTS 
 
There were no unexpected serious adverse events relating to either treatment. 
Three patients from the SNS group had procedure related complications. One had 
mild ipsilateral leg pain during temporary testing but this resolved after removal of 
the temporary lead. This patient's improvement in FI was marked and therefore she 
elected to proceed with a permanent operation. Further implantation of the 
permanent device did not lead to a recurrence of this problem. Two further patients 
had stimulator site pain after the insertion of their neurostimulators which resolved 
with the adjustment of their stimulator settings. In the PTNS group, one patient had 
paraesthesia and another mild discomfort in the foot directly after sessions of 
stimulation. Both adverse events resolved spontaneously within 24 hours. In 
subsequent therapy sessions, the stimulation level for these patients was decreased 
slightly to alleviate the unwanted symptoms. These mild adverse events did not 
discourage either patient from completing their full course of PTNS. There were no 
infective complications and no premature treatment termination in either group. 
 
 





3.3 QUALITATIVE INTERVIEW STUDY OF SACRAL AND PERCUTANEOUS TIBIAL 
NERVE STIMULATION IN PATIENTS WITH FAECAL INCONTINENCE 
 
3.3.1 PARTICIPANT DESCRIPTION 
 
Out of 40 participants eligible for the study, 10 agreed to participate in qualitative 
interviews. Five participants were from the group undertaking SNS and five from the 
PTNS group. After an iterative process of review after each interview the steering 
group decided that 10 participants would be enough to reach data saturation. In the 
SNS group four patients successfully passed their temporary testing phase and 
therefore proceeded to a permanent implant. One patient however failed their 
temporary test and although invited for a post treatment interview, she declined. All 
participants in the PTNS group completed a full course of treatment and returned 
for a post treatment interview. Therefore 19 interviews were completed, 
transcribed and analysed. All the participants were female aged from 34 to 72 years. 
There were a mixture of those who were still currently working and those who had 
retired in both groups. There was also a mixture of participants in stable intimate 
relationships and those without partners at the time of the interviews.   
  





3.3.2 EXPERIENCE OF SNS THERAPY 
 
Five participants undertook SNS therapy. Four participants completed the therapy 
and returned for a post therapy interview. The three main super-ordinate themes 
were: acceptability of therapy, results of the therapy and feelings of psychological 
support. 
 










Physical Operation was fine, No side effects, No negatives, Easy to 
get used to, Control of therapy, System  just continues to 
work, Easier than previous treatments, Confusion with the 
temporary system, Discomfort, Implant could be better 
positioned, Worried about remote controller 
 Social and 
Economical 
Concerns Going abroad, Time off work, Cost, Specialist 
centre, Helpful to have treatment at local hospital, Go 
through a lot of batteries, 6 weeks of reduced activity 
 Emotional Scared , Unsure, Prepared, Good trade off, Positive outlook, 
Good experience, Feels at home, Praise to staff 
Results of therapy 
 
Positive More optimistic / hope, Freedom, Success, Feel in control, 
No concerns, Psychologically much better, Not worried 
about incontinence, Toilet not a second thought, Able to 
socialise, Better than other treatments, Improved 
Confidence, Improved self esteem, Can get on with life, 
Warning to visit toilet, Doesn't feel isolated, can fulfil role at 
work, Relaxed, Open, Dress appropriately, Able to socialise, 
more  spontaneous,  Psychologically happier, Not so self 
deprecating, Improved Intimate relations, Psychological 
control, Better attitude to her health, Becoming normal, 
Stopped support aids, Met expectation 
 Negative Not 100%, temporary system had only little effect, In 
between temporary and permanent therapy back to normal 
Psychological 
impact 
 Accessible service, Paradoxical food mapping, Still wears 
padding, Still planning/preparing 
 





3.3.2.1  Acceptability of therapy 
 
The acceptability of SNS based on the physical, social and economic and emotional 
sub-ordinate themes drawn from the coding was analysed. In general there seemed 




The participants found the operations themselves easy to tolerate. They were 
pleased that the operation was carried out under local anaesthetic and that they 
could be discharged on the same day. Some patients had felt some pain or 
discomfort around the site of the operation after the procedure but they did not 
view this as a limiting problem or a side-effect.  
 
"The actual operation itself was fine, they put you to sleep don’t they and you wake 
up and it's done. The operation itself was quite fine and there weren’t any 
complications afterwards or anything. I had a time, I think it was about 3 weeks after 
the operation, it all got a bit red and inflamed and I went to the GP and he said it was 
just dry, there wasn’t anything, it was alright, it was healing, don’t worry. And it all 
healed up quite well" 
 





On first use, participants were nervous that they may set the stimulator incorrectly 
or may somehow damage the implant but after some practice they started to enjoy 
the control they had over their new therapy. They felt the stimulator was easy to 
tolerate and after some time even became unaware of its presence.  
 
"Initially I think you are a little bit nervous at first turning it on and off it is new, but I 
think once I had done it a few times, like now if you told me to do it, I would do it and 
it beeps and I can play with it and I like it. It is alright, I feel quite in control." 
 
One patient found the temporary system confusing and uncomfortable but was 
pleased with the permanent implant which was much more discreet. Some of the 
participants interviewed found SNS treatment easier to use than previous 
conservative measures and had a sense that once it was set up it would continue to 
work for them without problems. 
 
"I just think it will get better. Yes I think I will get more and more used to it being 
there. I mean to be honest sometimes I forget it is there. You forget it is there and 
then some days I don’t give it a second thought." 
"I wouldn’t dare not to be honest. Just in case it went back like before. I presume that 
this will stay in forever and it will just get checked and everything is ok, it will just 
stay as it is, that is my understanding," 
 





Social and economical 
There were some concerns about the need to attend a specialist hospital in London 
for their treatment rather than a local hospital. This meant that they required more 
time off work and extra costs for travel. For convenience they expressed a wish to 
have a service setup locally that could provide this type of operation and follow-up.  
"So although sometimes it is a bit inconvenient when you come and have time off 
work and come for your appointments because it is not just down the road it is a fair 
way to come. So I have to have a day off work, but I think, the treatment from the 
beginning up until now has been closely monitored and sort of been aware of what is 
going on, so as far as I am concerned, it has been marvellous." 
"I think obviously coming up to London is a fair way to come. I mean I feel lucky that I 
have been asked to come up and it is working, but it is a shame that there aren’t 
more local things, maybe there might be some people in my position as well, but who 
maybe couldn’t get to London on a regular basis, so it is a shame that there are no 
opportunities like this in other hospitals." 
 
Another concern for those with an implant was the ability to proceed through a 
flight terminal with the implant. Although they had appropriate documentation 
there were still some concern that they might be stopped at the security check in 
and would be interrogated about their medical device.  
 





"No, there is no down side. On my mind, I am thinking about going on holiday and 
things like that.  Obviously I have got my card, I have got my letter. I wouldn’t say I’m 
stressed, but it is in the back of my mind. The process of going through of saying 
“Look I can’t walk through that” it's do I turn it off, you know what I mean, but no 
worry. When the time comes I will deal with it." 
 
For those that had already ventured abroad they found that this was usually a more 
discreet process than they had anticipated. The enforced six weeks of reduced 
activity after implantation was limiting but not too onerous for our participants. 
They expressed the opinion that these small inconveniences were an acceptable 
trade-off for the benefits of the therapy.  
 
"Yes I am fine. Yes. I think whatever I have had to do, on balance, it will always pay 
for the life that I am leading now" 
 
Emotional 
Initially some of the patients did delay the therapy because they were scared of 
having an operation for their condition. They were apprehensive about the possible 
complications of the procedures and also unsure whether it would give them any 
real benefit.  
 





"I was quite scared, really scared. Anyone I spoke to so, because nobody knows about 
it only me I suppose, I was scared of having the operation, quite scared. I put it off for 
quite a few months, like dragging my heels thinking “I don’t know, having an 
operation, what if this and what if that” 
"It's of little while to decide whether to go ahead with little not. I really wanted to 
stick my head in the sand and forget about it" 
 
Despite their initial reservations they all felt well prepared and once they had 
undertaken it, generally found it to be a positive experience.  
 
"Um, yes it has been much better and much easier, yes I mean I haven't had a lot of 
treatment as such but yes it has been much better, there seems to be a minimum of 
fuss and that was very pleasing" 
 
The participants praised the staff and found them to be attentive, kind and 
professional. This allowed patients to feel well looked after and even comfortable 
when attending for appointments at the Royal London Hospital. 
 
"I felt the staff everyone has been so kind and helpful" 
"It has all been fine and if I had any problems I have got a phone number, I can ring 
Tatenda or whatever, she will get back to me and they will every time, they have 
been really really good" 





3.3.2.2  Results of therapy 
 
In general the results of the therapy in the four patients who completed SNS were 
remarkably good. In all cases the treatment had met the expectations of the patient 
and they were pleased with the results. As the their FI improved there was a 
significant impact on their psychological health and lifestyle. 
 
Positive 
Our participants found the treatment of FI was very successful with SNS. They 
describe improvements in both the constant leakage of stool and also urgency 
symptoms.  
 
"I personally think that it has worked. I mean, like I said I have had the odd blip and it 
seems to go into, like I have a couple of days and I think I hope things are not going 
back to how they used to be, but then it just seems to pick up again" 
"But overall, no major accidents. Even today, in the car and going places and getting 
on the train, I have got no concerns" 
"Yes, in fact it has exceeded my expectations. Because it was a trial, you have to keep 
thinking to yourself oh whatever. You have to keep thinking this might not work. 
Some patients it doesn’t work. But it really really 100% has worked for me, because I 
was just leaking diarrhoea all the time. Now I can sit here comfortably" 
 





They describes feelings of abdominal discomfort which acted as a warning sign to 
alert them to a need to evacuate imminently. Patients also felt they could defer 
defecation longer and this allowed them to visit the toilet in a controlled fashion.  
 
"And I think to myself in my mind, it that wasn’t in there I would have had an 
accident. Because I would have sat there and it would have happened. Because that 
it is there telling me now, it is giving me that uncomfortable feeling like it is there and 
it is coming, I feel confident that I will not have accidents" 
"Yes, I feel in control. I think overall, going to the toilet and that, I know when I am 
going to the toilet now. I think for some reason, whatever that’s doing, sending 
messages to my brain, I haven’t had an accident since I have had it in" 
"But it is control and knowing and knowing that I am going to be alright, do you 
know what I mean. It takes the panic and embarrassment and that kind of thing 
away" 
"That is the control. I feel like I have got the control back in my life and I will know 
when I have to go to the toilet" 
"I know I want to go to the toilet, so psychologically, 10 times better, 100 times 
better, because I have got no fear now. I might have to go quickly sometimes, but I 
know I will get to the toilet" 
"I think basically, I think mentally, physically, it has made a big difference. I think the 
key word is “control”. I think I have got control in my life" 
 





Participants found that SNS yielded better results than the other previous 
treatments they have tried.  
 
"Nothing else worked. Even before this .... So this is actually the first thing that has 
worked" 
 
They all expressed benefits to both their symptoms and also their lifestyle. For the 
first time since the start of their condition our participants expressed a feeling of 
control in their lives which led them to be less anxious and worried about their 
incontinence. They felt much more relaxed, open and sociable. They felt that they 
could get on with their life and they felt freedom to be more spontaneous without 
giving extra thought to the need for a toilet.  
 
"Whereas now, in the summer, when my sister says let’s go here, let’s go there, it will 
be like “Yes”. So I think it will make a big difference and I think in the summer I will 
notice it more" 
"it's just made it less anxious life which is a good thing and it has given me more 
confidence. I think those are the two things mainly. Yes more optimism I think" 
""It’s oh my gosh I am late to the appointment, I must get on the train, let's do this, 
let's do that." But the toilet was not even a second thought, whereas two years 
before the operation, it was like my whole life revolved about going to the toilet and 
the need to go to the toilet" 





"but I don’t worry so much if I do go out now, so if it is something unplanned and on 
the spur of the moment, you know, I think, well ok, I don’t need to pack a bag of 
pants and pads and everything else. I mean I am not saying that accidents don’t 
happen because they do. I have had a couple of blips, but it is nothing like it was and 
you feel like you can actually do more and not embarrass myself" 
 
They became optimistic and had hope that the treatment might even improve with 
time. They had improved self-confidence and self-esteem and began to feel normal 
again.  
 
"But I feel so much more confident and happier" 
"I do feel more confident in the fact that I haven’t had an accident, a big accident for 
a long time 
"So you tend to feel that they are happening a lot lot less so, yes, you are more 
confident, you know it is, fingers crossed, not going to happen like it did" 
"It's funny, I think my self-esteem has risen. I am a different case, because I had been 
widowed just before the treatment, but my confidence, but mostly my self-esteem 
has been raised, yes, by this treatment, knowing that I am not going to get whatever. 
Yes it has, it has made a hell of a difference" 
 
Physically they are able to stop some of their support aids such as pads, pants and 
spare clothes and did not need to hide behind baggy clothes any longer.  





"I am going on holiday soon with my pal and I can off not wearing anything. No sorry, 
I didn’t mean not wearing anything. No incontinent protection" 
"and I am not having to keep checking on myself, that is much better, I feel confident 
to go out now. Whereas before I would still go out but I would be sort of worrying 
about certain stuff, about finding the right loo."  
"Honestly I can’t explain how wonderful it is not to be encased by Tena lady 
incontinence  pants" 
"No I don’t carry knickers or anything, all I have got is a pad. A normal Tena pad as 
well. So it is just in case of a little bit of leakage" 
"Yes, yes, and now like before I was having proper big what I call nappy pads now it is 
just like a panty liner pad, so I feel better" 
 
They were able to be more open about their condition and no longer felt isolated or 
fed up with life. Our participants reported improved intimate relations with their 
partners although many were still wary that they could still have accidents. They felt 
that they would gain confidence and be more relaxed in these situations over time.  
 
"So have you told them [workplace] about the treatment? Yes, they are all like in 
shock because they have never known anybody, because I say to people I’ve got a 
pacemaker. I say it’s in my bum! It is a standing joke that I have got a pacemaker in 
my arse! But they are quite – ooh. And I say it is all connected to the nerves and 
muscles, because it is new and nobody has heard of it." 





"Yes, I am not as miserable anymore. Because I was quite miserable and depressed 
and things like that. Whereas now I feel a lot better" 
"I think I have been looking it in a positive way, because I wanted it to be positive. I 
don’t know. It is like a whole cloud over you where you can’t go out because you 
know you might mess yourself, embarrass yourself, and it is almost like someone has 
taken that away, you can go out" 
"Because obviously after the operation and to be honest I think we are just getting 
back on track now, but I mean ideally, because before I had a couple of accidents on 
him, like I would have an accident while I was having sex, so I think ideally I don’t 
worry about having accidents now, but at the moment we are just getting back on 
track......but I can imagine once we get back into the swing of things it will be much 
better." 
 
Overall the expectations of the patients were met by the treatment results and 
therefore they were generally very pleased with the control they had with their 
condition. Overall SNS seem to give them the immediate and impactful change in 
their symptoms that they had hoped for. 
 
"And you know, like before I would walk places because I knew I could get back in 
time and it sounds really stupid, but you can go further, you can walk a bit more, you 
can do a bit more..... I honestly don’t think there is anything negative at all. It is so 
nice just to be able to do things that everyone else takes for granted you know" 






During the interviews, there were a few negative comments regarding the results of 
SNS. Although the treatment was successful in the eyes of the patients, they did 
comment that they still continued to have occasional incontinence episodes and 
therefore the treatment could not be considered a cure.  
 
"I still have little bits of problem completely opening my bowels and then through 
that I will have 2-3 days where I get a little bit of leakage and that I think is when I 
haven’t emptied my bowels properly and it will be a couple of days later at work, I 
feel uncomfortable and I need to go, but it is a little bit of leakage, but not much." 
"Sometimes my bowels don’t empty; sometimes I do have a little bit of leakage, so 
the physical side just needs a little bit of time" 
"now I have the odd blip, but it is nothing to what I used to have" 
"Um, well I still have the odd accident from time to time but then I think it's dietary 
based" 
 
They also mentioned discrepancies between the effect of the PNE which in some 
cases was deemed not to be as effective as the permanent implant. Another 
drawback of the treatment was the period between the PNE and permanent 
implantation which meant that symptoms returned to their normal baseline levels.  
 





"the temporary one I had a few problems with, because I really didn’t know what I 
should be doing. And it didn’t seem to have a lot of effect" 
"We went up Romford and I had this hell day, because I didn’t have the temporary 
one on and it was like back to hell and there was one point where I was rushing to 
the toilet and sitting down with pains, do you know what I mean, having accidents, 
getting panicky. Just like I can’t cope, I’ve got to go home, I’ve got to go home. Just 
miserable" 
 
As the second operation needed to be scheduled, there could be a slight delay until 
final therapy could be instigated. All in all these negative feelings were minor 
compared to the success that they had felt the treatment had provided. 
 
3.3.2.3  Psychological impact 
 
It was well recognised by patients' themselves that the process of having SNS 
treatment had given them some emotional and psychological support in their battle 
against incontinence. They felt comforted that they had a service which was 
accessible and expertise that could help them with their symptoms even if the 
therapy started to fail. 
 





"I am yet to see if it keeps on; if not I know I can ring up and say “I am having a 
problem here”. I know that I will be seen; well I know Dr Thin has already seen me for 
a year, but I do know I can ring and if I have a problem they will do all they can" 
 
Patients could not completely rely on the therapy only as they had still encountered 
incontinence episodes. Many still felt they had to wear underwear padding whilst 
planning their public outings carefully in order to maximise their chance of 
successfully avoiding incontinence accidents. In some cases this was done more out 
of habit and was difficult to give up completely.  
 
"Yes, physically comfortable, mentally. I think it is habit. Like I said I get up in the 
morning, shower, dress put on a pad, so it is habit, but then it's like my little safety 
thing cos if I do have a little leak" 
"Oh yes, I do slightly still yes. I take Imodium from time to time and I feel I need it, 
um, and I always take precautions anyway and that's just me I think so that is yes, 
how I feel about it" 
"Like before when I used to go out, it would be planning where you are going, how 
long is it going to take. To some extent I still do that, because old habits die hard" 
 
Despite these measures the patients felt much more comfortable with the use of 
these safety aids becoming rarer. Overwhelmingly these patients felt that 





prevention of incontinence episodes was due to the actions of the device rather 
than psychological support they had received. 
 
3.3.3 EXPERIENCE OF PTNS THERAPY 
 
In a more deductive approach to this analysis, we use the super-ordinate themes 
already accounted for in the SNS group as a framework for analysis of the PTNS 
group. These included: acceptability of therapy, results of therapy and psychological 
support. This allowed us the ability to loosely compared these two treatments. 
 
 









Physical No problems with treatment, Simple treatment, Not painful, 
Needle treatment acceptable, some discomfort, No negative 
effects, Minimal physical restriction 
 
 Social and 
Economical 
Could fit around other responsibilities, Hospital 
appointments take priority, Valid treatment, Less self 
directed treatment preferred, preference for local treatment 
options, Preference for medically trained person administer 
their treatment 
 
 Emotional Glad to have tried therapy, Less invasive than other 
treatments - seen as entry level treatment, Praise for staff,  
Literature was a well explained but scared the patient, 
Providing hope 
 
Results of therapy Positive Gained More confidence, Success - good treatment, had 
better control of bowels, Better effect than other 





 treatments, Keen to continue treatments,  
 
 Negative Subtle improvements difficult to attribute to PTNS 
treatment, Possible temporary effect,  Sceptical, 
expectations of results, Not met expectations, Not had big 
impact of daily living, Some patients didn't want to continue 




 Psychological aspects of treatment, Positive effects on 
confidence, Keen for group therapy, Still using coping 
strategies to combat FI, Still concerned about intimate 
relationships, Still worried when going to new environments, 
Still embarrassed about therapy 
 
 
3.3.3.1 Acceptability of therapy 
 
On the whole there was a high acceptability of PTNS therapy for faecal incontinence. 
Exploring the participants attitudes to the treatment we found that their opinions 
could be further subdivided into the physical acceptability, social and economic 
acceptability and emotional acceptability of this treatment. 
 
Physical 
Although PTNS is minimally invasive, it is a treatment that needs to be repeated 
initially on a weekly basis for 12 weeks. Currently this is administered by a trained 
medical health professional in a specialist clinic setting. Although this was a new 
technique participants were generally happy having the treatment carried out. They 
found that there were no significant problems in the treatment done and felt that it 
was generally a simple process. 





"It was quite easy going to be honest. I didn’t know it was going to be that simple. 
Yes it has been good" 
"The actual treatment itself was made as comfortable as possible and it wasn’t a 
terrible thing. I felt comfortable about having that" 
 
Most participants found that the needle placement was well tolerated although 
there were some who felt that there was some discomfort on stimulating the 
needle.  
"Sometimes it was, it depends whereabouts in the nerve it was. If it was really 
painful. The needle was alright, but it was when they turned the electric on, it would 
be really painful, not all the time. So if that was the case, they would take the needle 
out and put it somewhere else" 
 
Despite this the patients generally felt comfortable having control of the stimulator 
and settings which they could increase and decrease as they tolerated. Patients 
cited only very minimal restriction to their movements with this stimulate 
connected. 
 
"it wasn't you know painful or anything, I mean sometimes you could have a little bit 
too high and it would be uncomfortable but um, you know you could always adjust it, 
um setting and um, and it seemed to, you know it wasn't any trouble" 





"Yes. Initially you didn’t know what you were looking for, but as soon as you got to 
grips and what you should be looking for and how you were able to tolerate it, it was 
fine. You just switch it on and I sat there reading my book" 
 
In general the physical process of nerve stimulation was well tolerated without any 
ill effects. Even those who cited a needle phobia were able to tolerate the process 
without any difficulty. 
 
"I didn't mind it, no, I didn't mind it, it didn't cause any problems, I don't like needles 
so I was quite surprised that I was, you know, all right" 
Conversely when asked directly if there were any negative effects some did report 
some discomfort in their feet after the treatment episode, although this was also 
well tolerated. 
 
"I did get sometimes and achy afterthought feeling I think from it, um, but it only 
lasted a day or so and that's it. um, but it wasn't any trouble" 
 
This simple process did make some sceptical of how this treatment could happen 
effect on their faecal incontinence. 
 
"I think I was a bit sceptical. You know, how on earth is this going to do any 
stimulating, because I was almost hoping that I would get the implant. I was very 





open minded and when you have had this problem for so long, you are willing to try 
anything" 
 
Social and economical 
The social and economic burden to the patient to attend appointments was very 
much dependent on how far they lived away from the specialist Hospital where the 
treatments took place. Some participants lived up to a two-hour train journey away 
and therefore their weekly travel burden was greater. Some participants expressed 
the wish that the treatment could be carried out at a local facility because of the 
time and expense needed to make the journey. 
 
"and apart from the journey up here you know it was fine. That was the only thing, 
it's a shame they can't do this sort of thing at your local hospital" 
"Well, I made it convenient, because I so wanted it to work. You could say travelling 
up here, I mean I got subsidised, but the fare was quite expensive, I had to leave early 
in the morning, so because I wanted the treatment, I didn’t look at that side of it. And 
up here they made it so nice and easy" 
 
Although it was an inconvenience to travelling long distances, this group of 
participants were well motivated and when given a theoretical choice of completing 
treatment independently at home; they preferred to have their treatment 
conducted in a medical facility by train medical professional. 





"No I mean obviously you've got to make the time to come down, especially from 
where I live, I had to clear it with work, but obviously hospital treatment they can't 
really say anything um they have been good and supportive time really just flies by 
and I have tried to make it an early appointment or a late appointment to 
accommodate with work. But I have the end of the day you've got to put your health 
first and so um, it shouldn't really be seen as negative to make time for your own 
health." 
"I think is err better because you're coming down to an appointment and someone is 
doing it for you, you know you don't have to be disciplined to do it, if you see what I 
am saying, so it has been good." 
"In one sense, this treatment I found more comfortable because I felt the doctor was 
there and if there  was any problems there was 1:1 discussions, doesn’t matter how 
small or how big. That was one of the comforting factor in terms of away from the 
medication aspect." 
 
Paradoxically because the treatment was done in a hospital facility it seemed that 
the participants could more easily make plans to attend. There was some validation 
to the disease and also for the treatment. During the trial participants did not mind 
attending therapy once a week but there was some concern over the number of the 
therapies required and whether they could keep up with the "top-up" therapies. 
 





"Thinking about the top ups now that I've spoken to the doctor about it really 
depends on how many of those I may have, you know it's difficult when you work full 
time" 
 
If the patients are unable to attend therapies, it will obviously decrease compliance 
and therefore the effectiveness of the treatment. 
 
Emotional 
The participants were glad to have tried the therapy as they had felt that it had 
provided hope that their condition could be treated. 
 
"Yeah it's been a good thing I'd rather have had a rather not have had an if you see 
what I mean" 
"But you know apart from that time when I wasn't getting any treatment even like 
the thought of getting treatment I think probably psychologically helps you to some 
extent to think that you know that you are not just having to deal with it and accept 
that it is problem that can't be solved sort of thing" 
 
Participants also felt that because of the simplicity of the treatment it should be 
offered as a initial therapy on which to build on. 
 





"One thing I was quite pleased about was that I had this stimulation, because it was 
the lowest treatment if you like and I thought well, it’s a start. If that works and is 
not invasive, that is a good start" 
 
With regular treatments the patients felt comfortable in the environment and 
praised the staff for their role in providing support and professionalism in their 
treatment. 
 
"So I mean I've only got praise for them here, all very efficient, I come and I am seen 
straightaway and it takes half an hour. I think they were all very good and made it 
easy, um, any questions I had it all answered, no problems whatsoever" 
"The main thing was how exceptionally, whether it was Noel or somebody else, how 
professional they were. Within that professionalism they were really really kind, 
that’s not quite the word, but in tune and how they approached it and they made it 
very comfortable and talk about it. It was excellent. So firstly, everything was made 
so easy and everybody was so very very nice and nobody was difficult or abrupt or 
anything. That was really good" 
 
With a prolonged treatment schedule, it was very important that the patients felt 
comfortable and benefitted from attending the service. When patients attend 
appointments at regular intervals, it is not unusual for a friendly relationship to 
develop between the patient and health worker. Just knowing there is someone 





supportive in clinic may also indirectly increase the benefit of therapy to patients. 
Obviously this human interaction may not be so evident in other treatments where 
personal interactions are limited. 
 
3.3.3.2  Results of therapy 
 
Results were generally positive or negative depending on degree of benefit they 
received from the therapy versus the expectation of the patient. 
 
Positive 
Some participants had positive accounts of how the treatment had worked for 
them. They found that control of their bowels had improved and were pleased to 
have had the treatment.  
 
"I think I've noticed a difference in how long I can hold it and I do credit to that" 
"but I think with the treatment I have had that little bit longer where I can, so I 
definitely think it's been successful" 
"But I do feel better and myself, definitely. I think it has helped" 
Although their accounts were positive, our patients' did not report remarkable 
improvements in their control. In some patients this small improvement in control 
made a huge difference in their perception of their symptoms. Despite this, our 





participants found it difficult to credit all the improvements on just the PTNS 
treatment. 
 
"So I think that where before I had lots more, it is hard to accredit it just to this 
because lifestyle is a big part it, I know looking back and analysing it, ...Errm now my 
life is kind of changed away from  that, errm yes I do think that when I go out and if I 
do drink a lot I have got that couple of minutes or five minutes more to think I need 
to go to the toilet.... So I kind of think a lot more about that and it has given me that 
little window of opportunity not to have that accident. And that is a matter of pride 
and you know the night going really badly wrong then you know having a good night 
out so even that five minutes is life changing for me." 
"I have just thought a lot more about it but umm, it has had an effect because it just 
gives me that little more opportunity to get to the toilet without having an accident if 
I need it, I mean now I don't have it, as many things anyway, so that is definitely an 
improvement, umm, but as I say I don't think it is one hundred percent the treatment 
but who knows it could be errm but also my lifestyle changed" 
"I suppose the change of having the treatment is that I use those precautions less, 
that's how I gauge that it has actually worked......Yes I think it has um, it was 
explained to me that it was not going to be um, a cure. And I think I will always have 
a weakness but I do think it's less severe than it was before.....but I feel that it is 
better than it was and I guess that's probably the main thing" 





"Yes, um, that I would see an improvement but um, not necessarily a total cure. I 
mean I had to keep a bowel diary um, at the start, I think I have done three overall 
actually in the last one I don't, I think Dr was a bit disappointed that I had had a 
couple of accidents but I felt that it wasn't as bad as before, so I think is a good 
treatment" 
 
Despite only subtle improvements, the patients with positive results wanted to 
continue their treatment to ensure that the severity of their symptoms did not 
return. The consideration for these patients was the balance between the social 
economic burden of travelling and giving time to have further treatment and the 
positive effect it had on their lives. 
 
"I think I will have to top up, again it might just be peace of mind or psychological but 
I don't think there is any harm is there really, because I have seen an improvement in 
the time I have been able to, the urgency that I have had errm I think I would be silly 
not to have a top ups.  
And do you see it continuing to like work and effect, quite positively affect stuff? 











Although the overall experience of the treatment seemed mostly to be positive 
throughout, some patients did not find the benefits they had expected from their 
treatment. 
 
"No not really, it hasn't made the difference, I thought that it was going to make. I 
would say I am marginally better. I have got a little more control than I did have. It 
was the improvement I thought I was going to get, but it is better I would say 
marginally better" 
"I didn’t meet the expectation, and I still have days when it is not so good, but I would 
say that it is definitely, I will have to think back now because it is more than 6 
months. I would say that I am probably 30% better" 
 
It seemed that this slight benefit could not make a difference to their overall quality 
of life and therefore they did not feel it was worth continuing their treatment. They 
felt that they could manage the symptoms adequately themselves. 
 
"No I don't think so at the minutes, no, it hasn't made a dramatic difference, so I 
don't think, unless it gets worse or anything. At the minute I am not looking at 
carrying on with it" 
the participants looked for the next stage of treatment which they assumed to be 
sacral nerve stimulation. 





"If they felt that having the implant may give me additional control, well I would go 
for it" 
 
One patient although improved in their incontinence started have symptoms of 
constipation instead which she attributed to the treatment. She therefore also 
didn't want to continue the treatment in case it was caused by PTNS. 
 
3.3.3.3  Psychological impact 
 
Just as with SNS, there was a feeling from these patients that they had been 
supported psychologically and emotionally by the process of seeking and instigating 
treatment. This produced a positive result in increasing our participant's confidence 
levels. This may have been a product of going through the process rather than just 
improvements in symptoms. 
 
"Yes it has had an effect. I am more confident to go out. It is still there, it hasn’t gone 
away totally, but not as much as before. It is coming back to where I was before 
when I would think about if I need to go out and I would just go out.  Like today, just 
before coming today, I rang my sister to see if she was available and would want to 
go out. So these are the things I wouldn’t have possibly done. Yes." 
"No I have gained confidence in one respect because of the support from you all here 
and knowing there are other people, I know you know there are other people like me, 





but knowing there are a lot of other people like me. With socialising. I think I have 
got a bit more courage to do a bit more" 
"You make it easy and you and Noel, it is emotional really and it has helped my 
confidence and even if this hasn't improved, you have helped me mentally. You have 
helped me thank you" 
 
One suggestion was to have a group session with other FI suffers in order to share 
experiences. Despite improved confidence in the participants they were not 
confident enough to stop relying on the crutch of their coping mechanisms.    
 
"it is not too bad now I don't think it has now been too bad just need to be sure that 
there is a toilet on standby. I do panic a bit if I'm going somewhere and it isn't but I 
mean especially when I'm going out with my boyfriend he thinks I've got bladder 
problems I reckon because I'm always going ooh you know where is the toilet, better 
go and check like an old lady." 
 
Despite the participants improvement in symptoms and confidence, they were still 
unable to resume intimate relationships or feel open about their condition.  
 
"I am still very wary you know because if I have had a day where it has been physical, 
or I have not emptied myself, my bowel and it is all to do with control.... then the 
pressure.  So I am like, I can’t put myself through that" 





"they are okay about time off but you always feel a bit a little bit awkward asking for 
time off and obviously you don't want to go into discussion about what treatment 
having, and they are always wondering why you're having to go all the way up to 
London when there's a hospital just 10 min away, you know what I mean"  
 
PTNS did seem to bring about an improvement in patient symptoms but it did not 
seem to be the dramatic improvement in symptoms and daily living that some of 
our patients were striving for. Despite this, some found this improvement to be 

















4.1 STUDY 1: A REVIEW OF CLINICAL EFFECTIVENESS OF NEUROMODULATION 
IN FAECAL INCONTINENCE  
 
4.1.1 SUMMARY OF EVIDENCE 
 
From the data summarised, the initial success rate of SNS based on ITT was found to 
be 63%; with a long-term success rate of 54% (median of 56 months). Although an 
approximately 10-20% loss in effectiveness was demonstrated within 5 years, SNS 
still appeared to be an effective long-term treatment option. To put this figure into 
context, most patients seeking treatment for FI can be successfully managed with 
conservative measures alone; in over half of the remainder of patients, SNS can 
provide a ≥50% improvement in continence maintained into the long term. With 
regards to PTNS, success rates could only be determined in a limited number of 
studies reporting short-term outcomes, which seemed comparable to that of SNS. 
Two PTNS studies reported a 63% 283 and 71% 178 success rate immediately after 
treatment. Only one study reported a 59% 283 success rate at the longest reported 
follow-up term of 1 year. A single study 178 also reported a 39% cure rate at 5 









series. There was no current data on the medium-term and long-term clinical 
effectiveness of PTNS or TTNS.  
 
Further support for the long-term clinical effectiveness of SNS was also 
demonstrated by changes in the CCIS and the number of FIE per week, with 
improvements of 8 points and 7 episodes respectively at a median of 50 months. 
Furthermore 20% of all patients undergoing SNS continued to have perfect 
continence at 56 months. With respect to QoL, both disease-specific and generic 
QoL measures demonstrated improvements in aggregate scores after SNS 
throughout all terms, although the magnitude of this improvement declined slightly 
with time. In the long-term, the FIQL assessments corresponded to results found 
with clinical continence measures much more closely than the generic QoL measures 
(SF-36), substantiating Matzel’s opinion 288 that the therapeutic impact of SNS was 
most evident when disease-specific QoL instruments were applied. The most 
significant long-term improvements were found in the mental health component 
scores of the SF-36 questionnaire. This is an important finding as often these 
patients are anxious and self-conscious; with the fear of embarrassment rather than 
the actual number of episodes limiting their social interactions. SNS therapy may be 
able to return lasting confidence to these patients.  
 
With PTNS, short-term improvements in the CCIS (median score change of 4 points), 
weekly FIE (median change of 4 episodes per week) and QoL outcomes were 





demonstrated. In comparison to SNS the magnitudes of these improvements were 
less. This may indicate that PTNS could be more suitable in targeted patients with 
less severe FI in the first instance. Indeed the median baseline CCIS and number of 
FIE per week were lower for PTNS than those for SNS (13 vs. 15 and 5 vs. 8 
respectively). The evidence for TTNS is equivocal with only one of four studies 
showing a statistically significant improvement in the CCIS at 6 months. In the other 
three studies there was a general trend towards clinical improvement but this could 
not be proven statistically.     
 
4.1.2 PREVIOUS LITERATURE REVIEWS 
 
There have been five systematic reviews 167, 171, 188, 265, 289 and another 35 review 
articles on SNS for the treatment of FI. Despite enthusiasm to summarise the 
available evidence, the lack of homogeneous outcomes and the uncertainty of 
possible duplication within reported data sets have been a consistent problem. 
Attempts to limit bias have led to the exclusion of the majority of the available 
reports leaving only a paucity of evidence for review. For example, two systematic 
reviews published in 2004 171, 289 considered only the most recently published series 
from each country to avoid double counting, leaving only 6 case series and one 
cross-over study (of only 2 patients). Similarly a Cochrane review in 2007, due to 
very strict inclusion criteria included only 2 cross-over studies with a total of 36 
patients 167. In 2011, Boyle et al. 265 reviewed SNS success and perfect continence 





rates based on an ITT analysis. This review reported success rates in 19 studies and 
perfect continence rates in 8 studies. At the time of writing, available data may have 
been limited since the reviewers included four reports containing only five patients 
or fewer and only two reports with a median follow-up of more than 36 months. 
Previously there has only been one review article on PTNS and TTNS for FI 290; 
reporting eight case series which were not systematically assessed.  
 
4.1.3 THE PLACE OF SNS AND PTNS IN CURRENT TREATMENT ALGORITHMS 
 
In 2004 NICE published guidance (Interventional Guidance Procedure 99) 291 for the 
use of SNS after a systematic review commissioned by the institute. They found the 
evidence on the safety and efficacy of sacral nerve stimulation for FI to be adequate 
to support its use. They further specified that SNS should only be performed in 
specialist units by clinicians with a particular interest in the assessment and 
treatment of FI. Since then SNS has become an established treatment in the UK for 
FI. Further to their previous guidance, NICE Guideline 49 (2007) 1 recommended SNS 
first line surgical option for people with FI who had failed conservative treatment 
and for whom sphincter surgery was deemed inappropriate 292. Certainly in the UK 
and in Europe, SNS had established itself as the main first line surgical therapy after 
failure of conservative measures in almost all cases of FI. In the USA the Food and 
Drug Administration approved its use for the treatment of FI in 2011 after a pivotal 
US multicenter trial showed good results 256. In 2010, there were 20 specialist 





centres providing SNS treatment across the UK 293. Until more recently, there has 
not been a viable alternative to this type of therapy. 
 
In these times of financial constraint, those looking for a cheaper, simpler and even 
less invasive method of delivering neuromodulation championed the use of PTNS in 
FI. Initial studies found that the success rates were somewhat comparable to SNS 
and therefore it became another exciting potential treatment for FI. Even today, 
evidence regarding PTNS is somewhat limited but interest and momentum is 
gaining. In 2011 NICE brought out guidance on PTNS (Procedure Guidance 395) 294, 
which reported the evidence on PTNS for faecal incontinence raised no major safety 
concerns. There was evidence of efficacy in the short term in a limited number of 
patients and therefore, PTNS should only be used with special arrangements for 
clinical governance, consent and audit or research. Similar to SNS guidance they 
further stated that this procedure should only be carried out in units specialising in 
the assessment and treatment of faecal incontinence, as one of a range of 
treatment options. 
 
Despite the increasing use and popularity of these treatments, questions about how 
and where SNS and PTNS should feature in the treatment algorithm of FI have not 
been answered. Like other countries, commissioning in the UK has been confusing 
294, 295. The initial draft of the UK commissioning policy included that a trial of PTNS 
must be undertaken as a requirement before SNS commissioning, although later this 





was amended 295. The current commissioning position of NHS England states that 
PTNS and/or other conservative measures should have been tried and not yielded 
adequate continence before SNS can be considered. The RCS commissioning 
document has been firmer in its commitment to PTNS, publishing an algorithm 
including PTNS as nurse led therapy to be undertaken before SNS 296. They 
advocated the use of SNS as a specialist surgical intervention after these 
conservative measures had been exhausted.  
 
Conflicting statements from different regulatory bodies prove that there is still 
uncertainty regarding the role of PTNS as an adjunct prior to SNS or as a viable 
alternative, and whether the same specialist centres should be offering both 
treatments or whether PTNS could be undertaken in community settings, making it 
more accessible. Although the position of PTNS in the FI care pathway remains 
unclear due to limited evidence 14 offering PTNS as second line treatment may, 




4.2 STUDY 2: QUANITITATIVE OUTCOMES FROM THE EXPLORATORY STUDY 
 
The results of the randomised exploratory study determined that both treatments 
provide some short-term patient benefit (manifest in reduction in main symptom 
frequencies, validated summative symptom scores, as well as disease-specific and 





generic QoL measures). The pilot design did not allow for direct statistical 
comparison of SNS and PTNS, however for nearly all outcomes, the within group 
effect estimates were larger for SNS than PTNS. This was especially true at 6 
months, when SNS effects were either maintained or increased compared to 3 
month data; in contrast, the effect of PTNS on some clinical and QoL variables 
appeared to decline at 6 months. The analysis of permanent implanted patients (per 
protocol) undergoing SNS showed that outcomes were better still than on available 
case analysis. 
 
The outcomes obtained for SNS were comparable to those in published case series 
where the denominator used was the number starting treatment at the temporary 
phase. The systematic review 166 described in Chapter 3 (section 3.1.2), of 61 
published series demonstrated a median short-term ‘success rate’ (based on 
proportion of patients with a 50% reduction in FIE per week) of 63% (range 33-66%) 
compared to 61% in the current study. Reported as the proportion of patients 
undergoing permanent implantation (as has been the fashion for most previous 
series), our success rate at 6 months was 67% which compares less favourably with 
published short-term follow-up results of 79% (range 69-83%) 166 from European 230, 
251 and US 256 specialist centres identified by the systematic review. This may be 
accounted for by several factors including: the use of the temporary (unipolar) 
rather than tined quadripolar lead for the test phase leading to failure to reproduce 
outcomes at permanent implantation; patient preference; and more objective 





recording and interpretation as a result of third party blinded acquisition and 
analysis of data 297. However the mean difference in FIE per week (9 episodes per 
week) and CCIS (7.2 points) on this analysis were in keeping with improvements 
found in reviewed short term series conducted in this thesis (see Chapter 3, section 
3.1): median 7 (range 1 to 13) FIE per week and 9 (range 3 to 15) points respectively 
166. Further, the median CCIS in implanted patients at 6 months reduced below the 
notional threshold of 10 points which has been considered to equate with improved 
quality of life 298 (noting the general limitations of such scoring systems including the 
possibility of scoring 12 points on the CCIS without having incontinence to faeces). 
 
The results for PTNS were disappointing compared to published data found in our 
review. Based on the same notional measure of ‘success’ a 6 month positive 
outcome was achieved in only 47% patients: c.f. 65% (range 59-71%) at review 166. 
This cannot be explained by analysis of all available cases, since 16 of 17 recruited 
patients completed the treatment regime. Changes in raw symptom measures e.g. 
FIE per week (mean change of -4.3 [CI: -10.5 to 1.9]) and CCIS (-3.2 [-4.8 to -1.5]) 
were, however, comparable with nearly all previous studies 196, 299. Changes in FIQL 
scores were greater for patients receiving SNS than PTNS [Table 3.10]. The FIQL 
scale 82 defines 4 subscales all of which are calculated from the mean response to 
specific sets of individual scale items giving a range of 1 to 4 points for each where a 
score of 1 indicates lowest functional status. PTNS patients had negligible 
improvements in subscale scores (0.1 to 0.3) at 6 months compared to values of 0.7 





to 1.1 for SNS patients. The differences with SNS equate almost to those between FI 
patients and controls in the original validation of the scale 82. In common with other 
studies of either therapy, effects on generic QoL measures (SF-36 and EQ-5D) were 
small for both SNS and PTNS. This finding is consistent with the lack of specificity of 
these measures to patients with FI 300.  
 
Results from the health economics analyses suggest that SNS is associated with 
significantly higher short-term costs compared to PTNS: £12,748 (SD 4,175) versus 
£2,356 (SD 122). These figure did not include the cost of treatment-specific adverse 
events, which would be higher for SNS compared to PTNS according to published 
studies 196, 245, 301, 302. Published studies have previously evaluated the costs and 
consequences of treating patients with SNS for FI 213, 218, 241, 243, 259, 302, 303. These 
studies from multiple different countries (England, Spain, Italy, France and 
Switzerland) have concluded that SNS is cost-effective compared to conservative 
measures when offset by the quality-adjusted life-years (QALY) gained. The 
associated incremental cost per QALY fell within the threshold range of £20,000 - 
£30,000 used by NICE, and therefore SNS was considered as a cost-effective 
treatment for FI. As PTNS is certainly cheaper than SNS (with no overlap in average 
total costs) with little difference in QALY over 6 months, our results would also 
suggest that PTNS is a cost effective treatment for FI in the short term. 
 





Despite the exploratory nature of this study and the inadequacies of the presented 
health economic data, to test the above theory and in keeping with other studies 218, 
302-304 there may still be some value in estimating the cost effectiveness between 
these two therapies. If one was to try to make a decision about which strategy to 
employ given limited financial resources, there would be a need to compare the cost 
effectiveness between the two strategies. In actual fact there are three strategies to 
choose from: (1) conservative management only, (2) SNS after conservative 
management and (3) PTNS after conservative management.  The alternatives to SNS 
therapy for FI cannot be ignored and therefore these are found to be mutually 
exclusive strategies 305. In this setting, the incremental cost effectiveness ratio (ICER) 
exposes the true cost of more expensive medical interventions 306. Therefore 
analysing the cost effectiveness of SNS and PTNS by calculating the ICER between 
them is appropriate. 
 
Using the in-trial health care resources for the 6 month period, on an intention-to-
treat basis, the total costs of the intervention were £2,356 (SD £122) per person for 
PTNS and £12,748 (SD £4,175) per person for SNS with QALYs of 0.299 (0.170) for 
PTNS and 0.343 (SD 0.102) for SNS. In the absence of a full trial and longer follow up, 
we elect to use our own data to extrapolate an ICER. To calculate the ICER between 
SNS and PTNS, the following formula where SNS is the established strategy can be 
used: 
 





ICER =  
Cost Strategy 1 - Cost Strategy 2 
Effect Strategy 1 - Effect Strategy 2 
 
Strategy 1 = SNS, Strategy 2 = PTNS 
 
ICER =  
12,748 - 2,356 
0.343 - 0.299 
 
 
Calculating the available data, there is an ICER of £236,182 per QALY, more 
expensive for SNS when compared with PTNS. These results suggest that PTNS is 
economically dominant. 
 
The small differences in EQ-5D results has led to relatively small changes in QALYs, 
with an impact on ICER, which was calculated to be higher than previously reported 
estimate for SNS versus conservative treatment (£25,070 per QALY) 218, 241, 293. The 
use of the EQ-5D to calculate the QALY in this study may have further limited our 
results. In common with other studies of either therapy, the effect on generic QoL 
(SF-36 and EQ-5D) was small. This finding is consistent with the lack of specificity of 
these measures to patients with FI 300. It should be advised that the above calculated 









4.2.1 CRITICAL APPRAISAL OF OTHER SNS AND PTNS COMPARISON STUDIES 
 
To the authors knowledge, at the time of study inception there were no ongoing 
studies comparing clinical and/or cost measures between these two 
neuromodulation therapies for FI. Since then, three studies have been published 
broadly attempting to compare SNS against PTNS, based on treatment efficacy and 
cost. Recently Al Asari et al. 307 published their results from a single centre non-
randomised case controlled study in France concentrating on the comparative 
clinical effectiveness of the two neuromodulation therapies for FI. From our own 
centre in the UK, Hotouras et al. 308 also described a non randomised prospective 
audit of FI patients treated with either SNS or PTNS and attempted comparisons of 
clinical efficacy and costs between groups. The final study from Martinson et al. 304 
was the first to attempt comparisons of direct healthcare costs and cost 
effectiveness between SNS and PTNS, using a hypothetical economic model for the 
treatment of over active bladder. Although the this condition differs from FI, the 
technical aspects of treatment are similar and thus similar costs may be incurred. 
We can therefore reasonably extrapolate the comparative costs from this study and 
consider them for FI. Below we attempt to critically appraise these studies with 









4.2.1.1  Clinical outcomes and effectiveness 
 
Clinical effectiveness was evaluated in Al Asari et al.'s non-randomised case 
controlled study of 78 patients with chronic severe FI. The study included 21 
patients having PTNS and 57 patients having SNS from a single centre in France. The 
main outcome measures were the CCIS and FIQL scores at 6 and 12 months post 
intervention. Their results showed improvements from baseline CCIS, means (SD) 
for; PTNS 14.9 (2.4) and SNS 14.4 (2.75) to mean post-treatment CCIS at 6 months; 
PTNS 8.1 (3.2) and SNS 7 (4.8) respectively. Their denoted "success measure" was a 
50% improvement in CCIS. This was identified at 6 and 12 months in 47% and 30% 
of PTNS patients and in 50% and 58% of SNS patients. Overall mean FIQL scores at 
baseline were PTNS 2.1 (0.5) and SNS 2.1 (0.5) improving to PTNS 3.2 (0.6) and SNS 
3.1 (0.8) at 6 months. 
 
In this study the results of SNS treatment were similar to the ones presented in this 
theisi. However, Al Asari's treatment response from PTNS was notably superior to 
ours. The author's results using the same success measure showed only 19% of PTNS 
patients gaining a 50% improvement in CCIS at 6 months. Looking at mean changes 
in CCIS, Al Asari's study demonstrated a 6.8 point mean improvement in CCIS in the 
PTNS group, double that of the curently presented results (an improvement of 3.2 
points at 6 months). A difference in treatment protocols meant that Al Asari's 
patients undertook approx 19 sessions in 6 months where the current study's 





patients had only 15 sessions. Although increasing the number of stimulation 
sessions may have increased the effectiveness of PTNS, it is difficult to tell whether 
this could have improved the CCIS by more than double. In both studies FIQL scores 
improved with PTNS and SNS at 6 months in all domains although these results 
could not be directly compared because we did not feel it appropriate to synthesise 
the data as average summative scores. 
 
Hotouras et al. also attempted to compare clinical outcomes between SNS and PTNS 
at 3 months using CCIS and FIEs 196. In their pseudo case matched model: the mean 
pre-treatment CCIS score (SD) for permanent SNS 14 (4) and PTNS 13 (3) improved 
to 9 (5) vs. 9 (4); a mean score improvement of 5 points for SNS and 4 points for 
PTNS. These mean changes were in keeping with the current study's results. In the 
SNS group, Hotouras et al. reported a more impressive median reduction of FIEs of 
almost double that of PTNS but unexpectedly found that this was not statistically 
significant (p = 0.07). It is felt that due to the limited sample size, this statistical 
calculation must be treated with caution. Given the results from both studies SNS 
seems more effective for patients with higher number of baseline FIEs. Hotouras et 
al. did not describe any QoL measures or denotations of success in their analysis. 
 
As both Al Asari's and Hotouras' studies were not blinded or randomised, the effect 
of substantial selection bias was a concern. There was no mention as to why or how 
patients were stratified to receive either PTNS or SNS in either study. From the 





presented qualitative study results, patient preference and expectations of therapy 
can have a large impact on the effect of treatment. Furthermore the article authors 
themselves felt that the patient samples included were small and the follow-up 
times short. In both studies the SNS analysis was only conducted on a per-protocol 
(PP) basis and therefore no ITT analysis (or equivalent) was attempted. In Al Asari's 
study four patients (28%) shifted from PTNS to SNS during the course of the study. A 
description of their course of treatment was included but how this affected the 
analysis was not clear.  
 
4.2.1.2  Cost effectiveness of SNS vs. PTNS 
 
Although it is strongly suspected that PTNS is an altogether cheaper intervention 
then SNS, there have not been any authoritative studies comparing the cost 
effectiveness between the two therapies for FI. The costs of PTNS are less well 
established compared to SNS, however from the current literature direct medical 
costs would be expected to be reduced, if PTNS replaced SNS, by an estimated 
£9,787 (£11,594 SNS to £1,807 PTNS 179, 265). This would clearly have major cost 
implications in respect of the £3.7 million spent on SNS implementation in the UK. 
 
Martinson et al.'s single institution study involved a simulated cost-effectiveness 
analysis using a Markov model to compare the cost-effectiveness of PTNS and SNS 
as second line therapies for overactive bladder from the perspective of the health 





care payer. The simulation modelled a 2 year period using available outcome 
measures from previously published data 309. Similar to our study, uncertainties on 
probability variables and cost variables were varied in 1 and 2-way sensitivity 
analysis, varied at half the rate estimated from the literature and also at twice the 
rate. Costs were varied from the minimum Medicare payment in the United States 
to the maximum.  
 
They calculated that for PTNS, the costs of initial therapy were $1,773 (approx 
£1,171) for 12 weekly percutaneous tibial nerve stimulation treatments and $1,857 
(approx £1,226) for PNE. For ongoing therapy the cost of the SNS implant was 
$22,970 (approx £15,167). Effectiveness was measured as the percent of patients 
still on therapy at a given time. Effectiveness rates were therefore 48% for PTNS and 
49% for SNS, respectively, at 2 years. From the model, the incremental cost-
effectiveness ratio (ICER) was $573,000 (approx £378,343) per additional patient on 
sacral nerve stimulation over 2 years (therefore £189,171 per year). This figure is 
congruent with our own study data, predicting an ICER for SNS vs. PTNS to be 
£236,182 more expensive for SNS per QALY gained, using an all available case 
analysis. When considering a PP analysis, Martinson et al. demonstrated the costs 
were $24,342 (approx £16072) and $4,867 (approx £3,211) for SNS and PTNS 
respectively with an ICER of $99,872 (approx £65,944). 
 





Base costs increased with time, primarily due to the accumulating costs of therapy 
sessions for PTNS, and for adverse events and explantation with SNS. When the 
number of PTNS treatments per month was varied from 0.5 to 2 during ongoing 
therapy, ICERs were $639,333 (approx. £422,142) and $516,667 (approx. £341,147), 
respectively. Using sensitivity analyses, when PTNS was at its lowest predicted value 
of 34% success and SNS was at its high value of 78% success, the cost difference was 
greater by only $16,400 (approx. £10,828). Thus, the cost-effectiveness of SNS was 
more favourable at an ICER of $35,900 (23,704) per additional patient on SNS. This 
suggests that to become a cost effective treatment over PTNS, SNS would have to be 
at least twice as effective as PTNS. 
 
One key criticism of Martinson's study is their choice of effectiveness outcome, 
presented as the percentage of patients continuing treatment. Despite good rates of 
compliance, patients may choose to continue therapy without having any real 
benefit in symptoms. This has been found to occur in SNS patients previously 
(approximately 33% of patients with a permanent implant 310). However PTNS 
patients may also want to continue ineffective therapy because they want to avoid 
surgery.  
 
The limitations of Hotouras et al. study design have been previously discussed, but 
the cost analysis also demonstrated several limitations. Only initial direct healthcare 
costs were analysed with a cost difference shown of treating a patient for 1 year of 





£11 374 ($18 223) for permanent SNS vs. £1740 ($2784) for PTNS. It may be 
considered that some of the costs had been neglected without mention of: ad hoc 
phone calls, extra clinic appointments, GP appointments or hospitalisation in 
relation to these interventions which could add to NHS costs. Although there was an 
attempt to extrapolate these costs to ten years by multiplication and itemised 
hypothetical costing, there does not seem to be any economic modelling to include 
alternative decision making pathways, analysis of treatment failures or adverse 
events leading to other therapies or surgical revision. There was no mention of 
patient drop outs, patients changing treatments, patients not wishing to undergo a 
battery change which would all have consequent costs implications. Indeed no 
comparative cost effectiveness analysis were performed, only descriptions of "up-
front" costs of each procedure. This is a simplistic attempt at costing and is at best a 
financial audit of one units operational costs rather than a reproducible cost analysis 
for the whole NHS.  
 
 
4.3 STUDY 3: QUALITATIVE OUTCOMES - EXPERIENCES AND ACCEPTABILITY OF 
SNS AND PTNS 
 
The experiences of both SNS and PTNS could be demonstrated through the three 
super-ordinate themes of: the acceptability of the therapy, results of therapy and 
psychological support that were found to be correlating features of both therapies.  





4.3.1 ACCEPTABILITY OF THERAPY 
 
In both therapies the author was able to categorise the open codes into physical, 
social and economical and emotional sub-ordinate themes. In general both 
treatments had very high physical acceptability levels which were largely equivalent. 
As SNS was undertaken as a day-case operation, all participants tolerated it well. 
Our PTNS participants described their therapy to be very simple and easy to 
undertake. Both groups of patients enjoyed having control over their therapy, 
allowing them to set their own stimulation parameters. It is possible that this gave 
them the first sense of control over the disease. Many of the patients felt validated 
in coming to hospital for treatments and preferred these treatments to previous 
therapies tried. Both groups did mention some stimulation discomfort either from 
the needle or sacral electrode causing aching or pain in leg or foot. This was most 
often well tolerated and self-limiting and did not dampen the enthusiasm for either 
treatment.  
 
In both groups the social and economic burden of treatments were considerable. 
Most of our participants did not live nearby to the hospital which made 
appointments inconvenient. Many had to travel for one to two hours on the train to 
reach the hospital and some had to request time off from work because of hospital 
appointments. In both groups our participants had quite a considerable number of 
hospital appointments either for the treatments directly or for peri-operative care. 





They expressed a wish for these services to be conducted at local hospitals and GP 
practices. Interestingly when asked if they would have self-administered treatments 
in their own homes, they felt this may be inappropriate and that the treatment 
should be undertaken in a professional environment supported by appropriately 
expert staff. Both sets of participants were pleased with the discreetness of the 
therapies especially with the implant. In the SNS group, one particular concern was 
the ability to travel through the security terminals without commotion. Those who 
had already experienced foreign travel had not found this to be problematic. 
Emotionally all participants felt well supported and prepared for their treatments; 
mainly put this down to the kindness, attentiveness and professionalism of all the 
staff involved in the process. Two of the patient's in the SNS group admitted that 
they had been scared of the operation and had delayed the therapy for a short time. 
Once they had undertaken their procedure they were pleased that they had done 
so. 
 
4.3.2 RESULTS OF THERAPY 
 
In this super-ordinate theme there were some marked differences between the 
accounts of those undergoing SNS and those having PTNS. Regardless of this it must 
be kept in mind that one of the SNS candidates did not complete her therapy 
because of a lack of effect, also declining to participate in a follow up interview to 
discuss her therapy. Although there is no firm evidence, it can only be hypothesised 





that her experience of the therapy was not a positive one and her account would 
have significantly changed the dynamics of this study. From the four remaining 
participants who underwent SNS, there were extremely positive reflections on the 
improvements in their condition. They described stark results with impressive 
improvements in both leakage and urgency symptoms. They felt that SNS had 
yielded much better results than other previous therapies and became much more 
optimistic about their lives, explaining that their experience of the treatment had 
resulted in improved self-confidence and self-esteem. The participants also 
expressed some negative feelings on still not having a cure for the disease but 
overall they were pleased with the results of their treatment. The PTNS participants 
in general also found their treatment was effective but the change was more subtle 
when compared to the accounts of SNS. In some PTNS cases, symptoms had 
improved marginally but this led to a larger impact on QoL. In other cases it was 
difficult for our participants to separate the positive effects of PTNS from other 
lifestyle or dietary changes. A proportion of participants in the PTNS group did not 
find that the treatment had improved their symptoms at all and therefore it had not 
meet their expectations. Although this was disappointing, this was still acceptable 
because of the ease of having the treatment. Many thought that PTNS was a good 
initial stage treatment but considered that they may have had more benefit from an 
implanted device. This was an interesting conclusion from our PTNS participants as 
we had always maintained that the effectiveness of both therapies was equivalent.   
 






4.3.3 PSYCHOLOGICAL IMPACT 
 
Along with both SNS and PTNS therapies, the study participants found psychological 
and emotional support through participating in the process of seeking and 
undertaking treatment for their condition. They felt an understanding and support 
network from the healthcare professionals at the specialist hospitals and 
appreciated that this had aided improvements in the psychological aspects of their 
disease. They felt validated in their condition and gained hope that there were 
treatments that could improve their condition. Overall self-confidence improved in 
both groups although in the PTNS group our participants felt this was more overtly 
due to support provided by the service rather than just the effects of the treatment. 
It can be hypothesised that the human interaction of healthcare professions was 
much greater during the treatment of the PTNS group as there were many more 
treatment session. Despite reporting improvements in symptoms, participants also 
found old habits of wearing pads and checking for toilets difficult to break. Again the 
use of these ‘emotional crutches’ were less evident in the SNS group. In both 
groups, participants found that intimate relationships were most difficult to re-
establish even if they felt more confident about themselves. This may be because in 
those circumstances they were most likely to give up control of their bodies and any 
incontinence episodes would be seen as a major setback in their progress.  
 






4.3.4 COMPARISONS WITH OTHER NOVEL QUALITATIVE STUDIES 
 
The data regarding both SNS and PTNS for FI currently exists only as quantitative 
measures focussing on quantifying success 284, 311. Qualitative research has already 
been used to inform therapeutic outcomes in other surgical disciplines 312 but as yet, 
has not been widely adopted in the surgical field of FI treatment. The taboo subject 
of FI and its treatments lends itself well to personal analysis and investigation into 
the patient’s psychological, physical and social well-being 78. Previously Cotterill et 
al. had demonstrated that a patient centred approach was fundamental for 
understanding the true nature of these issues which are poorly explored by 
quantitative measures alone 78. Issues regarding FI as a condition have been 
explored through qualitative analysis in a few studies previously 78, 313-319. None have 
yet looked at the psychological and emotional implications of the results of 
therapies in a qualitative way.   
 
To the author's knowledge, this is the only study that has attempted to compare 
two treatments for FI in a qualitative way. Ultimately the aim of treatment is for the 
patients to gain freedom, control and feel normal again. Rasmussen 319 claimed that 
the health of a human being depended on whether he/she had a ‘repertoire’, i.e. a 
capacity to reduce the divergence between the actual and the ideal ego. Even 
though neither treatment was seen as a cure, our participants' improved control 





over FI decreased the distance between their actual and ideal egos. The treatment 
bringing them closest to attaining their targets was the one subjectively identified to 
be most successful.  
 
Two published studies have investigated the aspects of treatment which seem most 
important to patients living with FI. The first study by Manthey et al. 320 used semi-
structured interviews in 189 subjects and the method of content analysis to code 
and theme data. The findings of Manthey's study suggest that even when complete 
continence of stool may not be possible, individuals could identify goals of 
management that were important to them. The study showed that patients with FI 
have numerous management goals with the most important ones being: decreases 
in liquid consistency, decrease frequency of stool leaks and having greater 
confidence in controlling FI. A further study by Cichowski et al. 321 conducted focus 
group discussions with 11 women on non-surgical treatments. The data was 
analysed using the constructivist, grounded theory methodology and revealed 12 
themes: embarrassment, worry, ability to do things that you enjoy, effect on 
lifestyle, smell, no treatment recommendations from physicians, wanting to be/feel 
healthy, will to get better, desire to get better, personal effort, hope, and living life.  
 
Interestingly these two studies highlighted themes that were also important for our 
own participants. The subjects in Manthey's study mainly focused on the physical 
results of treatment. They described the top priority for successful treatment as 





being "a decrease in the frequency of leakage and having more confidence in 
controlling FI". Participants in both of our treatment groups gained positive results 
with concerns to these physical issues although this seemed to be achieved to a 
greater degree in the SNS group. Once our patients felt that the amount of leakage 
and frequency of incontinence episodes had improved significantly, as a secondary 
phenomenon we found that their other measures to disguise or protect themselves 
from accidents were being used less often.  
 
Chicowki's study highlighted psychological themes that his subjects had been 
concerned about. These were very similar to our own theme of psychological 
support. In Chicowki's overarching themes, his patient's wanted doctors to 
communicate hope, to tell them to continue to live their lives and to advise them on 
personal coping strategies. Concerning these issues PTNS treatment seems to have 
provided greater support which we could attribute to the longer human contact 
between the healthcare workers and the patient's. This highlights the importance to 
the patients of well trained, knowledgeable and empathetic staff. This adds further 
weight to the suggestion patients may prefer to attend outpatient clinics rather than 













4.4.1 LIMITATIONS OF THE SYSTEMATIC REVIEW 
 
4.4.1.1  Intention-to-treat analysis 
 
To be able to compare differing modalities of treatment adequately, it is crucial that 
there is parity in the way outcomes are measured. Most previously reported SNS 
data were assessed on a per-protocol basis including only patients already 
responding to a successful PNE. The per-protocol approach uses PNE as a diagnostic 
test to identify patients who may benefit from permanent stimulation and may also 
be used to identify potential new indications for treatment. An alternate analysis 
uses ITT, which considers the PNE phase as part of the treatment. The success of 
PNE itself is variable, with an approximate 25% failure rate 262 and therefore impacts 
upon the ITT analysis. Failure of PNE may be due to several factors: 1) technical 
issues, 2) patient selection: especially in the early phase of the evolution of SNS 
when new indications were explored 3) issues related to the monitoring of the 
clinical effect or 4) patients’ own preferences for implantation. Centres who have 
reported a higher drop out from temporary testing to permanent SNS will have a 
lower overall success rate. As an example, in Govaert’s study of 245 patients 248 who 
underwent SNS testing, the success rate of permanent SNS at an average of 35 





months on a per protocol basis was 77%. If results from the same cohort are based 
on ITT, because of a 29% failure at the testing phase, the overall success rate 
decreases to 53%. Although both ways of assessment are meaningful, other 
treatments do not have an evaluation phase, so it is not possible to compare them 
to SNS using existing data; rather, to be an effective comparator, the success of SNS 
must be presented on an ITT basis. This was calculated where possible from the 
reported number of patients undergoing PNE. 
 
4.4.1.2  Review methods 
 
We acknowledge that there were methodological limitations to conducting this 
systematic review. The most obvious being study heterogeneity in relation to data 
collection and method of analysis. Some studies reported average outcomes for a 
whole cohort with an average follow-up period whereas others reported outcomes 
at specific time points. The heterogeneity of reported outcomes (some reporting 
means and some medians) and the wide variety of reporting styles made statistical 
formal synthesis impossible. We acknowledge also that the evidence base was poor 
(especially for PTNS and TTNS), mostly made up of case series with low patient 
numbers and only short-term follow-up. Even when long-term follow-up was 
available for SNS there was an approximately 25% drop out rate to follow-up. A 
selection bias could not be excluded, as it is possible that patients with the longest 
follow-up maintained the most treatment benefits and therefore remained keen to 





be included in their respective studies. Regrettably on detailed evaluation of these 
long-term series, none have used strategies such as 1) the last observation carried 
forward or 2) worse case scenarios (considering missing data as failures) to 
represent any data loss, avoiding this potential bias.   
 
The paucity of randomised controlled trial data has deterred us from attempting to 
summarise the data using the meta-analysis method. We note that this has been 
attempted before using baseline data as a comparator to treatment 192. Uncertainty 
concerning the validity of using baseline data as treatment controls led us to provide 
only summary variables as median and range data. Along with this it was difficult to 
ascertain if large cohorts from the same centres contained duplicate series which 
had already been previously reported. We have attempted to minimise this by 
separating each series into different follow-up terms (short, medium and long) 
therefore expecting a minimal amount of repetitive data within each category.  
 
4.4.1.3  Safety data review 
 
The remit of the original systematic review presented in this thesis was to detect the 
true clinical effectiveness of SNS and PTNS with the most current published evidence 
at the time. The safety profile had previously been highlighted in a systematic 
review 188 as an important issue regarding SNS and therefore this was not repeated 
in thesis. However it is important to comment on suboptimal therapeutic effects 





and complications following SNS especially as Maeda et al. found that there was 
significant underreporting of complications throughout the literature 188. Out of 94 
articles included in the review only 48 were identified as studies reporting on 
adverse events and suboptimal outcomes.  From Maeda et al.'s review it was 
determined that during PNE, there was an adverse event rate of 6.3% with the most 
commonly reported event being lead displacement in 5.3% of patients 188. The 
incidence of suboptimal therapeutic response was identified in 12.1% of the pooled 
data. The most common attributed causes were problems relating to the implant 
lead displacement or mechanical damage. Thirteen percent of patients reported 
pain around the stimulator site, attributed to haematoma, device protrusion and 
suboptimal programming. Management was usually analgesia, repositioning of the 
stimulator, reprogramming and explantation of the device. The incidence of 
infective complications was 3.9%. Other complications included lead displacement, 
dislodgement, dislocation, migration or fracture. This often necessitated reoperation 
of explantation. Other less frequent complications sited included perineal, leg and 
foot pain. Complications associated with the existence of the device and surgical 
techniques such as skin erosion, hematoma, cellulitis, local allergic reaction, and 
seroma and wound dehiscence have been reported 188. Functional adverse effects 
from stimulation included constipation and urinary retention that required 
deactivation during defecation and urination, sleep disturbance that required 
switching off the stimulation during the night time, and increased sexual drive.  
There is also a report that a patient reported the sensation of minor electric shock 





when passing through an ambient electric or magnetic field 188. In a more recent 
publications the surgical revision rate in SNS patients has been shown to be around 
20% 322, 323.  
 
Although the safety profile of PTNS treatment has not been systematically reviewed, 
the largest recent study demonstrated that there were only 7 related adverse 
events and another out of 43 possibly related adverse effects from PTNS treatment 
in 107 patients having weekly PTNS treatments for 12 weeks 324. All adverse events 
were minor and resolved with little or no intervention. No PTNS interventions were 
withheld or  stopped during the study 324. Although PTNS does seem advantageous 
in relation to its safety profile, it is important to note that SNS complications tend to 
occur in the medium and long term for which the safety profile of PTNS has yet to 
be studied. 
 
4.4.2 LIMITATIONS OF THE QUANTITATIVE AND QUALITATIVE EXPLORATORY 
STUDIES 
 
As  the two prospective studies were devised to run in parallel and from the same 
pool of recruited patients, the limitations of the studies are generally shared by their 
design. Therefore the limitations of both studies have been discussed together. 
 
 






4.4.2.1  Small sample size 
 
The limitations of the exploratory RCT study are implicit in its pilot design and small 
number of recruits. As designed, the number of recruits reflect a compromise 
between a meaningful sample size for data analysis and the feasibility of project 
completion within the elected 24 month period. The calculations behind the sample 
size for this study have already been discussed within Chapter 2 (section 2.9.2.4). 
The author is aware that as a pilot, the small number of participants did not allow 
statistical comparisons between groups to be made which limits the informative 
nature of the outcomes measured.  
 
Even with this small sample size there were challenges to recruitment. As 
mentioned in Chapter 2 (section 2.9.2.1) individual Primary Care Trust (PCT) funding 
approvals were required prior to SNS therapy. Our inclusion criteria ensured that 
every recruited participant was equally eligable for either SNS or PTNS and therefore 
all 40 patients had funding approved (for SNS) before randomisation. These 
individual funding requests were often complex and time consuming requiring the 
PCT to convene and discuss authorisation on an individual case basis. Midway 
through the recruitment process, some of the local PCTs could not afford to 
maintain their support for SNS. This made the recruitment of patients from our own 
trust very difficult. As a solution we decided to enlist the aid of another hospital 





(University College Hospital, London) with the requisite expertise in 
neuromodulation. The expansion of the trial allowed us to recruit the required 
amount of patients to cost and schedule. Our detailed protocol ensured that all 
aspects of the trial were conducted in a standardised manner. Another difficulty 
that arose was that many patients that were otherwise eligible to have either 
procedure did not want to be randomised to an intervention. Often FI patients are 
well informed and have strong views as to which therapy they can commit to. As has 
been discussed within the qualitative interviews, patients personal circumstances 
often guide patients to one treatment over another.   
 
With respects to the qualitative aspect of the study; in contrast to quantitative 
research, a “small” sample size is typical of the nature of this work and sampling is 
stopped when “a thorough understanding of the phenomenon studied has been 
reached” 206. While the number of patients having interviews was purposely less 
than the whole (10 of 40 patients), this is usual in qualitative research 325, the 
sample chosen was considered adequate based on qualitative methods literature 
325. Our study indeed achieved data saturation and determined by the clinical 
research fellow and Senior Supervisor Professor Stephanie Taylor (Professor in 
Public Health and Primary Care) who reviewed all the transcripts iteratively,  the 
findings are described in Chapter 3 (section 3.3). Although this study was 
informative, the small number of participants limited the generalisation of results. 
However, it did fulfil its aim as an insight into the minutiae of the participants’ 





experiences, adding a new dimension to the understanding of those who are treated 
for FI.  
 
4.4.2.2  Sample population 
 
Due to our selected sample, the trial results may not have been truly representative 
for the general population of FI sufferers. Having been recruited from tertiary 
hospitals with a special interest in FI, our participants were all well motivated and 
had made conscious decisions to seek further investigation and treatment. All of our 
participants had already experienced treatment with conservative measures and 
therefore were deemed to have sufficiently severe FI to warrant NM therapy. This 
exposed the study to a degree of self-selection bias. When compared to others with 
less severe FI, it is likely that our patient sample had a greater knowledge of 
treatment options and furthermore, their expectations, views and perceptions of 
care may have differed significantly. Incidentally all the participants in the 
qualitative study were female. Out of 40 available recruits, there was only one male 
participant (who had SNS). He was approached to partake in the qualitative study 
but unfortunately he declined because of personal time constraints. We can only 
speculate whether the result would have been different if more men had 
participated in this study. We may also wonder whether men and women deal with 
their medical conditions in different ways. It may be hypothesised that women put a 





heavier emotional emphasis on the effects of their condition; consequently 
benefitting more from the counselling aspects of therapy.  
 
4.4.2.3 Short follow up period 
 
We accept that the short follow-up interval, due primarily to resource constraints, 
also present a significant limitation. A longer follow-up interval of one year and 
ideally two years, even for a pilot study, would have been preferrable. FI is a chronic 
disease and the interest in terms of clinical outcomes and cost are in the medium 
and long term. The durability of these treatments is extremely important and the 
long-term clinical and cost effectiveness including adverse events and treatment 
compliance rates, are still to be determined. The effects of long-term PTNS are 
unknown, and although unlikely, it is unclear whether there are any associated 
chronic adverse effects. Furthermore, it is not known how many patients having 
PTNS ultimately go on to have SNS therapy and whether there is a cost burden or 
benefit from delaying this process.  
 
4.4.2.4  Limited economic analysis 
 
Considering the above limitations and exploratory design of this study, the 
appropriateness of a cost effectiveness analysis, rather than the cost utility 
presented in the results (Chapter 3, section 3.2.3) can be questioned. It is already 





known that the cost of SNS seems to be greatest up-front (discussed in Chapter 1, 
section 1.8) and therefore, in a short-term study there is a large bias favouring PTNS. 
Admittedly like almost all other economic studies on FI interventions, we only 
collected short-term direct health care costs from the view point of the NHS. 
Although an assessment of indirect costs has not been performed, it could be 
hypothesised that the societal costs with PTNS are greater over the long-term; due 
to requirements for repeated hospital attendances and an overall more modest 
effect. In a fully powered study, direct and indirect costs from the patients 
perspective (transportation, loss of earnings) and unit costs of protective measures 
(incontinence pads and clothing etc bought by the patient) should be collected. 
 
Cost-effectiveness ratios between treatments should be measured over a time 
frame which can determine loss of efficacy of treatment with time and also for any 
cost of additional interventions that may be required due to complications or drop 
outs. From other studies it is likely that SNS patients will develop some complication 
lead (displacement, simulator re-setting and changing the battery) during the first 
year of treatment and also in subsequent years 260, 326. Ideally a full scale analysis 
should be performed over a seven-year window, this being roughly equivalent to the 
time that the average InterStim implant battery lasts. If medium-term data had been 
collected then modelling the predicted outcome of the two therapies would be 
appropriate. In the long-term, PTNS patients would require top-up sessions at least 
every 6 months and therefore additional outpatient appointments. However, these 





visits may be partially offset by 6 to 12 month review appointments of SNS patients 
for auditing purposes recommended by NICE for the management of patients with 
FI 87.   
 
Further criticism could be targeted towards the reproducible application of our data 
for those outside the UK. As this study was funded by the NHS, the health economic 
evaluation was conducted from its perspective. However this data would also be 
relevant for other countries with public funded single-payer healthcare systems such 
as Canada, Norway, and Taiwan and indeed the itemised cost could be useful in all 
countries. 
 
4.4.2.5  Lack of placebo control 
 
Another limitation of this trial, was the lack of a placebo comparison arm. The 
placebo effect of NM treatments has been an ongoing concern for many because 
the true mechanism of NM treatment has not yet been consistently identified. In 
this randomised trial, it would almost be impossible to design a plausible placebo 
control arm that would faithfully recreate a sham stimulus, comparable with both 
techniques. Although SNS is now well-established as an effective therapy for FI, 
patient trials of this treatment vs. placebo are limited to short-term cross-over 
studies 168, 327. Furthermore, the use of ‘stimulator off’ as a placebo is questionable 
since described 'subsensory' stimulation is in reality still usually perceivable in most 





patients. In addition, there has been only one trial to date of SNS vs. a comparator 
(optimal medical treatment) 169. However, the long-term positive effects of SNS, 
with data more than 10 years has also shown sustained improvements in FI with the 
system 197, 268, 328. This would suggest that SNS does not work through a placebo 
effect. Sham studies for PTNS have been designed and undertaken in the urological 
literature by Peters et al. 329 and these have demonstrated that PTNS is more 
effective than sham. A UK multicentre randomised controlled trial: CONFIDeNT has 
just been completed which aimed to address this knowledge gap in FI; published 
results are still pending. In our parallel arm study design we used SNS (current 
established therapy), as a positive control for the evaluation of PTNS. As long-term 
effectiveness data for PTNS is not available, at this present time a substantial 
placebo effect cannot be excluded. From the qualitative study, our participants did 
identify a psychological effect from undertaking treatments. Even the process of 
obtaining treatment and interaction with staff within treatment sessions provided 
substantial positive psychological effects. As the number of treatment sessions and 
therefore personal interaction with PTNS was greater, it could be hypothesised that 
PTNS could provide a greater placebo effect. Long-term effectiveness data for PTNS 
in addition to the results of CONFIDeNT will be pivotal in assessing the magnitude of 









4.4.2.6 Lack of investigation into mechanisms of action 
 
It was beyond the scope of this thesis to identify possible mechanisms of action for 
either SNS or PTNS. It was also felt that the patients in the study would not benefit 
from the burden of extra hospital attendances and repeated invasive anorectal 
assessment. Although baseline physiology tests were performed (Table 3.07), 
available resources were limited and repeated anorectal physiology tests on these 
patients after therapy was not undertaken. In fact during the period of the project 
the anorectal manometry testing facilities changed from a standard water perfused 
pull through system to high resolution manometry using a solid-state probe. As 
discussed previously (Chapter 1 section 1.6.3.1) these different methods of 
assessment could not reliably be calibrated against each other and therefore pre- 
and post-intervention changes would not have been accurately detected.  
 
Reviewing the literature on both SNS and PTNS mechanisms of action 173, 271, 330-332; 
there have been no widely reproducible changes in anorectal 
physiology/neurophysiology in humans to support a particular or even a shared 
mechanism of action for SNS or PTNS. Most of the hypothesised mechanisms of NM 
therapies have been deduced from the studies of SNS 214, 220, 279, 333-337. The exact 
mechanism of SNS's effects are uncertain, as there is a discrepancy between 
symptom-improvement and the relatively minor changes on easily measurable 
anorectal function 338, 339. Recent data suggest that SNS, but not sham stimulation, 





increased the frequency of retrograde propagated sequences throughout the colon. 
In contrast, SNS increased colonic propagating sequences in constipation 340. 
Perhaps differences in baseline colonic motor activity partly explain why SNS may 
have different effects on colonic motility in constipation and FI but this seems 
counter-intuitive. While SNS has no consistent effect on basic anal motor functions 
(contractile force) 339, some FI patients may have reduced rectal sensation which is 
rapidly restored after SNS 341. Several studies now indicate modulation of afferent 
functions including effects on ano- and recto-cortical signalling 342, 343. It is also likely 
that SNS modulates the afferent limb of local and spinal reflexes that participate in 
transient anal sphincter relaxations (TASRs), anal sampling and rectal emptying akin 
to those observed in bladder and urethral functioning 344.   
 
4.4.2.7  Limitation of available outcome measures 
 
The planning of investigations and subsequent treatment requires a judgment on 
the severity of incontinence. To provide objective assessment, most previous studies 
have employed the use of a combination of either FI bowel diaries (usually over a 2 
or 3 week period), symptom severity score/indices and/or quality of life measures 









Faecal incontinence bowel diaries 
With self completed FI diaries, patients record the number of controlled defaecation 
episodes, urgent FI episodes, passive FI episodes and use of pads per day (see 
Appendix i). Despite the popular utilisation of this assessment instrument there has 
been criticism of its usefulness. Individual FI episodes can be difficult to categorise 
and measure discretely. Standardising definitions such as the subtle differences 
between episodes of passive incontinence and soiling can depend on patient's 
interpretation, expectation and judgement 186. In fact, even unconscious behavioural 
modification can greatly influence diary recordings. As a simple example, patients 
who stay close to a toilet or avoid leaving home can reduce the frequency of 
incontinence episodes despite having no real improvement in symptoms 186. It can  
also be considered that the accuracy of self recorded data entry may not always be 
optimal, as paper diaries can be damaged/lost and data entered 
retrospectively/incompletely before submission.  
 
Despite their limitations, patient completed bowel diaries are still widely used both 
clinically and in the research setting. Of possible outcomes, the most frequently 
used and probably least affected by subjective reporting differences is the number 
of FIE per unit time (usually per week). This outcome, obtained directly from the 
mean of 2 or 3 week bowel diary frequencies has been employed in almost all 
contemporary studies of FI interventions including recent SNS studies 167-169, 171, 218, 
230, 237, 241, 345. The problem with this variable is that, being a count, it has a Poisson 





distribution and is over-dispersed i.e. has greater variability than expected. This 
raises major difficulties in defining a clinically significant mean reduction in FIE 
within a population of patients with widely dispersed starting FI frequencies. To 
counter this problem, contemporary studies have adopted a primary outcome for 
"success" using a categorical measure of percentage reductions i.e. the proportion 
of patients who have a 50% or greater reduction in FIE per week 167-169, 171, 218, 230, 237, 
241, 345. The most accepted criterion for “successful treatment” has previously been 
defined as a greater than 50% improvement in the number of FI episodes per week 
164. 
 
The principal use of this outcome measure is at the PNE stage to identify patients, in 
whom continence is adequately controlled and might therefore benefit from an 
implanted neurostimulator for chronic treatment (accepting the expense and 
limitations of a permanent implant). This criterion has been taken as received 
wisdom, born from the urology literature from which much of SNS FI methodology 
has been developed.  Because of the life altering consequences and expense of a 
permanent implant, it is necessary to carefully select patients in whom continence is 
adequately controlled and can gain lasting benefit from a second stage operation.  
 
As demonstrated from the systematic review findings, there is still an approximately 
20% [Table 3.03] medium to long term failure rate, i.e. those unable to maintain the 
original PNE effectiveness (>50% improvement in FIE) with their permanent 





implantation. With this consideration the 50% improvement criteria, based on 
objective measurements, may give a false evaluation of the success of therapy. In 
addition, patients with severe incontinence who obtain a “successful” reduction in 
incontinent episodes may continue to experience incontinence at a level that 
continues to impair social functioning and quality of life 186.  
 
Faecal incontinence severity scores 
To overcome the problems with subjective self reporting, many have developed and 
employed FI symptom grading instruments to provide objective measures of FI 
severity. A universally agreed upon standard scoring/grading system does not exist. 
Authors have often devised their own systems in an effort to describe baseline 
patient symptomatology before and after interventions. These classification systems 
are numerous and diverse. Many are not validated and have been used only by the 
author who devised them. Therefore reproducibility across clinicians, patients, 
procedures and treatments remains unknown. Many of the grading/scoring systems 
recorded in the current literature suffer from a variety of shortcomings including: a 
lack of objectivity, being descriptive in nature 346, 347, using objective parameters 
such as anal manometry or difficult to classify subjective parameters 348 which often 
do not correlate with clinical conditions, or do not account for frequency of the 
incontinent episodes in individual patients 349, 350. Several anal incontinence grading 
or scoring systems have been prospectively developed and tested.  





The simplest scale method was initially presented by Browning and Parks in 1983 
(Table 4.01) 130. This scale includes four main categories in which the lowest grade is 
normal continence and the highest is total incontinence: it was originally used to 
assess the success (or otherwise) of a posterior Parks’ anal sphincter repair. The 
Parks’ scale, whilst easy to use and remember, had several major shortcomings as it 
did not address symptom severity or the frequency of incontinence episodes. 
 
Table 4.01: Browning and Parks’ incontinence scale 
Grade Severity of incontinence 
I Normal continence (i.e. continent for solids, liquid stools 
and flatus) 
II Continent for solid and liquid stools but not for flatus 
III Continent for solid stools only. Usually presented with 
faecal 
leakage 




Later scoring systems have added more relevant parameters pertaining to severity 
of incontinence. Currently four FI instruments - Cleveland Clinic Incontinence Score 
(CCIS)  191 [Table 4.02], St Marks (Vaizey) 351 [Table 4.03], Pescatori Anal Incontinence 
Score 352 [Table 4.04] and the Faecal Incontinence Severity Index (FISI) 353 [Table 
4.05] - are the most established and are commonly used in clinical studies to rate 
the severity of FI 11, 354, 355. All these scales for rating the severity of FI incorporate 
the type and frequency of leakage.  
 
 






Table 4.02: Cleveland Clinic incontinence score  
Type of incontinence Frequency 
 Never Rarely Sometimes Usually Always 
Solid 0 1 2 3 4 
Liquid 0 1 2 3 4 
Gas 0 1 2 3 4 
Wears pads 0 1 2 3 4 
Lifestyle alteration 0 1 2 3 4 
0, perfect continence, 20, complete incontinence 
Never, 0; rarely, <1/month; sometimes, <1/week and >1/month; usually, <1/day and >1/week; always, 
>1/day   
 
Perhaps the most widely used scale or grading system is the CCIS developed by Jorge 
and Wexner 191. This was the first system to account for the use of pads, changes or 
alterations to lifestyle, consistency and frequency of incontinence. The CCIS is 
derived from numerical values assigned to the frequency of occurrence (scored 0-4) 
in each of several categories including type of incontinence (solid, liquid, gas), pad 
use, and lifestyle alteration. A minimum score of 0 indicates perfect continence, and 
a maximum score of 20 indicates complete incontinence [Table 4.02]. Each of the 
incontinence presentations is graded equally in this scoring system and no 
psychometric items are included, other than the non-specific ‘Lifestyle Alterations’ 
item. 
 
Criticisms of the CCIS may be that it does not take specific account of faecal urgency, 
even in the absence of specific incontinence episodes, nor of the importance of the 
use of a pad in terms of continence, which are both given equal weighting. Pad use 





may also reflect urinary incontinence or patients’ hygienic concerns, independently 
of episodes of incontinence; further, it does not assess the use of specific anti-
diarrhoeal medications. These deficiencies are addressed in the St. Mark’s (Vaizey) 
score, published in 1999 351, is also commonly used in clinical studies and reports 
and was based on the CCIS but added two further items for assessment: the use of 
constipating medication and the presence of faecal urgency. The relative weighting 
of pad (or anal plug) use was decreased in this score, where the designers felt that 
such use may represent more the subjective fear of social embarrassment, rather 
than actual frequency. This revised score was validated against clinical expert 
assessment in the primary evaluation as well as in estimations of therapeutic 
efficacy and in pre- and post-surgical assessments [Table 4.03]. 
 
Table 4.03: The St. Marks (Vaizey) incontinence score 
Type of incontinence Frequency 
 Never Rarely Sometimes Usually Always 
Solid 0 1 2 3 4 
Liquid 0 1 2 3 4 
Gas 0 1 2 3 4 
Lifestyle alteration 0 1 2 3 4 
    No Yes 
Need to wear a pad or 
plug 
   0 2 
Taking constipating 
medicines 
   0 2 
Lack of ability to defer 
defecation for 15 minutes 
   0 4 
Never = no episodes in the past four weeks; Rarely = 1 episode in the past four weeks; 
Sometimes =>1 episode in the past four weeks but <1 a week; Usually = 1 or more episodes a week 
but <1 a day; 
Always = 1 or more episodes a day. 
Add one score from each row. 
Minimum score is 0 = perfect continence; maximum score is 24 = totally incontinent. 





The Pescatori Anal Incontinence (AI) score 352 [Table 4.04] is another grading system 
widely used throughout Italy and also combines both degree of incontinence 
(flatus–mucus/liquid stool/solid stool) with frequency. Incontinence ratings of A, B 
and C indicate AI for flatus/mucus, liquid stool, and solid stool, respectively; 
frequency scores of 1, 2 and 3 indicate occasional, weekly, and daily AI. A score of 
zero is given for normal continence. The combined score is the sum of the degree 
and the frequency (e.g. A3 = 1 + 3 = 4; C2 = 3 + 2 = 5). The minimum score is 0 and 
the maximum score is C3 (= 6). 
 
Table 4.04: The Pescatori incontinence score 
 Degree Frequency  
A Incontinence for flatus/mucous Less than once a week 1 
  At least once a week 2 
  Every day 3 
B Incontinence for liquid stool Less than once a week 1 
  At least once a week 2 
  Every day 3 
C Incontinence for solid stool Less than once a week 1 
  At least once a week 2 
  Every day 3 
Anal Incontinence (AI) score = AI degree (A = 1, B = 2 or C = 3) + AI frequency. 
 
 
The Faecal Incontinence Severity Index (FISI) [Table 4.05] developed by Rockwood et 
al. 353 applies an external weighting scheme to a 20 cell matrix table and has been 
evaluated as a questionnaire for assessing the severity of AI 353.  The researchers 
constructed the FISI by looking at type (gas, mucus, liquid and solid) and frequency 





(5 categories) of incontinence episodes. The FISI was then distributed to both 
physicians and patients for weighting and scoring. Although there was good 
correlation between the two groups, clearly some aspects of FI were more 
important to patients then to clinicians, generating two different graded numerical 
results. The final weighted score is therefore dependant on who is completing the 
FISI assessment tool. The severity score ranges from 0 to 61 when using the 
recommended patient-derived weights and from 0 to 59 when using the surgeon-
derived weights. In this approach there is an assumption that the frequency with 
which different types of FI events occur, the coping mechanisms used and how 
lifestyle is altered, is not equal and because of that weighting mechanisms are 
valuable 353, 356. Although the weighted approach probably provides for making more 
accurate and valid inferences regarding severity, it is not known if such accuracy is 
truly required. 
 
Table 4.05: The Faecal Incontinence Severity Index 
Patient 
checklist 
2 or more 
times a day 





1-3 times a 
month 
Never 
Weights A B A B A B A B A B A B 
             
a. Gas 12 9 11 8 8 6 6 4 4 2 0 0 
b. Mucus 12 11 10 9 7 7 5 7 3 5 0 0 
c. Liquid stool 19 18 17 16 13 14 10 13 8 10 0 0 
d. Solid stool 18 19 16 17 13 16 10 14 8 11 0 0 
             
NOTE. A denotes patient rating of severity, and B denotes surgeon rating of severity. “Never” always 
receives a score of 0. 
 
 





The bowel version of the International Consultation of Incontinence questionnaire 
(ICIQ-B), the Faecal Incontinence and Constipation Assessment (FICA) and the 
Revised Faecal Incontinence scale are the most recently developed and validated 
instruments; however, they have not been widely used in clinical studies 357-360. Out 
of these newer grading systems the most innovative is the ICIQ-B which will be 
discussed in more detail later in this section. 
 
Faecal incontinence quality of life measures 
Clinical outcome measurement tools such as prospective bowel diaries and clinical 
grading systems have been suggested as helpful aids in the assessment of FI severity 
but in contrast to many other disorders, currently no universally accepted 
symptomatic index of FI accurately reflects clinical severity 91. Therefore, conflicting 
opinions remain regarding the most suitable assessment measures for determining 
intervention outcomes with questions over their accuracy and utility 168, 237. 
Problems with, leakage, hygiene, social embarrassment and the ability to reach the 
toilet in time are all other limiting factors to patients' daily living which may not be 
formally assessed through these measures 168. Inadequate clinical outcome 
measures may not reflect changes to individual patient’s lives and this raises 
problems when evaluating treatments. 
 
It is believed that even the most commonly used scoring method, CCIS 191, may not 
be sensitive enough to pick up subtle improvements in patient condition 168. Leroi 





argues that two criteria (used to calculate the CCIS), wearing protection and the 
impact on social life often require more than 6 months to change, even if the 
treatment is effective, as patients may need time to regain confidence 168. Some 
authors have felt that the success of interventions cannot be measured by changes 
of involuntary stool loss alone and strongly advocate analysing QoL 227, 237. Previous 
studies have shown there to be correlation between QoL variables such as 
depression/embarrassment and symptom measures (i.e., frequency of FI episodes, 
of urgency and delay to postpone defecation and CCIS); demonstrating the 
emotional improvement that accompanies incontinence recovery 168 
 
Self recorded bowel diaries and severity scores do not account for any quality of life 
improvements which often depend on the patient’s confidence and ability to 
interact within society. Inadequate clinical outcome measures may not reflect 
changes to individual patient’s lives and this raises problems when evaluating FI 
treatments. Some authors have felt that the success of SNS cannot be measured by 
changes of involuntary stool loss alone and strongly advocate analysing QoL 
measures 227, 237. Although many different QoL measures have been used to assess 
the impact of FI, FIQL score, SF-36 and EuroQoL EQ-5D assessment instruments are 
the most commonly used and therefore chosen to be employed in this study. 
 
The FIQL 82 is a disease specific QoL measure providing subscale scores for each of 
the four domains: lifestyle, coping/behaviour, depression/self-perception and 





embarrassment. A higher score within the domain signifies an improved QoL. The 
SF-36 198 is a generic QoL assessment tool; it rates quality of life on a scale of 1–100 
(a high score indicates better function) in eight subscales: physical functioning; 
physical role; bodily pain; general health; vitality; social functioning; emotional role; 
and mental health. These subscale scores can be summarised to provide scores 
within the physical component and mental component categories. The EuroQoL EQ-
5D 199 assessment tool comprises of five dimensions of health including mobility, 
self-care, usual activities, pain⁄discomfort and anxiety⁄depression. It has been found 
that the EQ-5D scale substantially correlates with selective scales of the SF-36 361. 
Each dimension comprises three levels including no problems, moderate problems 
and extreme problems.  
 
Several issues must be resolved before an ideal scoring system is developed: the 
definition of incontinence must be standardised; the optimum method of data 
collection must be decided on (i.e., diaries and severity scores versus patients’ 
recall); the need for data beyond type and frequency must be assessed; and the 
assignment of numerical values to the combinations of type and frequency must be 
validated 21.    
 
Another limitation of our study could include our choice of outcome measures and 
denotation of success in FI treatment. Research into treatment of FI is currently 
hampered by the lack of a valid and reliable tool that allows standardisation of 





outcomes. Inadequate clinical outcome measures may not reflect changes in 
individual lives and thus raises problems when evaluating FI therapies. With these 
considerations the 50% improvement criteria, based on objective measurements, 
may give a false evaluation of the success of therapy in this study. With this type of 
measure the starting point of severity of symptoms or number of FIE is the 
overriding factor. For instance, patients with severe incontinence who obtain a 
“successful” reduction in incontinent episodes may continue to experience 
incontinence at a level that continues to impair social functioning and QoL 186. Even 
those with less severe baseline symptoms may find it relatively easier to attain 50% 
reduction in symptoms without a change in effect.  
 
The use of multiple different clinical measures within the literature reflect efforts to 
compensate for the known limitations of this success measure with many 
institutions electing to use their own definitions of treatment success (from: a 50% 
improvement in CCIS to patient satisfaction with SNS) 253, 260, 287, 362; particularly in 
the evaluation of the medium and long-term effects of SNS. These reports may 
provide a more realistic rate of treatment success, but without consensus across 
studies, results remain inconclusive [see Table 4.06] .  
 
 

























Short Term Follow Up (up to and including 12 months) 
Jarrett M 229 12 46 46 100 Improved continence 44 96 75 
Rasmussen O 231 6 37 37 100 Functioning SNS system  32 86 71 
Uludag O 232 12 50 50 100 Improved continence  48 96 76† 
Hetzer FH 185 1* 13 13 100 Decrease in CCIS  13 100 65 
Jarrett M 233 12 12 12 100 Improvement in FIE  9 75 69 
Leroi AM 168 6* 34 27 79 Chosen as "on" stimulation  19 70 n/a 
Faucheron J 234 6* 29 29 100 Improvement in continence 24 83 60 
Navarro J 240 12* 24 24 100 Decrease in CCIS  16 68 62 
Roman S 273 3* 18 18 100 Sig imp in FI  14 78 n/a 
Gallas S 280 6* 200 189 95 >30% imp in CCIS 103 54 52 
Uludag O 279 6* 12 12 100 >50% imp in continence 12 100 n/a 
Medium Term Follow Up (between 12 and 36 months) 
Kenefick N 235 24 19 19 100 Improved continence  19 100 100 
Hetzer FH 237 13 37 37 100 Sig imp in continence 34 92 77† 
Holzer B 238 35 29 29 100 Marked improvement in 
continence  
28 97 78 














Koch SM 252 24‡ 19 19 100 Persisting continence 17 89 49† 
Michelsen HB 253 36* 126 107 85 Decrease in CCIS scores  87 81 52 
Ratto C 278 33 10 10 100 Sig imp in FI  10 100 n/a 
Maeda Y 260 33 176 163 93 Good and Acceptable 
outcome (some clinical 
benefit) 
103 63 44 
Pascual I 261 13 48 48 100 Patient perceived success 45 94 90 
Wong MT 262 31 61 61 100 CCIS <8 or failed if > 1 FIE per 
week  
36 59 40 
Long Term Follow Up (more than 36 months) 






>50% improvement of CCIS,  







Vallet C 249 44‡ 32 23 72 Patient satisfaction with 
“Good result” 
12 38 27 
Sharpe A 255 50 44 44 100 Patient satisfied + CCIS 10 or 
less 
37 84 62 
Key: * = values taken at time point; † = inten on to treat reported; ‡ = mean values (integer values); 
n/a = not able; FU = follow up; SNS = Sacral Nerve Stimulation; FIE = faecal incontinence episodes; 
CCIS = Cleveland Clinic Incontinence Score; Sig imp = significant improvement; A = group with anal 
sphincte defects; B = group without anal sphincter defects.  All values are calculated to nearest 
integer. This table demonstrates the multiple methods of determining "successful SNS treatment" as 
found in the SNS literature; ranging from subjective improvements in symptoms to arbitrary 









Current study outcome measures used 
Despite the considerable limitations of current clinical outcome measures, we have 
shown that the reporting of CCIS, FIE and "success measures" are prevalent and 
provides most of the evidence for the effectiveness of SNS. This is most likely due to 
their ease-of-use and standardised methods, with this outcome data providing 
readily interpretable discreet numerical scores or counts. As many of the centres 
providing SNS have also investigated the use of other NM systems for incontinence, 
it is not surprising that these outcome measures have also been integrated into the 
assessments of alternate FI therapies. 
 
In keeping with the tenets of the pilot design, there was no pre-specified primary 
outcome. To try and address limitations of specific outcome measures we used a 
range of alternative measures of success including proportional reductions in FIEs 
75% and 100% and also 50% reduction in CCIS.  Akin to previous reports on NM, 
we further measured the effectiveness of each treatment by presenting the mean 
changes in total FIE, mean changes in CCIS and changes in QoL scores. These data 
outcomes may better represent improvements in severe incontinence which may in 
turn reflect patient perception of treatment outcome more accurately.  
 
Unsure of whether available outcome measures would adequately capture patient 
perspective symptom changes, due to NM treatment; the PCOM assessment tool 
was developed especially for the trial. The PCOM was designed as a two part 





questionnaire. The first part (question 1), a simple Likert type scale between 1-10 (1 
being least effective and 10 most), aimed to demonstrate subjective satisfaction of 
the patient's current therapy. All recruits had received maximal conservative 
management (i.e. physiotherapeutics, dietary advice and medications) for their FI, 
changes in this score from baseline would indicate patient satisfaction with NM 
intervention as compared to previous therapies. Likert type scales in questions 2-6 
of the PROM focused on exploring the current effect of FI on different aspects of 
patient wellbeing regardless of treatment. These five questions were loosely based 
on the assessment of factors found to be of particularly importance to FI patients as 
determined by Cotterill et al. in 2008 78. The formal International Consultation on 
Incontinence Questionnaire for anal incontinence (ICIQ-B) assessment tool was the 
primary development from Cotterill's original studies but was only published in 
entirety in 2011 363 (see Appendix i for full questionnaire). The PROM assessment 
tool used specifically in our pilot trial in 2009 was developed completely 
independently from the ICIQ-B. Despite this, the similarities between the two 
outcome tools focussing on patients' subjective assessment of the consequences of 
their FI are marked. It may be consequently considered that our PROM assessment 
tool provides an alternative modified short form version of the ICIQ-B questionnaire.   
 
Unlike other validated and globally used symptom scores in this trial, the PCOM 
provides a completely subjective outcome measure based on the opinions of the 
patients in the trial only. There can be no inference of meaningful comparisons 





between the PCOM scores and other outcome clinical or QoL scores as there have 
not been any prospective rigorous tests or assessments to prove its validity. The 
authors expect that the within group differences may represent a degree of change 
in satisfaction with treatment but also cannot be sure that there is any statistical 
usefulness in analysing these changes as Likert type scores are notoriously subject to 
"central tendency bias". However, there is a pattern of PCOM score improvements 
after treatment as compared to baseline, with greater within group improvements 
found in the SNS group over PTNS. This correlates with all other clinical scores and 
the FIQL measure used in the trial. The authors found that being brief (one side of 
A4) the patients did not find it difficult or onerous to complete this questionnaire 
which was reflected in its 100% completion rate for those that remained in the trial. 
This was equivalent to all other clinical measures used. 
 
4.4.2.8  Use of qualitative methodology 
 
Given the aim of the study and participant numbers, the authors considered it was 
appropriate to use "thematic content analysis" as the method of data analysis. 
Alternative methodologies already used for these types of interviews have been 
Interpretative Phenomenological Analysis and Grounded Theory approaches. The 
aim was to maintain a phenomenological perspective although the larger number of 
our participants and the comparative analysis between interviews would be too 
complex to undertake with these methods. In the project's qualitative interview 





design, there was a trade-off between having a deeper emersion into exploring the 
life world of our participants and allowing them to provide honest unbiased 
accounts. To this end its was felt that the flexible and highly idiographic method of 
thematic content analysis was the most suitable and achievable method of analysis 
for this study. 
 
An added complexity was the conduct of interviews by a neutral person 
(independent research assistant) and then subsequent analysis by a different 
member of the team (CRF). The SSG felt that given the resource restrictions 
(especially as each interview transcription and analysis taking many hours each), it 
would be difficult to find an independent researcher who could undertake the study 
in entirety. Therefore the division of labour was the most appropriate arrangement 
for ensuring all information given was as valid, truthful and complete. It is 
conceivable that when the CRF analysed the audio recorded interviews, expressions 
and emotions which are usually acknowledged through non-verbal communication 
may be lost. In truth some information such as gestures may be significant, most 
subtle interactions could be determined through analysis of the use of language and 
tone of voice from both interviewer and patients. A preferred set-up may have been 
to use video recorded interviews for data collection. However, it could be argued 
that patients may have found a video camera to be more intrusive and therefore 
when being recorded become self conscious and less open; defeating the ideals of 
the  study. 





4.4.2.9  An optimum PTNS treatment protocol 
 
A further criticism of the study regards the optimal interval between maintenance 
sessions required to maintain symptom relief. Hotouras et al. have acknowledged 
that the lack of published data on the long-term efficacy of PTNS may require some 
patients  to require therapy sessions more frequently than the recommended 6-
monthly intervals. In fact in both Martinson's 304 and Al Asari's studies 307 (discussed 
earlier in this chapter, section 4.2.1), maintenance therapies of approximately once 
a month was required to maintain benefit. In these studies the effectiveness of 
PTNS may have been greatly improved because of frequent "top-up" therapies. 
There is still no consensus agreement over a standard protocol for PTNS therapy 
making long-term cost effectiveness impossible to model. 
 
4.4.3 SUMMARY OF LIMITATIONS 
 
As pilot studies, the limitations of the small sample size, short follow up and lack of 
comparative placebo on the ability to determine meaningful conclusions over 
treatment superiority are undisputed. The investigators have avoided attempting to 
analyse the data in directly comparative way and have instead provided descriptive 
statistics using median and mean estimates,  interquartile ranges and confidence 
intervals, only as a guide for informing further studies (see Chapter 3, section 3.2). 
The results demonstrated that for all clinical outcome measures there have only 





been small differences in within group mean improvements between SNS and PTNS 
at both 3 and 6 months with overlapping confidence intervals indicating that neither 
treatment was clearly superior in clinical effectiveness. A full equivalence trial would 
be necessary to test this hypothesis.  However this unique study has attempted to 
be innovative in its use of a mixed method design including the use of established 
and novel clinical outcome measures, qualitative interview studies and an analysis of 
costs. The study was completed as designed, to cost and time and therefore has 
been successful in accomplishing its designated remit in producing detailed 
feasibility information, both quantitative and qualitative, upon which decisions to 
undertake a fully powered randomised study can be based. 
 
 
4.5 CONDUCTING A FULL MULTICENTRE TRIAL: SAMPLE SIZE AND FEASIBILITY 
 
Before conducting the trial, an estimated sample size calculation for a suitably 
powered  RCT of SNS vs. PTNS revealed that more than 2000 patients would be 
required to detect a difference in proportions of at least 5% (see Chapter 2 section 
2.9.2.4). The overall rationale for our pilot study was to acquire, using an exploratory 
trial design, the necessary quantitative and qualitative data to inform a subsequent 
definitive RCT comparing SNS and PTNS. We aimed to determine the variability and 
distribution of clinical endpoints as well as qualitative data to inform the most 





suitable and responsive outcome measures for a subsequent well designed and 
sufficiently powered RCT.  
 
If, accepting the difficulties of design and conduct, a full equivalence trial would be 
required to provide meaningful results, the equivalence margin would first need to 
be determined. While the effect estimates from this pilot trial, which included all 
common currently used outcome measures, are undoubtedly useful, the 
interquartile ranges (and large standard deviations) will have a significant impact on 
future trial design. It must be accepted that an adequately powered randomised 
trial of these two complex interventions would be a major and costly undertaking. 
The current data could be used to design such an equivalence trial but the sample 
size would need to be very large. Even using the simplest outcome measure, the 
binary responder (>50% improvement in weekly FI episodes) and an non-inferiority 
margin of 20%, assuming 40% success in PTNS and 50% in SNS, we would require 
506 patients in each group 364. However, assuming that a third fail temporary 
stimulation or withdraw from treatment (as in the current data): the SNS group 
would need 759 patients. With further attrition in both groups of 10%, 843 patients 
would be required in the SNS and 562 in PTNS. Extrapolated back from the current 
data, 3189 patients would need to be screened to recruit to the trial. Such a trial 
would also need to address the other major weakness of the current study, that of 
the short follow up time (6 months only). It is well-acknowledged that the outcomes 
of interventions for functional disorders in the short-term may not reflect accurately 





those at later follow-up. While a minimum of 1 year follow-up would have been 
desirable, there are sufficient data for SNS to suggest that accepting a degree of 
long-term attrition in outcome (10-20%) and need for re-intervention and re-
programming 260, benefit is usually maintained in the long-term, with some patients 
now having implants for over 15 years 197, 268. Such data do not exist for PTNS and it 
will be important to know whether short-term outcomes are maintained and at 
what intensity (and therefore cost) of top-up treatments are required to sustain 
benefit. Detailed cost-effectiveness modelling would then be required to fairly 
compare SNS and PTNS to a long-term time horizon. Qualitative findings support 
concern that for some patients, repeat hospital visits for treatment might prove 
onerous for patients who have a life-long illness. In contrast, other patients 
expressed a clear preference (2 withdrawals before therapy) against surgical 
intervention with SNS. These factors will also be considered in any future studies. A 
definitive RCT directly comparing SNS and PTNS even in a international multicentre 
trial would probably be unfeasible. 
 
 
4.6 THE CLINICAL IMPACT OF THESE EXPLORATORY STUDIES 
 
The review adds to the literature by presenting summaries of the available short, 
medium and long-term clinical scores and success rates of two of the most popular 
NM therapies: SNS and PTNS. We believe that these summarised outcomes may be 





useful in informing both clinicians and patients considering NM therapy for FI. The 
simple estimates presented in this review may be used as a counselling aid, enabling 
patients to understand the true effectiveness of each technique. This information 
together with consideration for individual circumstances may help determine the 
most suitable treatment options. We have presented data for SNS both on an ITT 
and per-protocol basis with the rational that each is useful depending on whether 
the patient has already undertaken PNE.  
 
Given the cheaper initial outlay of PTNS and a possible delay in gaining funding for 
SNS, PTNS could offer a relatively affordable 'first line' outpatient treatment to 
many FI patients who have failed conservative management. It could also be 
considered as an adjunct to SNS and a useful ‘stop-gap’ treatment for those awaiting 
the more permanent solution of SNS.  As well as providing some form of treatment 
above conservative measures to those unable or unwilling to have surgery, it would 
be a very useful treatment if there is a delay in gaining SNS funding. TTNS is an 
attractive alternative to PTNS but at present it is still in the evaluation phase (see 
section 4.7). 
 
This randomised trial has provided the first direct comparison of clinical outcome 
and health economic data for both SNS and PTNS, contextualising quantitative 
findings with qualitative appraisal of acceptability of both the interventions and the 
outcome measures. Our exploratory study is a step towards providing the evidence 





base to expand treatment choice for patients including those currently marginalised 
from interventional therapy e.g. elderly care home residents. Indeed, our results 
and others discussed, have demonstrated that PTNS could become the routine first 
‘invasive’ intervention in patients with FI failing prior conservative physician- and 
nurse-led approaches with significant reductions in operations, hospital stay, 
complications, waiting times and cost of treatment. In the absence of a fully 
powered equivalence study, and with the assistance of appropriate regulatory 
bodies e.g. NICE, it is likely that this project can provide some background evidence 
for the accelerated roll-out of PTNS nationally, with significant impact on NHS policy 
and resource utilisation. PTNS improves clinical outcomes in FI in the short term 
although it may not be as effective as SNS. It is also a highly acceptable treatment 
for patients and is certainly less invasive than SNS. It is notable that in a recent study 
comparing percutaneous with transcutaneous PTNS, which showed the superiority 
of the former technique, some patients responded so well to PTNS that they were 
taken off the SNS waiting list 365.  
 
Due to the paucity of long-term data we cannot recommend PTNS as a complete 
alternative to SNS. Accurate cost-effectiveness studies in long term timescales will 
be very important to determine if PTNS is a true financial competitor for SNS 
especially with the need to have regular ongoing top-up treatments. At the moment 
the optimum interval of top-up treatments to maintain affect whilst preserving 
resource is still being investigated. The other suggestion that PTNS can be a 





predictive or evaluative tool for SNS is so far unfounded. As we are unsure of the 
mechanisms of both SNS and PTNS, we cannot determine whether they effect a 
shared neurological pathway. In fact akin to Thomas's observations 366, no PTNS 
studies have ever been proven to elicit an anal motor reflex seen with SNS. 
Furthermore a previous study at the author's centre 367 could not determine 
whether patients  who had initial success with PTNS but needed frequent top-up 
treatments had a greater chance of success with SNS than those who failed PTNS 
outright.  
 
It would make sense that patients who failed the more conservative PTNS proceed 
to SNS therapy but there have not been any studies that have trialled the effect of 
PTNS in those failing SNS. It is possible that if these treatments worked via different 
mechanisms that PTNS could offer some treatment benefit to this group. An 
alternative theory may be that SNS innervates nerves more centrally and therefore 
provides a larger stimulation "dose" to the end neural interface providing improved 
action. The use of pudendal nerve stimulation is also of interest as this technique 
claims to provide even more focused stimulation to the pudendal nerve, although 
this has not been proven to be effective in all patients who failed SNS 368. 
Unfortunately the pudendal nerve stimulation is no longer licensed for use in FI and 
therefore cannot be further investigated this point. 
 
 





4.7 FUTURE TRENDS AND FURTHER RESEARCH 
 
Currently, the largest centres internationally 197, 245, 253, 268 are able to report their 
long-term experience with SNS; demonstrating a maintained clinical benefit. 
Furthermore there is growing interest in the potential of newer, less invasive and 
less costly NM techniques (like PTNS and TTNS). Unfortunately, direct comparisons 
with more established surgical therapies (e.g. sphincter repair) are almost 
impossible given the heterogeneity of current NM outcome reporting; as 
demonstrated in the review. To enable fair comparisons with other interventions; all 
future outcome reporting must include an ITT analysis.  
 
As mentioned, there is continuing controversy regarding the classification of 
'treatment success' for FI therapies and it is likely that a combination of outcome 
tools will continue to be used for this purpose. It is recommend that a consensus to 
standardise the use of outcome measures and indicators of success for FI in order 
that further reports can be compared in a meaningful way. This could be attained by 
the enrolment of all patients undergoing SNS into a national registry. 
 
Currently only 8-10 UK centres offer PTNS as an NHS treatment and some feel it is 
still an underutilised treatment option. In the future, as  PTNS is simple to 
administer and easy to learn, it may become available in local hospitals or 
community-based settings. From the results of the presented qualitative  study 





there has been some reservations about the use of self-administered "home" PTNS; 
as many of the participants expressed a preferrence for treatment to be undertaken 
by trained experts. It is also difficult to know whether the efficacy of treatment 
would be better or worse than current published data if it were self-administered. 
Further studies will have to be undertaken to provide validation for self-
administration methods. This does not preclude however a mobile or outreach 
service which could be conducted either in secondary care or in community practice. 
The main advantage of PTNS are its initial costs and simple mobile equipment 
especially when compared with SNS. It is therefore a particularly good alternative to 
for those currently marginalised, i.e. nursing home residents or house-bound 
patients. 
 
Patient selection and the mechanism of action of NM therapies are topics that have 
not been specifically addressed in these studies, but a deeper understanding of 
these may help to improve clinical outcomes. Currently, the unknown mechanisms 
of NM and concerns over the high numbers of case series and selection bias due to 
lack of clear reporting of subsequent withdrawals or losses to follow up, mean a 
placebo effect still cannot be confidently excluded. Understanding the mechanism 
of action of these treatment will be key in determining the correct FI aetiologies to 
focus on and therefore improve outcomes. As anorectal physiological assessment 
techniques and aetiological understanding evolve, FI stratification will be improved 
and therefore therapy can become more targeted. In fact two pivotal PTNS studies 





324, 369 demonstrated that when patients were stratified into those with 
predominantly urgent FI, their outcomes with PTNS were superior to those of 
passive FI. In Hotouras et al.'s prospective case series on short term outcomes, 
patients were stratified into either passive, urgent or mixed FI. In the urgent FI 
group, following treatment, there were statistically significant improvements in the 
CCIS, from 11.0  (SD:4.1) to 8.3 (4.8), the time to postpone defaecation (from 1.0 to 
5.0 min) and the average number of weekly incontinence episodes (from four to 
zero per week). Whereas in the passive FI group, the mean CCIS improved from 11.5  
(4.1) to 9.4 (4.3), accompanied by similar improvements in the median defaecation 
deferment time (5.0 to 12.5 min) and median number of weekly incontinence 
episodes (from four to three per week) which were not significant on statistical 
testing. Equally in the eagerly awaited Horrock et al.'s multicentre study 
(CONFIDeNT) of 227 patients randomised to either PTNS treatment or sham, PTNS 
did not show significant clinical benefit over sham electrical stimulation in the 
treatment of FI based on number of patients who received at least a 50% reduction 
in weekly FIE. There was, however, a significantly greater decrease in total weekly 
FIEs in the PTNS arm than in the sham arm (difference in means –2.3, 95% CI 
–4.2 to –0.3; p = 0.02). This included a reduction in the number of urge FIEs weekly 
(–1.5, 95% CI –2.7 to –0.2; p = 0.02) but not in the number of passive FIEs (–0.64, 
95% CI –1.67 to 0.40; p = 0.23)324. In view of the results, there may be a justification 
in continuing to treat a subgroup of patients with troublesome urge FI symptoms in 
whom directed therapy may cause symptomatic improvement324, 369. Further studies 





of PTNS should be directed at those with urge FI to determine the clinical 
effectiveness. 
 
On the horizon, it is predicted that even more non invasive methods of 
neuromodulation using skin contact devices will be increasingly used. We have 
already presented some data with small participant numbers detailing the use of 
TTNS. Although they have not yet managed to prove their effectiveness against the 
more established PTNS for FI 173, 370, TTNS treatments are attractive because of the 
ease of use, non invasive technique and now ambulatory devices. A pilot study on an 
ambulatory device has been published recently by Rimmer et al.371 Many are looking 





Long-term equivalence between the effectiveness of SNS and PTNS outcomes would 
have to be proven before PTNS can be recommended as a complete alternative to 
SNS.  Despite PTNS being seemingly cheaper than SNS, the true long term patient 
costs of either treatment are still unknown; particularly as PTNS requires regular 
repeated treatments for an unknown and potentially prolonged period of time. 
Further well-conducted randomised trials comparing different therapies, using 





standardised protocols and outcome measures, may supply the high quality clinical 
evidence required to design a definitive treatment algorithm. 
 
This body of work including a pilot randomised trial suggests that in the short-term, 
both SNS and PTNS confer some clinical benefit for patients with FI. Within group 
effect estimates were in general larger for SNS based on analysis of all patients 
embarking on treatment with greater effects seen when focussing the analysis to 
only those who progressed to permanent implantation. This finding is in keeping 
with non-randomised comparisons of SNS and PTNS identified in the review with 
results presented in Chapter 3 166. The qualitative study revealed some of the 
personal difficulties that living with FI brings and demonstrated that appropriate 
treatment can make a real difference to many aspects of individual life. In terms of 
the two treatments available, our participants were pleased with both novel 
therapies although SNS seemed to produce more noticeable symptomatic benefits. 
Both treatments were highly acceptable and well tolerated by patients although 
some had expressed a wish for more expertise to be available locally. The minimal 
invasiveness and positive side effect profiles of these treatments seem to have 
contributed greatly to the enthusiasm for both treatments. Even if the treatment 
did not work as well as participants had expected, they found confidence and 
comfort in the process of treatment. This helped them to cope better and be more 
open about their problems. 





These studies provide evidence that SNS analysed on an all-available-cases principle 
(similar to intention-to-treat) was a more expensive treatment in the short term 
with only a potential small treatment benefit over PTNS. Unfortunately the pilot has 
revealed that a definitive full scale non inferiority RCT would probably be unfeasible. 
While longer-term outcomes and economic modelling will be required to make firm 
conclusions. However, as the short term costs are advantageous and the technique 
easily tolerated and accepted, it may be considered that PTNS can be employed for 
patients with FI failing prior conservative approaches or are awaiting SNS. 
Furthermore, the author believes localised/mobile PTNS treatments could be 
relatively easily implemented throughout primary care settings requiring only 
modest training and little financial outlay. The author believes that these types of 
community services would greatly assist those who are currently marginalised 
because of time, financial or physical restraints. Excitingly, further work on 
ambulatory transcutaneous devices is being undertaken which if prove to be 
effective, would also make a welcome addition to the armamentarium against FI. 
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Patient Identification:    Hospital Number:   Date: 
 
 
Please answer each statement by circling the most appropriate answer: 
 
 
1. I feel my current treatment is helping me with my faecal incontinence. 
 
Strongly           Strongly  
Disagree          Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
2. I feel I can cope with my faecal incontinence problems. 
 
Strongly           Strongly  
Disagree          Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
3. I feel confident to go out in public without feeling embarrassed. 
 
Strongly           Strongly  
Disagree          Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
4. I feel I can predict and prepare for any incontinence accidents. 
 
Strongly           Strongly  
Disagree          Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
5. I feel I am no longer looking for the nearest toilet. 
 
Strongly           Strongly  
Disagree          Agree 
0 1 2 3 4 5 6 7 8 9 10 
 
6. I feel my incontinence problems no longer restrict my social activity. 
 
Strongly           Strongly  
Disagree          Agree 
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Date:            
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Section A: Resource use questionnaire 
This section is about the health care you have received 
 
All questions refer to the three months before completing this questionnaire. 
 
We would like to know about contacts you have had with health professionals in the last 
three months. This is just in regard to your faecal incontinence. 
 
 
1. In the last 3 months, have you been seen by any of the following at your GP 
surgery?  
 
 Your own or another GP 
 Nurse 
 Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No         Please go to Question 2  
 
 
Yes      Please enter the number of times 
       
      GP 
    
Nurse    
 
 





2. In the last 3 months, have you been seen by any of the following at home?  
 
 Your own or another GP 
 Nurse 
 Any other health professional (e.g. dietician, physiotherapist, health visitor) 
 
No          Please go to Question 2  
 
Yes       Please enter the number of times 
 
      GP  
   
Nurse  
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3.   In the last 3 months, have you discussed your health over the telephone with any 
 
health professional (apart from to make or change appointments). 
 
 
No  Please to to Question 4 
 
Yes  Please enter number of times 
 
With anyone at your GP surgery 
With anyone at the hospital 




4. In the last 3 months, have you visited an accident and emergency department for 
problems related to the faecal incontinence or its treatment ? 
 
 
No  Please go to Question 4 
 
  












5. In the last 3 months, have you been admitted as an in-patient (i.e. stayed overnight in 
hospital) for problems related to the faecal incontinence or its treatment  
 
 
No  Please go to Question 5 
 
   
 
   
 
Yes  Please enter the number of nights you spent in hospital  
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6.  If you are in work, did you take any time off work either due to illness or in order to see any 
health professional, for your incontinence problems, in the last 3 months? 
 
 
No  Please go to Section F 
 
   
 
   
 





7. In the last 3 months, have you visited the Colorectal Outpatient department for 
problems related to the faecal incontinence or its treatment ? 
 
 
No  Please go to Question 4 
 
  














Section B: Drugs use questionnaire 
 
Have you taken any of the following prescribed drugs in the last 3 months? 
 
Drugs for incontinence (prescribed in the last 3 months) 
 
Name of Drug Strength Number taken 
per day 




    
Codeine 
Phosphate 
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Suppositories (prescribed in the last 3 months) 
 
 Strength Number taken 
per day 
Number of days Total number in 
3 months 
Glycerine     
Bisocodyl     
Other     
 
Enemas (prescribed in the last 3 months) 
 
 Strength Number used 
per day 
Number of days Total number in 
3 months 
Fleet     
Microlette     
Phosphate     
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Medication for general GI disorders (prescribed in the last 3 months) 
 









in 3 months 
Sennokot     
Lactulose     
Fybrogel 
(Ispaghula Husk) 
    
Dulcolax (Sodium 
Docosate) 
    
Movicol     
Buscopan 
(hyoscine) 
    
Colpermine 
(peppermint oil) 
    
Maxolon 
(Metoclopramide) 
    
Other     
 
Medication not listed (prescribed in the last 3 months) 
 
Have you been prescribed any other drugs regularly in the last 3 months that have not 
been listed here (excluding paracetamol, aspirin and ibuprofen)? 
 









If the medication is not taken continuously over the last three months, please tell us whether it is taken “as 
required” or whether it was a short course. 
 
Please also indicate the average number taken per day and the average frequency (N
o
 days per week) for drugs 
taken “as required” or the number of days it was taken for if a short course. 
 
Thank you for completing this questionnaire 
 
 
Wexner faecal incontinence score 
 
 




Pre – treatment□ 3 months after □   6 months after□ 
 
The aim of this questionnaire is to find out about the severity of your bowel 
incontinence. This information will help us to follow your progress as you have 
treatment. 
 
Please answer each question by ticking the statement that most relates to you: 
 
 
1. I accidentally lose control of solid motion from my bowel:  
 
□ Every day 
□ More than once a week but not every day 
□ More than once a month but less than once a week 





2. I accidentally lose liquid motions from my bowel: 
 
□ Every day 
□ More than once a week but not every day 
□ More than once a month but less than once a week 







3. I accidentally leak wind/gas from my bowel: 
 
□ Every day 
□ More than once a week but not every day 
□ More than once a month but less than once a week 





4. I have to wear a pad/plug of cotton wool or toilet paper: 
 
□ Every day 
□ More than once a week but not every day 
□ More than once a month but less than once a week 




5. Losing bowel motion or gas from my bowel makes me alter my daily life: 
 
□ Every day 
□ More than once a week but not every day 
□ More than once a month but less than once a week 








Thank you for completing this form 
